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BACKGROUND: Human gliomas account for the most common and malignant tumors in the 
central nervous system (CNS). Despite optimal treatments, survival of patients with high-grade 
glioblastoma multiforme (GBM) remains poor. Recent coordinated genomic analyses of a large 
cohort of clinical GBM specimens identified frequent co-alterations of genes in three core 
pathways—the P53, retinoblastoma (RB), and receptor tyrosine kinase (RTK) pathways that are 
crucial in gliomagenesis. Further multi-institutional efforts have sub-classified GBMs into four 
clinical relevant subtypes based on their signature genetic lesions. Among them, PDGFRA 
overexpression is concomitant with a loss of CDKN2A locus (encoding P16INK4A and P14ARF) 
in a large number of tumors within one subtype of GBMs. To better understand and design 
therapeutic strategies against gliomas driven by abnormal platelet-derived growth factor (PDGF) 
signaling, functional studies using human or mouse models are needed.  
MAJOR FINDINGS: In order to establish a model that allows us to assess contributions of 
different signaling pathways to PDGFR?-induced glioma formation, we generated Ink4a/Arf-
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deficient primary mouse astrocytes (referred to as mAst hereafter) and human glioma cells that 
overexpress PDGFR? and/or PDGF-A. We found that activation of PDGFR? confers 
tumorigenicity to Ink4a/Arf-deficient mAst and human glioma cells in the brain.  Restoration of 
p16INK4a but not p19ARF by retroviral transduction suppresses PDGFR?-promoted glioma 
formation. Mechanistically, abrogation of signaling modules in PDGFR? that lost capacity to 
bind to SH-2-containing phosphotyrosine phosphatase SHP-2 or Phosphoinositol 3'-Kinase 
(PI3K) significantly diminished PDGFR?-promoted tumorigenesis. Furthermore, inhibition of 
SHP-2 by shRNAs or pharmacological inhibitors disrupted the interaction of PI3K with 
PDGFR?, suppressed downstream AKT/mTOR activation, and impaired tumorigenesis of 
Ink4a/Arf-null cells, whereas expression of an activated PI3K mutant rescued the effect of SHP-2 
inhibition on tumorigenicity.  In clinical glioblastoma specimens, PDGFR? and PDGF-A are co-
expressed and such co-expression is linked with activation of SHP-2/AKT/mTOR-signaling. Our 
data thus suggest that in glioblastomas with Ink4a/Arf deficiency, overexpressed PDGFR? 
promotes tumorigenesis through the PI3K/AKT/mTOR-mediated pathway regulated by SHP-2 
activity. 
SIGNIFICANCE: We expect these findings will improve our understanding of the formation of 
the gliomas with PDGFRA and INK4A/ARF aberrations. There were studies that predicted SHP-
2/PTPN11 as one of the linker genes in clinical GBMs that interact with multiple commonly 
altered genes. Our results functionally validate this hypothesis and identify SHP-2 as a converge 
point of several signaling pathways such as PDGFR, EGFR, PI3K, and mTOR that are 
frequently deregulated in GBMs. It thus represents a promising target for treatments against this 
fatal disease. 
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  1 
1.0 INTRODUCTION 
 
 
1.1 MALIGNANT GLIOMAS 
 
Malignant tumors in the brain are relatively rare but deadly due to their insidious location and 
highly invasive capacity rendering them inaccessible to surgery or therapeutic drugs (1, 2). 
Clinically, these tumors are classified based on the predominant cell type as determined by 
histological approaches (3). Among them, malignant gliomas that originate from the glial cells in 
the brain represent the most common and aggressive type of tumor in the CNS (2, 4). Malignant 
gliomas in adults can be classified, based on histological features, into astrocytomas, 
oligodendrogliomas, and mixed oligoastrocytomas, and further within each type divided into 4 
grades corresponding to their malignancy and genetic alterations (WHO grade I-IV) (Figure 1). 
Grade I gliomas (pilocytic astrocytomas) were primarily found in childhood and young adults, 
and can mostly be surgically removed. Grade II gliomas (diffuse astrocytomas or 
oligodendrogliomas) are diffusely infiltrative and thus complete removal is nearly impossible. 
These tumors showed minimal nuclear atypia and low cellularity; Grade III gliomas (anaplastic 
astrocytomas or oligodendrogliomas) display marked anaplasia and tend to progress to Grade IV 
within a short period of time. These tumors are characterized by high cellularity, marked mitotic 
activity and nuclear atypia; Grade IV glioblastoma multiforme (GBM) is incurable and 
characterized by additional features such as robust microvascular proliferation and frequent 
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necrosis when compared to lower-grade tumors (3). Despite intensive treatments including 
maximal surgical resection, combined with radiotherapy and concurrent or adjuvant 
chemotherapies, the median survival of patients with GBMs remains 13-16 months after 
diagnosis (5). Clinical GBMs are composed of poorly differentiated glial cells with features such 
as uncontrolled growth, resistance to apoptosis, diffuse infiltration, cellular pleomorphism, 
nuclear atypia, mitotic abnormalities, microvascular proliferation, and focal necrosis (2, 3). 
Based on genetic and clinical presentation, GBM has been classified into two subtypes. The 
primary GBMs, which arise de novo with very short or no clinical history, mostly occur in older 
patients, whereas the secondary GBMs develop from lower-grade gliomas in younger patients (2, 
4) (Figure 1). Over the past decade, a plethora of data has accumulated on genetic alterations in 
human gliomas, including activation of oncogenes and inactivation of tumor suppressor genes (2, 
4, 6-8). It appears that in human gliomas, these genetic alterations occur in a pattern 
corresponding to distinct histological subtypes and different grades of tumors. For example, it is 
believed that low-grade astrocytomas and oligodendrogliomas may develop from common glial 
progenitor cells that acquire features of astrocytic tumors in the presence of TP53 mutations and 
oligodendrocytic tumors in the presence of 1p/19q chromosomal loss (Figure 1)(7). Additionally, 
PDGFRA/PDGF-A overexpression and IDH1 mutations are some of the major genetic 
alterations found in low-grade gliomas as well as secondary GBMs. When the low-grade tumors 
progress toward the high-grade secondary GBMs, additional changes such as 
CDKN2A/CDKN2B deletion are acquired (Figure 1). In the primary GBMs, however, a distinct 
set of genetic changes were observed, such as EGFR amplification/mutation, PTEN 
mutations/deletion, and MDM2 overexpression (Figure 1), suggesting that a different cell of 
origin of these tumors is responsible for generating primary GBMs (2, 4, 6-8). 
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Figure 1. Progression and genetic alterations in human malignant gliomas.  
The astrocytomas may originate from astrocytes or progenitor cells that accumulate genetic alterations and 
become transformed. IDH1 and TP53 mutations were believed to be the very first alterations that occur in 
these tumors. Oligodendrogliomas can come from the same progenitor cells or mature oligodendrocytes that 
acquire distinct set of genetic changes. The earliest changes that occur include IDH1 mutations and 1p/19q 
loss. Representative genetic changes are illustrated in this schematic with the estimated frequency of 
occurrence within each type of tumors (2, 4, 6-8). OE, overexpression; mut, mutation; del, deletion; met, 
promoter methylation; amp, amplification. 
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Recently, coordinated genomic analyses of a large cohort of clinical GBM specimens 
identified frequent co-alterations of genes in three core pathways—the P53, RB, and RTK (9) 
pathways that are crucial in gliomagenesis (10). Further analysis classified these GBMs into four 
clinically relevant subtypes based on gene expression profiles (11): Classical, Mesenchymal, 
Proneural, and Neural subtypes. 
 
1.1.1 Classical Subtype 
 
Classical subtype of GBMs are characterized by the presence of signature genetic aberrations 
such as chromosome 7 amplification and chromosome 10 loss (100%), EGFR amplification 
(95%) and mutation (55%), CDKN2A/CDKN2B deletion (95%), PTEN deletion (100%), as well 
as predominant expression of neural stem cell markers such as NES (encoding Nestin), and 
Notch and Shh pathways signaling molecules (11). 
 
1.1.2 Mesenchymal Subtype 
 
Mesenchymal subtype of GBMs are characterized by the presence of signature genetic 
alterations such as NF1 deletion (38%) and mutation (37%), PTEN mutation (32%), and 
predominant expression of mesenchymal markers such as CHI3L1, MET, CD44, and MERTK, 
and TNF superfamily and NF-?B pathways signaling molecules (11). 
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1.1.3 Proneural Subtype 
 
Proneural subtype of GBMs are characterized by the presence of genetic alterations such as 
PDGFRA amplification (35%) and mutation (11%), TP53 mutation (54%), IDH1 mutation 
(30%), PI3K (PIK3R1/PIK3CA) mutation (27%), CDKN2A/CDKN2B deletion (56%), EGFR 
amplification (17%) and mutation (19%), and predominant expression of oligodendrocyte 
markers such as PDGFRA, NKX2-2, and OLIG2, and proneural development genes such as SOX, 
DCV, DLL3, ASCL1, and TCF4. The Proneural GBMs are the most resistant among all subtypes 
to standard intensive ratio-/chemotherapy (11). 
 
1.1.4 Neural Subtype 
 
Neural subtype of GBMs are characterized by the presence of genetic alterations such as ERBB2 
mutation (16%), EGFR amplification (67%), and mutation (26%), PTEN deletion (96%) and 
mutation (21%), CDKN2A/CDKN2B deletion (71%), PI3K (PIK3R1/PIK3CA) (16%) and IDH1 
mutations (5%), and predominant expression of neuron markers such as NEFL, GABRA1, SYT1, 
and SLC12A5, and genes involved in neuron projection, axon and synaptic transmission (11). 
 
1.1.5 IDH1 Mutations 
 
The newly identified mutation in the IDH1 gene emerged as the first metabolic gene mutation 
found in the GBMs (12). IDH1 mutation was originally identified in a high-throughput 
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sequencing analysis and was later found to be present in as much as 70% of the grade II/III 
astrocytomas, oligodendrogliomas and secondary GBMs (13). Moreover, GBM patients with 
IDH1 mutations often had significantly better prognosis, and these alterations were frequently 
found in patients without most of the common genetic lesions, indicating IDH1 mutations as 
early events during the initiation of glioma development (13). However, the facts that IDH1 
mutations mostly occur in the Arginine 132 (R132) of the IDH1 protein and that there is a lack of 
LOH associated with IDH1 mutations indicate that these mutations may result in a gain- rather 
than loss-of-function of the IDH1 gene product (13).  Indeed, accumulation of a putative onco-
metabolite 2-HG was found in the IDH1-mutated tumors instead of the WT IDH1 product ?-KG 
(14). In a series of attempts to identify the mechanisms by which 2-HG initiates gliomagenesis, 
2-HG was suggested to confer a genome-wide histone and DNA methylation phenotype to a 
subgroup of gliomas by its inhibitory activity against certain ?-KG-dependent dioxygenases such 
as histone demethylases and 5-methylcytosine (5mC) hydroxylases (15, 16). These studies 
suggest that IDH1 mutations are responsible for altering a large number of genes that are 
important for gliomagenesis through its capacity of modulating the epigenetic controls of these 
genes. However, whether therapies targeting this specific genetic alteration will benefit patients 
with gliomas that have already undergone significant genetic and epigenetic changes conferred 
by the putative initiator IDH1 mutation warrants further investigations. 
 
1.1.6 Current Treatments and Future Prospects 
 
Standard treatment for newly diagnosed malignant gliomas includes maximal surgical resection, 
followed by radiotherapy, and concomitant or adjuvant chemotherapy with TMZ (4). The 
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introduction of TMZ into the therapy regimen improves the OS and the PFS of GBM patients 
(5). However, the presence of DNA repair enzymes such as MGMT in the tumor cells 
significantly reduces the efficacy of TMZ, and GBMs that recur after these first-line treatments 
generally are resistant to TMZ or radiotherapy (4). Consequently, treatment options for patients 
with recurrent gliomas remain limited. Many of the common genetic alterations in gliomas have 
been identified for years. However, none of them has substantially impacted the current 
treatment of this deadly disease. Large-scale genomic profiling has brought our understanding of 
glioma molecular pathogenesis to a new era, and other new findings will keep amassing our 
knowledge even more. Moreover, cancer genome profiling may enable early detection and 
prevention of tumor progression, and prediction of prognosis and responses to therapies. 
However, more challengingly, the current task is to transform these genomic data into better 
therapeutic strategies and eventually into personalized medicine (17-19).  
 
 
1.2 THE CDKN2A LOCUS IN MALIGNANT GLIOMAS 
 
1.2.1 P16INK4A 
 
Mitogens such as PDGFs trigger cell cycle progression through G1 phase to S phase, a process 
regulated by several CDKs, whose activities are in turn modulated by CDK inhibitors (CKIs) 
(20). One of the CKIs, P16INK4A, belongs to the INK4 family, and binds only to 
CDK4/6/Cyclin D complex, restricting their capacity to phosphorylate RB protein. 
Phosphorylation of RB is required for release of E2F transcription factor and the subsequent 
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expression of various DNA synthesis and S phase entry genes (20). P16INK4A is encoded by 
CDKN2A locus in the genome that also encodes an unrelated protein ARF. Expression of Ink4a 
and Arf uses different promoters and the first exons (E1? and E1?, respectively) that are spliced 
to a common second exon E2 and third exon E3 (21).  
 
1.2.2 ARF 
 
By using an alternative reading frame (9), the CDKN2A locus also encodes a protein, P14ARF 
(p19ARF in mouse), with an entirely different amino acid sequence from that of P16INK4A (22, 
23). The primary tumor suppressor activity of ARF protein has been shown to be its ability to 
antagonize the E3 ubiquitin ligase activity of MDM2, which inhibits p53 by mediating 
proteasomal degradation of p53, despite the presence of putative p53-independent tumor 
suppressor functions of ARF (24). P14ARF thus can stabilize p53 by sequestering MDM2 in the 
nucleolus, preventing its ubiquitin activity on the p53 (25). In normal tissues, expression of ARF 
is nearly undetectable, whereas under oncogenic stress such as Myc and Ras expression, ARF 
level is elevated (26). This regulation of ARF level is to ensure that normal cells have low level 
of p53 and when exposed to oncogenic damages, they undergo growth arrest or apoptosis to 
retain homeostasis of the tissue. 
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Figure 2. The CDKN2A locus.  
The CDKN2A locus on human chromosome 9p21 encodes two tumor suppressors with distinct amino acid 
sequences and biological functions by using alternative first exons spliced to common exons 2 and 3. 
P16INK4A is involved in pRB pathway in which it suppresses S phase entry in the cell cycle and induces 
senescence of cells. P14ARF (p19ARF is the mouse homolog) is involved in p53 pathway in which it promotes 
apoptosis and senescence by stabilizing the p53 protein. 
 
 
 
 
 
  10 
1.2.3 INK4A/ARF in cellular senescence and aging 
 
The first indication that in-vitro cultured cells undergo cellular senescence after serial passages 
came from the observations in normal human fibroblasts by Hayflick and colleagues in 1961 
(27). They proposed that factors within these cells dictate the cell senescence and these factors 
may be lost in cancer cells to confer immortality to them. The so-called “Hayflick factors” were 
later found to be telomere loss, accumulation of DNA damages, and derepression of the 
INK4A/ARF locus (27).  Several studies have shown that p16INK4a and ARF mRNA and protein 
levels significantly increased with aging in rodents (28, 29) and human tissues (9, 30). The levels 
of the transcription regulators of p16INK4a, Polycomb group (PcG) member Bmi1 (9) and 
transcription factor Ets1 (29), have been associated with the increased p16INK4a level in aging. 
The age-related increase of reactive oxygen species (ROS) is also another contributor to the 
increase of p16INK4a during aging (27). P16INK4a has also been implicated in stem/progenitor 
cell aging. Tissue stem/progenitor cells in the fetus are important for generation of tissues and 
organs, and in the adults they are responsible for tissue maintenance and regeneration (31). The 
tissue stem cell is a double-edged sword in that the aging of stem cells may have detrimental 
effects on tissue repairs, while the uncontrolled proliferation of them may also contribute to 
hyperplasias (31). Indeed, an increase in p16INK4a level was shown to result in decreased 
forebrain NSC number in the SVZ (32, 33) and in the cerebellum (33). Additionally, an increase 
in the p16INK4a repressor Bmi1 has also been linked to increased self-renewal of HSCs (34), 
and a decrease in p16INK4a activity to enhanced repopulating capacity of HSCs in serial bone 
marrow transplantation experiments (35). These results indicate that one of the mechanisms by 
which p16INK4a promotes aging may be its ability to limit stem cell self-renewal/proliferation. 
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Surprisingly, mice with increased Ink4a/Arf expression showed normal life span and aging (36), 
suggesting that p16INK4a-induced stem cell defects may not have impacts on the long-term 
longevity of the animals. Another explanation to this observation is that the anti-aging activity of 
p53 resulted from increased Arf negates the pro-aging activity of Ink4a expression. Intriguingly, 
mice that harbored two additional alleles of Arf gene present an extended life span and delayed 
aging (37), further suggesting an anti-aging effect of Arf or p53 overexpression. 
 
1.2.4 INK4A/ARF in malignant gliomas and other cancers 
 
The implication that the INK4A/ARF locus is involved in development of various types of 
human cancers came from the observation that this genomic region is frequently altered in 
human malignancies (38-40), including gliomas, lung cancers, prostate cancers, melanomas, 
head and neck cancers, pancreatic cancers, renal cell carcinomas, breast cancers, bladder 
carcinomas, and leukemias (41). Mice lacking the Cdkn2a locus developed spontaneous tumors 
and were more prone to carcinogenesis (42). Mice deficient in Ink4a (Ink4a
-/-
) (43) or Arf (Arf
-/-
) 
(23) alone were less tumor-prone than the Ink4a/Arf
-/-
 or p53
-/-
 mice, and displayed distinct 
spontaneous tumor spectra from each other and the double-knockout animals (44). Whereas no 
spontaneous tumors were found in the brain of the Ink4a/Arf-deficient mice, astrocytes and NSCs 
from these mice formed high-grade gliomas in the brain upon EGFR activation (45). 
Consistently, the Ink4a/Arf loss cooperates with constitutively active EGFRvIII expression 
targeted to either glial progenitor or astrocytes to generate gliomas in the mouse brain (46). 
Additionally, K-Ras activation was shown to cooperate with loss of Ink4a and Arf in mAsts or 
neural progenitor cells to generate GBMs (47). On the other hand, expression of an additional 
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transgenic copy of the entire Ink4a/Arf locus in mice rendered these animals resistant to 
oncogenic transformation (36). Re-introduction of p16INK4A into INK4A-null human glioma 
cell lines led to significant suppression of cell growth (48, 49). Clinically, deregulation of 
P16INK4A/CDK4/6/RB pathway frequently occurs with alterations in P14ARF/MDM2/P53 
pathway in both low- and high-grade gliomas (50). Recent coordinated efforts have also 
identified these two pathways as the core pathways that are altered in clinical GBM tissues (10, 
11). The homozygous deletion of the CDKN2A locus at chromosome 9p21, thus eliminating both 
INK4A and ARF genes, concomitantly deregulates two major tumor suppressor pathways, the RB 
and P53 pathways (26). In gliomas without INK4A/ARF alteration, there are often other genetic 
changes within the RB and P53 pathways to achieve the disruption of these two core pathways, 
such as CDK4/6 amplification, RB mutations, TP53 mutations, and MDM2/4 amplification (10, 
51), further demonstrating the importance of abrogation of the RB and P53 pathways for 
gliomagenesis.  In addition to allelic deletion (52), CDKN2A locus can also be inactivated by 
promoter hypermethylation (53, 54) or point mutations (55) in some cases. Given the role of 
p16INK4A in normal aging of NSCs (32), this molecule is important in maintaining a balance 
between aging and oncogenesis. 
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1.3 PLATELET-DERIVED GROWTH FACTOR (PDGF) SIGNALING 
 
1.3.1 Structures of PDGFs and PDGFRs 
 
PDGF was identified and purified more than 35 years ago as a molecule released by platelets into 
the whole blood serum that stimulates proliferation of various mesenchymal cells (56-58), as 
well as glial cells in the brain (59, 60). The mitogenic effect of this growth factor requires the 
target cells express the receptors for PDGF (PDGFR) (61). The PDGF family consists of four 
ligands, PDGF-A, -B, -C, and -D, and two receptors, PDGFR? and ? (Figure 3). The structures 
of PDGF-A and -B are largely similar, consisting of a PDGF/VEGF core domain with conserved 
cysteine residues called the cysteine knot motif, and a N-terminal propeptide region that is 
removed intracellularly for their activation prior to its secretion (Figure 3) (62). Additionally, in 
PDGF-B and a membrane-bound, long alternative splice form of PDGF-A, there is a C-terminal 
basic “retention motif” that can interact with heparan sulfate proteoglycans of the ECM (Figure 
3)(63). The retention motif needs to be cleaved prior to secretion of the ligands. Expression of 
long or short form of PDGF-A results from alternative splicing of the exon 6 of PDGFA gene 
and is cell-type specific. Human glioma cells produce mainly the long form (64), while normal 
human endothelial cells express the short form of PDGF-A. Interestingly, the differential 
alternative splicing of PDGF-A might determine its mitogenic capacity in these cells (64). The 
two novel PDGFs, PDGF-C and PDGF-D, contain a distinct N-terminal domain called CUB 
domain (Figure 3). It is cleaved extracellularly after secretion of the growth factors and this 
cleavage is important for their activity (65). PDGFRs shared a common structure including five 
extracellular immunoglobulin (Ig) loops and a split intracellular tyrosine kinase (TK) domain 
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separated by a kinase insert region (Figure 3) (62, 66). Similar structures can be also found in 
other RTKs such as VEGFRs, c-Kit, c-Fms, and Flt-3 (66). 
  
 
Figure 3. The Structures of PDGFRs and PDGFs. 
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1.3.2 Activation and Downstream Signaling of PDGFRs 
 
The PDGF ligands function as disulfide-linked homo- or hetero-dimers, PDGF-AA, PDGF-AB, 
PDGF-BB, PDGF-CC, and PDGF-DD (65). These dimeric isoforms are capable of binding to 
two structurally related RTKs with different specificities (PDGFR? and PDGFR?) (Figure 4) 
(65, 67).  
 
 
 
Figure 4. Specific binding between PDGF receptors and ligands. 
 
The binding of PDGF ligands induces dimerization of the PDGFRs and juxtaposition of 
their intracellular tyrosine kinase domains, leading to trans-autophosphorylation of multiple 
tyrosine residue sites (68). The subsequent association between different SH2 domain-containing 
signaling molecules and the phosphorylated tyrosine residues engages various downstream 
signaling cascades (Figure 5), gene transcription events, and various cellular behaviors, such as 
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cell proliferation, apoptosis, actin reorganization, and chemotaxis (62, 69). The SH2 domain-
containing signaling effectors include PI3K, PLC-?, SFK, phosphotyrosine phosphatase SHP-2, 
GAP for Ras, STATs, as well as adaptor proteins such as Grb2, Grb7, Shc, Nck, and Crk (69). 
PDGFR? and ? bind to distinct but overlapping sets of these signaling molecules upon ligand 
stimulation. Allelic series of mutant PDGFRs have been generated and it appears that, compared 
to PDGFR?, PDGFR? relies more on activation of specific signaling pathways to function 
properly in specific stages and organs during animal development (70, 71). For example, PI3K 
signaling is indispensable for PDGFR? during early animal development, while for PDGFR?, 
disruption of PI3K alone had little effect on normal development (66). Cytoplasmic domain 
swapping experiments further revealed that in contrast to PDGFR?, it is not the intrinsic 
properties of the receptor but the ability of PDGFR? to engage specific signaling molecules that 
determines the activity and functions of receptor signaling (72, 73). In this dissertation, we focus 
on the downstream SH2 domain-containing signaling effectors of PDGFR? (Figure 5). 
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Figure 5. The PDGF-A/PDGFR?  signaling.  
The PDGF-AA homodimers bind and induce dimerization, autophosphorylation of PDGFR??  homodimer 
receptor. Various SH 2 domain-containing signaling effectors are then recruited to the receptor by binding to 
specific phosphorylated tyrosine residues and initiate downstream signaling cascades.  
 
1.3.2.1  PI3K 
Members of the PI3K family consist of a regulatory p85 subunit and a catalytic p110 subunit. 
Upon association with the phosphorylated tyrosine residues 731 and 742 (Tyr-731/42) of 
PDGFR? intracellular domain (62), PI3K is activated and phosphorylates its preferred target 
phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2 or PIP2] to produce phosphatidylinositol 3,4,5-
triphosphate [PI(3,4,5) P3 or PIP3] in the plasma membrane. The PIP3 then recruits several 
downstream effectors such as Akt/PKB, p70 S6 kinase, c-Jun N-terminal kinase (JNK), and 
small GTPase of the Rho family to the plasma membrane (62, 69). The activation of PI3K 
  18 
pathway leads to several cellular effects including cell growth, survival, chemotaxis, and actin 
reorganization (Figure 5) (62, 69).  
 
1.3.2.2  PLC-?  
PLC-? shares the same substrate as PI3K. Upon association to Tyr-988 and -1018, it 
phosphorylates PIP2 to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), 
which then mobilize intracellular Ca
2+
 and activate the PKC family, respectively (Figure 5) (62, 
69). PDGF-induced PLC-? activation is responsible for cellular effects such as cell motility and 
growth. Full activation of PLC-?, however, is dependent on the PIP3 generated by PI3K, since 
recruitment of PLC-? requires association of its pleckstrin homology (PH) domain with the PIP3 
in the plasma membrane (62, 69).  
 
1.3.2.3  Src Family Kinases (SFKs) 
The SFK represents a family of tyrosine kinases including Src. Their binding sites on PDGFR? 
autophosphorylated tyrosine sites are Tyr-572 and -574. PDGFR?-mediated Src activation 
appears to be unnecessary for mitogenic responses in some cell types (Figure 5) (62, 69).  
 
1.3.2.4  SHP-2 
SHP-2 is an SH2-containing phosphotyrosine phosphatase that binds to phosphorylated Tyr-720 
of activated PDGFR?. Its phosphatase activity can potentially dephosphorylate the RTK and 
downstream effectors, leading to inactivation of these proteins. However, it has also been shown 
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that SHP-2 is involved in up-regulation of several effectors such as Ras/MAPK and Src 
pathways, possibly through its role as an adaptor (Figure 5) (62, 69). 
 
1.3.2.5  Crk 
Crk is an adaptor that binds to phosphorylated Typ-702 of PDGFR?. Upon binding, it then 
activates the nucleotide exchange protein C3G and the subsequent activation of the JNK/SAPK 
pathway (Figure 5) (62, 69). 
 
1.3.3 PDGFR Mutation Studies 
 
An allelic series of PDGFRA tyrosine-to-phenylalanine mutations disrupting association between 
the RTK with different downstream effectors and signaling pathways have been generated (74). 
This study demonstrated that PDGF-AA-induced DNA synthesis was strictly dependent on PI3K 
signaling only, while Src, PI3K, and PLC-? are required for PDGF-mediated mediated 
chemotaxis, with Src being the most important effector for cell motility (74). Surprisingly, all 
PDGFR? mutants in the “add-back panel” that can only initiate one of the five downstream 
pathways were not able to restore the PDGF-induced chemotaxis to the level achieved by WT 
PDGFR?, indicating that activation of multiple effectors are required for full activity of the 
receptor to mediate certain cellular responses (74). Using similar strategy, PI3K and PLC-? were 
shown to play predominant roles in preventing apoptosis of mesoderm cells during early 
Xenopus embryo development (75). These studies suggest that distinct downstream effectors of 
PDGFR may be required for different cell types, species, and stages of development. To further 
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dissect the contribution of signaling pathways emanating from the PDGFR?, Klinghoffer and 
colleagues further generated knockin mice that harbored one of the three mutants, PDGFR?-F7, 
PDGFR?-F731/42, or PDGFR?-F572/74 (70).  Interestingly, mice that homozygously harbored 
PDGFR?-F731/42, as well as PDGFR?-F7, displayed phenotypes comparable to PDGF-A- or 
PDGFR?-null animals, including growth retardation, skeletal and lung developmental 
abnormalities (70). However, Src association with PDGFR? was only required for 
oligodendrocyte development, possibly due to the role of Src in promoting progenitor cell 
migration (70). These experiments suggest that PI3K is the major effector of PDGFR? signaling 
during embryogenesis.  
 
 
1.4 PDGF SIGNALING IN NORMAL CNS DEVELOPMENT AND REPAIR 
 
1.4.1 PDGF-A in Oligodendrocyte Development 
 
The developmental functions of PDGFRs and PDGFs have been unveiled mainly through genetic 
studies in mice  [reviewed in (76) and (66)]. The role of closely related PDGF/VEGF 
superfamily in neural and glial development is evolutionarily conserved: in Caenorhabditis 
elegnas, the VERs, which are structurally similar to vertebrate VEGFRs, are expressed in 
neurons and glial cells (77); in Drosophila melanogaster, the PDGFR/VEGFR homologue PVR 
(and its ligand, PVF) is required for ventral midline glia cell survival (78). In the mammalian 
CNS, messenger RNA (mRNA) and protein expression of PDGF ligands and receptors were 
found throughout various brain regions (79). In rodents, the PDGFR?-positive OPCs (80) 
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originate at the ventricular surface near the floor plate of spinal cord in embryonic day 12.5 
(E12.5) of mice (E14 for rats) (81). Neurons and astrocytes throughout the CNS produce PDGF-
A that acts as a mitogen for OPCs (82-85). Early studies showed that PDGF-A knockout mice 
developed tremor caused by severe hypomyelination on neuronal projections throughout the 
CNS (86, 87); PDGFR?-null mice died prenatally and the OPC isolated from the premortem 
animals showed proliferation and differentiation defects (88). Subsequent studies using PDGFR? 
mutant knockin mice showed that downstream SFK and PI3K were important for normal 
myelination of the CNS (70). Further analyses revealed that PDGF-A, but not PDGF-B, is 
required for proliferation, migration, and normal differentiation of PDGFR?-positive OPCs (83, 
84, 89, 90), and that over-production of PDGF-A in the CNS neurons or astrocytes induced 
hyper-proliferation of the PDGFR?-positive O-2A progenitor cells in a paracrine manner (87, 
91). The mitogenic effect of PDGF-A appears to rely on various environmental cues endowed by 
the ECM, which activate various integrins (92) and chondroitin sulfate proteoglycan NG2 (93). 
The proliferation rate and the amount of PDGF-A available are proportional and the OPC 
population continues to grow until the concentration of PDGF-A becomes limiting, that is, the 
rate of PDGF-A consumption exceeds the rate of its production due to the increased number of 
OPCs (94). The OPCs may also be able to sense the amount of PDGF-A by the “rheostat-like” 
PDGFR? function, switching downstream signaling from PI3K pathway to PLC-? under higher 
PDGF-A concentration (88). Whereas in an autocrine situation, in which the PDGF ligand is 
over-expressed in PDGFR?-positive progenitor cells, the rate of PDGF-A production increases 
together with the number of the progenitor cells, theoretically rendering these cells capable of 
proliferating indefinitely (76). Thus in an autocrine situation, the growth factor sensing 
mechanism of OPCs might be lost. Similar mitogenic function of PDGFR?/PDGF-A signaling 
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has also been demonstrated during CNS injury. After experimental demyelination, the ensuing 
remyelination often involves increased proliferation of PDGFR?- and NG2-positive OPCs (95). 
A decrease in PDGFR? dosage in genomic level, as shown in heterozygous PDGFR?+/- mice 
(96), resulted in impaired remyelination after myelin damage to the CNS (97).  
Besides its role as a mitogen for OPCs, PDGF-A acts as a lineage specification factor that 
direct the differentiation of embryonic neural progenitor cells into oligodendrocytes (98, 99). In 
cultured O-2A progenitor cells isolated from rat optic nerves, PDGF-A and bFGF are also 
capable of maintaining the proliferation and self-renewal potential of these cells, and preventing 
their terminal differentiation into oligodendrocytes (100). Interestingly, the effect of these 
growth factors on OPC proliferation and differentiation appear to be reserved in the adult CNS in 
that following demyelinating damage, PDGF-A and bFGF levels are increased in order to 
promote OPC proliferation and subsequent differentiation into mature oligodendrocytes for 
remyelination (101). The observation that PDGF and bFGF convert the adult rat O-2A cells to 
their perinatal counterparts after injury to the adult brain (102) implied their capacity of 
reprogramming OPCs to earlier progenitors (103).  
In addition to the role of PDGF-A in the glial-restricted progenitor cell development, 
PDGF-A is also capable of stimulating proliferation of the PDGFR?-positive NSCs residing in 
the SVZ of the adult murine brain, which are capable of differentiating into both neurons and 
oligodendrocytes (104). The presence of the neuron/oligodendrocyte common progenitor has 
been appreciated long ago, which can be identified in embryonic mouse spinal cord by 
expression of basic helix-loop-helix transcription factor Oligs (105). By observations obtained in 
Olig2-null animals, one of the Olig genes, Olig2, was found to be important for oligodendrocyte 
development (105). In-situ hybridization experiments further revealed that expression of Olig2 
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gene precedes that of PDGFR? in mouse embryonic oligodendrocyte precursors (105, 106), 
suggesting a possible link between these two genes during glial development. Indeed, ectopic 
expression of Olig2 gene in vivo induces expression of transcription factor Sox10, which, 
together with Sox9, control transcription of the gene encoding PDGFR? (107, 108). Intriguingly, 
in mouse embryos, the Olig gene expression is regulated by Shh (106) that is also required for 
self-renewal of the embryonic forebrain progenitors induced by PDGF-A and bFGF (109), 
evincing a complex interaction of Shh, Sox, Olig, and PDGF in oligodendrocyte development. 
Surprisingly, normal astrocytic development does not seem to be affected in Olig2-null animals 
(105). Exactly which cell type (glial-restricted O-2A cells or neuron/oligodendrocyte common 
progenitor cells) do OPCs come from is still an open question (109). However, these findings 
suggest the existence of distinct PDGF-responsive neural progenitor cells, each of which is 
spatiotemporally responsible for generating various neural cells during CNS development. These 
observations in normal CNS development may not only help elucidate the identity of the long 
pursued cells-of-origin of the malignant gliomas, but also raise such questions as whether these 
intrinsic developmental and physiological properties and functions are preserved after cell 
transformation. 
 
1.4.2 PDGF-C and –D in CNS Development 
 
The roles of the two new members of the PDGF family, PDGF-C and PDGF-D, in CNS 
development remain relatively elusive. PDGF-C was first found in the spinal cord of chick 
embryo, thus it was originally named spinal cord-derived growth factor (SCDGF) (110). In rats, 
PDGF-C is expressed predominantly in embryonic brain and spinal cord, while PDGF-D 
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expression is evident in the adults than in the embryos (111). In addition, PDGF-C was detected 
by IHC in developing brain and spinal cord in mouse embryos (112). Interestingly, PDGF-C 
expression was also found in the transient EGL cells of the cerebellum in mouse E13 embryo 
(113). The requirement of PDGF-C for normal spinal cord development was further 
demonstrated by using PDGF-C knockout mice (114). These mice displayed a range of 
abnormalities and died perinatally due to difficulties in breathing and eating. Examination of the 
mouse embryos revealed the development of spina bifida occulta, an incomplete closure and 
deformation of the vertebrae (114). PDGF-D knockout animals have not been reported yet, and 
studies on its role in normal CNS development still fall behind. However, PDGF-D has been 
shown to stimulate blood vessel formation and wound healing processes (115), suggesting that 
PDGF-D might impact on tumor angiogenesis. The roles of PDGF-C and PDGF-D in brain 
tumor development will be discussed in the following sections of this chapter. 
 
 
1.5 PDGF SIGNALING IN HUMAN GLIOMAS 
 
1.5.1 Pre-Cancer-Genomic Studies 
 
The first implication that PDGF autocrine signaling can contribute to cell transformation came 
from the discoveries of amino acid sequence similarity between simian sarcoma virus (SSV) 
oncogene v-sis and PDGF-B chain gene (116, 117). In human glioma, a glioma cell line was 
shown to secrete a growth-promoting factor (118-120) that was later found to be three disulfide-
linked dimers, PDGF-AA, PDGF-AB, and PDGF-BB (121-123). Each of these dimers had 
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distinct binding affinities to receptors ? and ? (67). Subsequent studies revealed that mRNAs for 
PDGF ligands and receptors were expressed in a series of established glioma cell lines (124, 
125). In situ hybridization and IHC analyses further demonstrated that in human glioma tissues, 
tumor cells express PDGF-A, -B, and PDGFR?, while the surrounding hyperplastic endothelial 
cells express PDGF-B and PDGFR?, suggesting the presence of autocrine and paracrine PDGF 
stimulation in glioma development (126-129). Overexpression/gene amplification of PDGFR? 
occurred mostly in lower-grade gliomas as well as secondary GBMs (2, 4, 130-132), 
representing a distinct subtype from those with EGFR overexpression (Figure 1) (133). In a 
study of IHC staining on 103 grade II astrocytomas, PDGFR expression was found to be an 
independent prognostic factor for these patients (134). Overexpression of PDGF ligands, 
however, varies among gliomas of different grades, with PDGF-A being expressed in all grades 
and PDGF-B only in higher-grade GBMs (135), suggesting PDGF-B may be involved in the 
conversion of low- to high-grade gliomas. In fact, it has been shown that in human 
oligodendroglioma tissues (136) and in a mouse glioma model (137), the level of PDGF 
signaling may predict the grade and malignancy of these tumors. 
 
1.5.2 Cancer Genomics Studies 
 
Cancer is a disease of genomic alterations. For the past decade, high-throughput approaches such 
as microarrays and comparative genomic hybridization (CGH) arrays have been introduced and 
it was thus possible to profile gliomas in a whole-genome scale (12, 138-140). The most 
comprehensive and reliable analysis of genomic alterations in primary GBM tissues has been 
conducted by The Cancer Genome Atlas Network (TCGA), a project team funded by the 
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National Cancer Institute (NCI) (10). This multi-institutional effort provides invaluable resources 
for gene expression and mutation, DNA copy number alterations (CNA), and DNA methylation 
data for GBMs. Most of the previously appreciated genetic aberrations such as alterations in the 
RB, TP53, and RTK pathways were re-captured in the initial TCGA studies. However, an 
unexpected higher frequency (~13%) of focal amplifications of the 4q12 locus harboring 
PDGFRA was reported for primary GBMs in the TCGA collection than that published 
previously (10, 141). Further classification of these GBMs by the gene expression signatures 
revealed that PDGFRA overexpression occurs together with TP53 and IDH1 mutations in the 
Proneural subtype of GBMs, which also express oligodendrocyte lineage genes such as OLIG2 
and SOX (11). Interestingly, within this subtype of GBMs, PDGFRA amplifications and the 
PIK3CA/PIK3R1 mutations (leading to constitutively active PI3K subunits p110 and p85, 
respectively) mostly occur in a mutually exclusive manner (11), signifying an overlapping 
functionality between these two alterations in gliomagenesis. Indeed, analyses in different 
cohorts of gliomas of different grades using other methods such as single nucleotide 
polymorphism array (SNP-Chip) (142) or a western blot-based proteomic analysis (143) 
confirmed the importance of PI3K/AKT/mTOR pathway activation in PDGFRA-amplified 
gliomas.  
The Proneural subtype of GBMs that harbor PDGFRA amplification from the TCGA 
dataset shares similar gene expression profile with the previously reported pro-neural (PN) 
subclass (139). Nearly all WHO grade III tumors including astrocytomas, oligodendrogliomas, 
and mixed oligoastrocytomas were classified as PN subclass, as well as secondary GBMs (11, 
139). Patients with PN tumors were younger with better survival. A comparison of the PN 
tumors signature also revealed that they resemble the fetal and adult brain, as well as cultured 
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NSCs, indicating a possible cell of origin of this subclass of gliomas being the neural 
stem/progenitor cells (139). Indeed, putative NSCs residing in the adult mouse SVZ are 
PDGFR?-positive and responded to PDGF-A stimulation by forming a glioma-like lesion (104), 
suggesting the potential susceptibility of adult NSCs to oncogenic transformation by PDGFRA 
alterations.  
 
1.5.3 Constitutively Active PDGFRA mutations in Gliomas 
 
EGFR is the most frequently amplified RTKs in human gliomas (2, 6). It mainly occurs in a 
mutually exclusive manner with PDGFRA amplification in a distinct subclass of GBMs (11), 
although there were cases in which co-alteration of both RTKs were observed. Approximately 
50% of the EGFR-overexpressing GBMs also harbor an EGFR mutant allele with deletion of 
exons 2-7 (EGFRvIII or ?EGFR), leading to a constitutively active RTK (144, 145). Among 
PDGFR?-overexpressing gliomas, similar to the EGFR-overexpressing tumors, several 
mutations in the RTK also have been reported: an in-frame deletion in the extracellular domain 
of PDGFR? (146), a frameshift deletion (147), and a gene fusion product between kinase insert 
domain receptor (KDR/VEGFR-2) and PDGFRA (148). In particular, the complete deletion of 
exons 8 and 9 in the gene encoding PDGFR? (PDGFR??8,9), leading to a constitutively active 
and transforming RTK (149), was recently found to be more prevalent than was previously 
thought (148). In this study, Ozawa and colleagues demonstrated that the mutant PDGFR??8,9 
was capable of transforming mouse fibroblasts in vitro and in vivo, stimulating downstream 
Akt/Erk phosphorylation/activation, and responding to anti-PDGFR treatments (148). However, 
the fact that PDGFR??8,9 was not able to transform Ink4a/Arf-/- mouse glial cells (148) is 
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seemingly contradictory to the observation that PDGFRA overexpression can cooperate with 
Ink4a/Arf deletion to induce glioma growth from mAsts, as shown in the recent publication from 
our lab (150).  Therefore, it is possible that concomitant overexpression of WT PDGFRA is 
necessary for the PDGFR??8,9 mutant to be oncogenic, which also explains the fact that mutant 
PDGFRA occurs only within the PDGFRA-overexpressing GBMs (144, 148). 
 
1.5.4 PDGF-C and -D in Human Gliomas 
 
The two novel PDGF ligands, PDGF-C and PDGF-D, were first implicated in glioma 
development by a study that examined expression of PDGF ligands and receptors in glioma cell 
lines and primary glioma tissues (151, 152). Lokker and colleagues found that PDGF-C and -D 
were expressed at high levels in tumor tissues as compared with those in the normal brain 
control. Additionally, autocrine loops that involve PDGF-C/PDGFR? and PDGF-D/PDGFR? 
exist in all tumors they examined. However, the pathological consequences of PDGF-C and -D 
over-expression and whether they compensate PDGF-A and -B functions or merely initiate 
redundant signaling cascades remain elusive. Interestingly, in an s.c. tumor model, PDGF-C was 
associated with tumor resistance to anti-VEGF therapies. The resistant tumors tend to up-
regulate the level of PDGF-C after anti-VEGF treatment, possibly compensating the function of 
the inhibited VEGF in stimulating angiogenesis (153). Indeed, in patients with recurrent GBMs 
after anti-VEGF therapy, PDGF-C, together with c-Met, was expressed at high levels, especially 
in the center of the tumor mass (154). The mechanism of resistance to anti-VEGF therapy may 
involve the capacity of PDGF-C to alter the structure of blood vessels by recruiting perivascular 
cells (155), thus stabilizing the vessels and rendering them insensitive to anti-VEGF treatment. 
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The function of the PDGF-D/PDGFR? autocrine remains unknown despite its presence in 
several GBM cell lines and primary tissues (151, 152). However, it has been shown that PDGF-
D was responsible for inducing chemotactic tropism of PDGFR-positive stem cells toward 
glioma cells in the mouse brain (156). This observation is likely important for development of 
therapeutic strategies using stem cells as a drug carrier. 
 
1.5.5 Animal Models of PDGF-induced Gliomagenesis 
 
1.5.5.1  Transgenic Mice 
Despite decades of intensive research, the prognosis for patients diagnosed with high-grade 
gliomas remains dismal. One of the major hurdles to the progress is the lack of animal models 
that can accurately recapitulate the behaviors and the neuropathological features of the tumors in 
humans (157). Several GEM models of spontaneous glioma formation have been reported, by 
generating mice with astrocyte-specific transgenic expression of v-src (158) or H-ras (159), and 
with concomitant loss of NF1 and p53 tumor suppressors (160, 161). Recently, transgenic mice 
that harbor an astrocyte-specific expression of PDGF-B (hGFAPpPDGFB mice) were generated 
and assessed for spontaneous glioma formation (Table 1) (162). Neither loss of p53 nor 
overexpression of PDGF-B alone was able to induce brain tumor growth. However, when Hede 
and colleagues crossed the hGFAPpPDGFB mice with the p53-null mice, the resultant 
hGFAPpPDGFB/p53-null mice developed an aggressive GBM-like tumor with characteristics 
comparable to human GBMs (162). The researchers further showed that PDGFR? was highly 
expressed in tumor cells, while PDGFR? was expressed in the tumor vasculature, and that the 
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tumor expressed a series of lineage markers indicating presence of various cell types including 
neurons, astrocytes, and oligodendrocytes, especially in tumors of large size.  
More recently, spontaneous gliomas have been found to develop in transgenic mice 
overexpressing the long isoform of PDGF-A, PDGF-AL (Figure 3), under control of a GFAP 
promoter (Table 1) (163). Unlike hGFAPpPDGFB mice, hGFAPpPDGFAL mice did not require 
additional genetic aberrations such as p53 deletion in order to develop spontaneous tumors. 
These mice were further found to harbor neoplastic cells positive for PDGFR?, Olig2, and NG2 
in the SVZ, corpus callosum, hippocampus, and cerebellum (163), suggesting that the resident 
OPCs in these areas of the brain were likely the target of transformation in these mice. 
Alternatively, GFAP-positive neural stem cells could also be the cell of origin for PDGF-induced 
gliomas in the hGFAPpPDGFAL mice since PDGF-A has been reported to capable of biasing the 
cell fates of stem cells residing in the SVZ toward OPC-like cells (104). Histologically, the 
spontaneous gliomas formed in hGFAPpPDGFAL mice showed characteristics of both astrocytes 
and oligodendrocytes and thus were determined to be WHO grade III oligoastrocytomas (Table 
1). Although it is difficult to assess the tumor-promoting potentials of PDGF-B, short- and long-
form PDGF-A by comparing the transgenic mice generated by overexpression of these genes, 
due to the differences in promoter strength and transgenic copy numbers among these mice, 
these studies have suggested that the glioma-specific long-form PDGF-A may exert its 
tumorigenic effects through distinct signaling pathways than that stimulated by the PDGF-B and 
short-form PDGF-A (163). 
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1.5.5.2  Virus-induced GEMs 
Other GEM models of PDGF-induced glioma development have also been reported, most of 
which involved a single intracranial injection of retroviruses expressing PDGF-B ligand (Table 1) 
(164-168), targeted either nonspecifically, or to astrocytes (GFAP-positive) or neural progenitor 
cells (Nestin-positive) using cell type-specific promoters. In these studies, PDGF-B 
overexpression alone induces glioma growth from various cell types including glial progenitor 
cells, astrocytes, and neural progenitor cells, and the tumors frequently exhibited characteristics 
of oligodendrogliomas or mixed oligoastrocytomas (Table 1). These two models, the germ-line 
transgenic and retrovirus induction models, differ in many ways such as the incidence of 
tumorigenesis and histological features. The discrepancies may be due to different time of 
stimulation during animal development, different targeted cells, or retroviral-mediated 
insertional mutagenesis in genes that cooperate with PDGF to induce tumorigenesis (169). 
Additionally, the local injection of various agents including cells or viruses into the brain of mice 
may induce proliferation of VEGF-expressing Olig2-positive glial cells and a local increase of 
angiogenesis (170, 171). These factors may contribute to the differential tumor induction 
potentials observed in these models where PDGF-B alone was targeted to GFAP-positive cells in 
the brain. Despite the differences between the transgenic and the virus-mediated models, an 
increase in tumor malignancy by concomitantly introducing a loss of p53 function or Ink4a/Arf 
locus was evident in all studies (Table 1) (162, 165, 168, 172), demonstrating a cooperative 
effect of PDGF overexpression and disruption of p53 or RB pathway in glioma tumorigenesis. 
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Table 1. Summary of Animal Models of PDGF-induced Spontaneous Brain Tumor Formation 
 
Method Vector PDGF Strain Age Target Histology Ref 
                
        
Virus Sup 
I.C. Inj MoMuLV PDGF-B C57BL/6 Neonatal 
Non-
specific 
GBM / 
PNET (164) 
Virus Sup 
I.C. Inj MoMuLV PDGF-B p53
-/-
 Neonatal 
Non-
specific 
GBM / 
PNET (172) 
Virus Sup 
I.C. Inj MoMuLV PDGF-B Ink4a/Arf
-/-
,  Neonatal 
Non-
specific 
GBM / 
PNET (172) 
Packaging 
Cell I.C. Inj RCAS PDGF-B Ntv-a Neonatal nestin+  
Low-grade 
Oligo (165) 
Packaging 
Cell I.C. Inj RCAS PDGF-B Ntv-a, Ink4a/Arf
-/-
 Neonatal nestin+  
Anaplastic 
Oligo 
(163, 
165) 
Packaging 
Cell I.C. Inj RCAS PDGF-B Gtv-a Neonatal gfap+  
Low-grade 
Oligo / 
Oligoastro (165) 
Packaging 
Cell I.C. Inj RCAS PDGF-B Gtv-a, Ink4a/Arf
-/-
 Neonatal gfap+  
Anaplastic 
Oligo / 
Oligoastro (165) 
Packaging 
Cell I.C. Inj RCAS PDGF-B Gtv-a, p53
-/-
 Neonatal gfap+  
Low-grade 
Oligo / 
Oligoastro (165) 
Packaging 
Cell I.C. Inj RCAS 
ACC-  
PDGF-B-
HA Ntv-a Neonatal nestin+  
High-grade 
Oligo (137) 
Virus Sup 
C.C. Inj 
pQ 
(Retroviral) PDGF-B 
Sprague Dawley 
Rat Adult 
Non-
specific GBM (166) 
Virus Sup 
L.V. Inj 
pQ 
(Retroviral) PDGF-B 
Sprague Dawley 
Rat Neonatal SVZ  GBM (173) 
Packaging 
Cell L.V. Inj 
pCEG 
(Retroviral) PDGF-B C57BL/6 E14 SVZ 
High-grade 
Oligo 
(99) 
(167) 
Protein L.V. 
Infusion NA PDGF-A CD-1 Adult SVZ  
Low-grade 
Glioma (104) 
Zygote 
Pronuclear 
Inj  IRES?GEO PDGF-B 
Transgenic 
hGFAPpPDGFB, 
p53
-/-
 E0 gfap+  
GBM / 
High-grade 
Oligo (162) 
Zygote 
Pronuclear 
Inj  IRES?GEO PDGF-A(L) 
Transgenic 
hGFAPpPDGFA E0 gfap+  
Grade III 
Oligoastro (163) 
 
Abbreviations: I.C., intracerebral; C.C., corpus callosum; L.V., lateral ventricle; Inj., injection; Oligo, 
oligodendroglioma; Oligoastro, oligoastrocytoma; PDGF-A(L), PDGF-A long form. 
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1.5.5.3  Other Model Systems 
Sleeping Beauty Animal Model—A relatively new mouse model of generating de novo brain 
tumors using stereotactic injection of non-viral plasmid DNA into the brain of neonatal mice has 
been developed (174). In this model, a single injection of DNA plasmids encoding a Sleeping 
Beauty (SB) (175) transposable element, gene(s) of interest, and SB transposase into the lateral 
cerebral ventricle is performed on newborn mice. The tumors generated in this model can then be 
monitored by bioluminescent imaging of luciferase expression and the differences in tumor 
incidence in various mouse strains appear to be minimal (174). This approach, combined with 
the use of Cre-loxP system, is possible to restrict expression of various genes in a cell type-
specific manner (176). However, as in virus-mediated models, transposon-mediated mutagenesis 
and injection-induced reactive gliosis will also complicate the use of this system for pre-clinical 
testing. Whether PDGF overexpression via the SB transposon system in the mouse brain 
generates gliomas comparable to those in other animal models has not been determined yet.  
 
Xenograft Model—The traditional and most commonly used model of tumor formation is 
transplantation of human or mouse tumor cells into the immuno-deficient mice. Most of the 
evidence of interactions between specific signaling molecules and the PDGF pathway have been 
obtained from the human or mouse cell line models. Despite their limitation in recapitulating the 
human cancers, these models still play an important role in understanding the molecular 
mechanisms of tumor development and activity of therapeutic anti-cancer agents (177, 178). In 
fact, studies have shown that in many aspects human tumor cell line xenograft model may better 
predict the tumorigenesis processes that occurred in humans than do various mouse models (179, 
180), owing to the dramatic differences between mouse and human in genetics, tumor 
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susceptibility, and tumor microenvironment. A combination of human and mouse models to 
understand brain tumors and to design better therapeutic strategies might be necessary in the 
post-cancer-genomic era (181). 
 
1.5.5.4  PDGF Downstream Signaling and Gliomagenesis Revealed by Animal Models 
Using RCAS/tv-a system, Dai and colleagues have shown that combined activation of Akt and 
K-Ras generated astrocytomas while PDGF-B overexpression led to mostly oligodendrogliomas 
(182). They further showed that blockade of mTOR pathway converted PDGF-B-induced 
oligodendrogliomas into astrocytoma-like tumors (183). Thus it appears that, in the RCAS/tv-a 
system, PDGF-B and Ras/Akt/mTOR signaling pathways promote formation of distinct 
histological types of tumors in the mouse brain. However, in human gliomas, as shown by a 
proteomic study, activation of mTOR and RAS/ERK pathways frequently co-occurred in the 
PDGF-B-enriched subgroup (143), and two out of four oligodendrogliomas in this study were of 
the PDGF-B/mTOR/RAS activation subtype, suggesting that in human gliomas, a more complex 
connection between PDGF signaling and tumor cell lineage specification may exist than that 
found in the mouse models. Additionally, since there was no concomitant overexpression of 
PDGFR? in tumors generated from RCAS/tv-a-mediated PDGF-B expression, it will be 
interesting to determine whether targeted co-overexpression of PDGFR? and PDGF-B in the 
mouse brain will generate gliomas with same histopathological characteristics, as does PDGF-B 
alone.  
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1.6 PDGF SIGNALING IN OTHER BRAIN TUMORS 
 
1.6.1 Pediatric Gliomas 
 
Gliomas in children differ from those in adults in terms of location, frequency, and progression 
patterns, which may result from distinct cell of origin, genetic susceptibility, or tumor 
microenvironment present in relatively immature developing brain (3). However, focal 
amplification of PDGFRA, together with deletion of CDKN2A locus, was also found in high 
frequency in childhood gliomas, especially in pediatric high-grade gliomas (HGGs) (184), 
whereas other common alterations in the adults such as EGFR amplification/mutation and PTEN 
mutations are less frequent in pediatric HGGs (185), suggesting different cell of origin in 
pediatric from adult tumors. It is likely that the developing brain harbors more PDGF-responsive 
cells, which in the presence of additional genetic alterations such as TP53 mutations or CDKN2A 
deletion, are responsible for gliomagenesis in the childhood brain. The most common childhood 
glioma is the lower-grade juvenile pilocytic astrocytoma.  Studies have suggested that the cell of 
origin of this type of brain tumor is likely the human counterpart of the O-2A progenitor cells in 
the rat brain (80, 186, 187), which express both NG2 and PDGFR?. The presence of these 
lineage markers is reminiscent of the adult oligodendrogliomas (187). Whether these adult and 
childhood gliomas share the same or closely related cell of origin warrants further investigation.  
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1.6.2 CNS Primitive Neuroectodermal Tumors 
 
Primitive neuroectodermal brain tumors (PNETs), including medulloblastomas (cerebellar 
PNET), are the most common malignant brain tumor of childhood (3). They are highly invasive 
and often metastasize within the CNS prior to diagnosis. The cell of origin of medulloblastomas 
are likely multipotential cells residing in the EGL of cerebellum that can generate both neurons 
and glial cells (188). Studies on normal CNS development often enlighten understanding of the 
tumor initiation and progression. In normal neurogenesis, PDGF was reported to play an 
important role in the differentiation of premature neuroepithelial cells into neuronal lineage cells 
(189). In medulloblastoma tissues and cultured cell lines, PDGF ligands and receptors are also 
expressed at high levels (190-193). In particular, aberrant PDGFR? activation/expression was 
associated with abnormal neuronal development and likely the cause of medulloblastoma 
formation (107, 191, 193). Interestingly, microarray profiling of clinical medulloblastoma 
specimens revealed that PDGFRA expression levels corresponded to the degree of tumor 
metastasis (192), suggesting that PDGF signaling is responsible for the mobility of 
medulloblastoma cells within the CNS. Indeed, in vitro studies also showed that migration of 
cultured medulloblastoma cells relied on the PDGFR/ERK signaling cascade (194). The 
activation of PDGFR? in the medulloblastoma cells, however, appears to be largely associated 
with PDGF-C expression (193). In the CNS of mouse embryo, PDGF-C was exclusively 
expressed in the EGL of the cerebellum (113). Therefore, a PDGFR?/PDGF-C autocrine loop is 
most likely the driving force for medulloblastoma formation from premature neuronal precursors 
in the cerebellum, although further studies using animal models are required to test this 
hypothesis. 
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1.6.3 Ependymal Tumors 
 
Ependymomas are derived from ependymal cells lining the ventricular system in the CNS. The 
infratentorial ependymomas (in the brain) occur mostly in younger adults and children (3). Early 
studies using northern blot analysis has detected PDGFR? and PDGF-A mRNAs expression in 
human ependymoma tissue (195). Little is known about the significance of PDGF signaling in 
the development of these tumors. A large-scale genomic analysis of gene expression signature in 
clinical ependymomas suggested that the ependymoma initiating cells are embryonic radial glia 
(RG)-like cells (196, 197). In mouse embryos, RG cells are important for migration of 
PDGFR?/NG2-positive glial progenitor cells as well as neurons (198). Whether PDGF signaling 
plays a role in malignant transformation of these ependymoma stem cells is unknown.  
 
1.6.4 Meningeal Tumors 
 
Meningiomas are slow-growing intracranial tumors and mostly benign. However, the higher-
grade meningiomas are more aggressive and frequently recur after surgical removal of the 
primary tumors, and may be fatal upon relapse (3). Early studies showed that PDGF-A, PDGF-B, 
and PDGFR?, but not PDGFR?, mRNAs and proteins were detected in high levels on human 
meningioma tissues (199-201). Subsequent study further demonstrated the presence of 
phosphorylated/activated PDGFR? in meningiomas, indicating that autocrine stimulation of 
PDGF signaling is responsible for proliferation of this tumor (202). More recently, high 
throughput IHC-based tissue array identified PDGFR? as a useful biomarker for high-grade 
anaplastic meningiomas (203). Several in vitro studies also complemented these observations by 
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showing that PDGF-BB can stimulate downstream signaling and growth of the cultured 
meningioma cells (204). In particular, MAPK (205) and PI3K/AKT/S6K (206) pathways likely 
represent the major transducers of PDGF signaling in inducing the growth of human 
meningiomas. Interestingly, in some rare cases of patients with concurrent GBM and 
meningioma at adjacent sites, PDGFR? and PDGFR? were highly expressed in both tumor 
types, implying a possible causal role of paracrine PDGF that induces formation of one type of 
tumor by another (207). 
 
 
1.7 PDGF-TARGETED THERAPIES 
 
Decades of research performed on malignant gliomas have provided a better picture of the 
molecular alterations that frequently occurred in the tumor cells. The large-scale genomic 
profiling of GBMs such as the TCGA project identified PDGFRA as one of the most frequently 
altered genes in GBMs (10, 11). And the Proneural subtype of GBMs that frequently harbor 
PDGFRA alterations are the most resistant to standard chemo-/radiotherapy (11). Molecular 
therapies targeting PDGFR have been under intensive investigation both in preclinical animal 
models and in clinical trials (208). Most of the anti-PDGF therapies under investigation involve 
the use of small molecule tyrosine kinase inhibitors, which bind to the ATP-binding pocket of 
the PDGFR kinase domain. However, there is no kinase inhibitor that specifically binds to 
PDGFR? or ?. Various tyrosine kinase inhibitors in development that are able to cross-target 
PDGFRs as well as a PDGFR?-specific neutralizing monoclonal antibody will be discussed 
here. 
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1.7.1 Imatinib mesylate 
 
Imatinib mesylate (Gleevec, formally STI-571) blocks the ATP binding site of tyrosine kinases 
and is a multiple tyrosine kinase inhibitor targeting PDGFRs, c-Kit, c-Fms, and Bcr-Abl. It was 
initially developed for treatment of Philadelphia chromosome-positive chronic myeloid leukemia 
(CML) with constitutive activation of Bcr-Abl (209), and was later investigated for its anti-tumor 
activity against other types of cancers including malignant gliomas. In preclinical models using 
human glioma-derived cell lines implanted into brain of nude mice, imatinib dramatically 
decreased the size of tumor and prolong survival of mice (210, 211). However, several phase II 
clinical trials of imatinib monotherapy for recurrent gliomas have been disappointing (Table 2) 
(212-214). In one study with 55 patients, the 6-month PFS (PFS-6) was 3% for GBMs and 10% 
for anaplastic gliomas (212); in another one that enrolled 112 patients, PFS-6 was 16% for 
GBMs, 4% for oligodendrogliomas, and 9% for anaplstic astrocytomas (213). The minimal 
responses of gliomas to imatinib were not likely due to the poor accessibility of the tumor mass 
to the drug, since intact imatinib was detected in post-treatment tissue specimens (214). IB 
analyses performed on pre- and post-imatinib treatment biopsies revealed that p-Akt and p-Erk 
levels were not decreased in most of the specimens. However, cautions should be taken in 
interpreting these results since most of the pre-treatment tumors in this study expressed low or 
undetectable levels of PDGFR? by IB anslysis (214). Interestingly, in one of the tumors with 
decreased PDGFR? level after imatinib treatment, there were concomitant increases of EGFR, 
Akt, and Erk activation (214), suggesting that inhibition of one RTK may activate another, and 
the same set of downstream effectors may be activated by redundant RTK signaling (215). In 
addition, intratumoral hemorrhage observed in some of the glioma patients that received imatinib 
  40 
treatment was another factor that may affect the interpretation of the efficacy of imatinib (212). 
The cause of the hemorrhage was believed to be the off-target inhibition of PDGFR? in the 
normal perivascular cells in the brain (212). Based on these studies, the efficacy of imatinib as a 
single agent appears to be limited, at least in unselected patients with recurrent GBMs. Imatinib 
treatment of pre-selected glioma patients with PDGFR expression, however, yielded promising 
results, with a PFS-6 of 32.4% (18).  
Due to the disappointing results from imatinib monotherapy, new clinical trials have been 
focusing on testing the efficacy of imatinib in combination with chemotherapy drugs. The 
strategy is promising in that imatinib was shown to modulate the tumor interstitial hypertension 
(216), multidrug resistance transporter ABCG2 (217), and angiogenesis processes (218), 
conferring higher drug uptake into tumor cells. In initial phase II trials using a combination of 
imatinib and hydroxyurea (219, 220) for patients with recurrent grade III gliomas or GBMs, the 
efficacy of imatinib plus hydroxyurea were encouraging. However, the following phase II and III 
studies on unselected recurrent GBM patients again did not show clinical meaningful anti-tumor 
activity (Table 2) (221, 222). To improve the delivery of TMZ into the tumor, imatinib was also 
used in combination with TMZ in a clinical trial. In vitro, imatinib plus TMZ elicited a 
synergistic anti-tumor effect on cultured human glioma cell lines (223). In the phase I clinical 
trial, dose-intensive imatinib plus TMZ were well tolerated and showed durable anti-tumor 
activity in some of the glioma patients (Table 2) (224), although more definitive results need to 
be obtained from the subsequent phase II study. Imatinib has also been investigated for its anti-
tumor activity against other brain tumors. In vitro imatinib was able to inhibit PDGF-B-mediated 
Akt and Erk activation, and tumor cell migration and invasion of human medulloblastoma cell 
lines (225), whereas the effect of imatinib on clinical medulloblastomas is unknown. Also in a 
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phase I trial, imatinib doses have been determined for pediatric newly diagnosed brainstem 
gliomas and recurrent HGG (226). The efficacy of imatinib in treating childhood gliomas will 
necessitate design of a subsequent phase II study. 
 
Table 2. Summary of PDGF-targeted Therapies (Updated 4/14/2011) 
      
Generic 
Name Other Names 
Targeted 
Molecules 
Combination 
Drugs 
Completed and Ongoing Clinical 
Trials References 
            
      
Imatinib 
Mesylate  
Gleevec  
Glivec  
PDGFRs 
c-Kit 
Monotherapy 
 
Unsatisfactory (Low PFS in Phase II) 
 
(212), (213), 
(214) 
 
STI-571 
CGP 57148 
c-Fms 
Bcr-Abl 
Monotherapy 
 
Ongoing Phase I/II trial on recurrent 
brain tumor 
clinicaltrials.gov 
 
   
Hydroxyurea 
 
Unsatisfactory (Low anti-tumor 
activity in Phase II/III) 
(219), (221), 
(221), (222) 
   
Hydroxyurea 
 
Ongoing Phase II trial on low-grade 
gliomas 
clinicaltrials.gov 
 
   
Hydroxyurea  
+ Zactima  
Ongoing Phase I trial on recurrent 
gliomas 
clinicaltrials.gov 
 
   
TMZ  
 
Encouraging (Durable anti-tumor 
activity in Phase I) 
(224) 
 
         
      
Sunitinib 
Malate 
SU11248 
Sutent 
PDGFR? 
VEGFR2  
Monotherapy 
 
Unsatisfactory (Low anti-tumor 
activity in Phase II) 
(227) 
 
  
c-Kit  
FLT3 
Monotherapy 
 
Several ongoing Phase II trials on 
recurrent AAs and GBMs 
clinicaltrials.gov 
 
   
Cilengitide 
 
Pilot feasibility study on GBMs 
 
clinicaltrials.gov 
 
            
      
Cediranib 
Maleate  
AZD2171 
Recentin 
PDGFRs 
VEGFRs  
Monotherapy 
 
Encouraging (high PFS but with 
aggressive recurrences in Phase II) 
(228) 
 
  
c-Kit 
 
RO4929097 
 
Ongoing Phase I trial on advanced 
brain tumors 
clinicaltrials.gov 
 
   
Lomustine 
 
Ongoing Phase III trial on recurrent 
GBMs 
clinicaltrials.gov 
 
   
Bevacizumab 
 
Ongoing Phase I trial on GBMs 
 
clinicaltrials.gov 
 
   
Gefitinib 
 
Ongoing Phase II trial on recurrent or 
progressive GBMs 
clinicaltrials.gov 
 
   
TMZ + X-ray 
 
Ongoing Phase II trial on newly 
diagnosed GBMs 
clinicaltrials.gov 
 
   
Cilengitide 
 
Ongoing Phase I trial on recurrent or 
progressive GBMs 
clinicaltrials.gov 
 
            
      
Vatalanib 
 
PTK878 
ZK 222584  
PDGFRs 
VEGFR1 and 2 
TMZ + 
Radiation 
Encouraging (Phase I/II with high 
PFS but discontinued) 
(229) 
 
 
CGP-79787 
 
c-Kit 
c-Fms 
TMZ + 
Radiation 
Ongoing Phase I trial on newly 
diagnosed GBMs 
clinicaltrials.gov 
 
   
Imatinib + 
Hydroxyurea 
 Well-tolerated in Phase I 
 
(230) 
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Table 2 (Continued) 
     
Sorafenib 
Tosylate 
Nexavar 
BAY 43-9006 
PDGFR? 
VEGFR2  
Monotherapy 
 
Ongoing Phase I trial on recurrent or 
progressive GBMs 
clinicaltrials.gov 
 
  
c-Kit 
FLT 
TMZ  
 
Unsatisfactory (Low anti-tumor 
activity in Phase II) 
(231), (232) 
 
  
Raf 
 
TMZ + 
Radiation 
Several ongoing Phase I/II trial on 
newly diagnosed GBMs 
clinicaltrials.gov 
 
   
Temsirolimus 
 
Ongoing Phase I/II trial on recurrent  
GBMs 
clinicaltrials.gov 
 
   
Erlotinib + 
Temsirolimus  
Ongoing Phase I/II trial on recurrent  
GBMs 
clinicaltrials.gov 
 
      
 + Tipifarnib 
     
      
Pazopanib 
hydrochloride  
Votrient 
GW786034 
PDGFRs 
VEGFR1, 2, 3 
Monotherapy 
 
Unsatisfactory (Low PFS in Phase II) 
 
(233) 
 
  
c-Kit 
 
Lapatinib 
 
Ongoing Phase II trial on relapsed  
malignant gliomas 
clinicaltrials.gov 
 
      
      
Tandutinib  
MLN-518 
CT53518 
PDGFRs 
FLT3 
Monotherapy 
 
Ongoing Phase I/II trial on recurrent 
or progressive GBMs 
clinicaltrials.gov 
 
  
c-Kit 
 
Bevacizumab 
 
Ongoing Phase II trial on recurrent 
brain tumors 
clinicaltrials.gov 
 
            
 
Abbreviations: FLT, c-Fms-like tyrosine kinase; AA, astrocytoma. 
 
1.7.2 Sunitinib malate 
 
Sunitinib malate (SU11248 or Sutent) is a potent multiple tyrosine kinase inhibitor that targets 
PDGFR?, VEGFR2, c-Kit, Fms-like tyrosine kinase 3 (FLT3), and several other kinases (234). 
Like imatinib, sunitinib showed significant anti-tumor and anti-angiogenic activities in cultured 
human glioma cell lines in vitro as well as orthotopic mouse model in vivo (235). However, in a 
phase II study in patients with recurrent high-grade gliomas, sunitinib showed minimal efficacy 
as a monotherapy (Table 2) (227). Neither the gene copy number nor the protein expression of 
PDGFR?, VEGFR, or c-KIT was able to predict the response to sunitinib treatment. In 
medulloblastomas, sunitinib was also shown to display a potent activity against tumor cell 
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migration and survival in vitro (236). Whether this observation reflects its anti-tumor activity in 
the clinical medulloblastomas is not known. 
 
1.7.3 Cediranib maleate 
 
Cediranib maleate (AZD2171 or Recentin) is a potent inhibitor for PDGFR? and ?, VEGFRs, 
and c-Kit (237). A phase II study of cediranib in patients with recurrent GBMs has been 
performed (Table 2) (228). The results were encouraging with a PFS-6 of 25.8%. However, a 
recent finding suggested that potentially more aggressive tumors were able to recur after 
cediranib treatment of GBM patients (154). These recurrent tumors expressed increased onco-
proteins such as PDGF-C and c-Met, harbored more tumor-infiltrating myeloid cells (TIMs), and 
were potentially more aggressive than the untreated tumors (154). Thus whether cediranib 
monotherapy is a viable treatment option for GBM patients needs further investigations.  
The abnormal tumor vasculature is one of the cause of poor drug delivery to the tumor 
mass. The ability of cediranib or similar VEGFR/PDGFR inhibitors to normalize the tumor 
vessels (238) thus suggests that cediranib may potentially increase the efficacy of chemotherapy 
using cytotoxic drugs. A phase I/II clinical trial is currently being conducted using this regimen 
in patients with newly diagnosed GBMs (Table 2) (see http://clinicaltrials.gov/ for more 
information).  
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1.7.4 Vatalanib 
 
Vatalanib (or PTK878/ZK 222584) is an inhibitor for PDGFRs, VEGFR1 and 2, c-Kit, and c-
Fms (237). In preclinical models, vatalanib effectively suppressed PDGF- or VEGF-induced 
tumor growth (239, 240). The initial phase I/II trial using concomitant and adjuvant TMZ and 
radiotherapy with vatalanib showed promising results, with a PFS-6 of 63.2% (Table 2) (229). 
Although the initial trial was discontinued, a separate phase I trial using the similar regimen on 
newly diagnosed GBM patients have been initiated (Table 2) (see http://clinicaltrials.gov/ for 
more information). 
 
1.7.5 Sorafenib 
 
Sorafenib tosylate (or Nexavar/BAY 43-9006) is multiple kinase inhibitor against PDGFR?, 
VEGFR2, c-Kit, FLT, and Raf (237). Sorafenib was shown to exhibit significant anti-tumor 
activity in human glioma- or medulloblastoma-derived cell lines both in vitro and in vivo in 
orthotopic xenograft transplantation models, mechanisms of which were likely due to the 
inhibition of STAT3 activity in these cells (241-243). However, phase II studies using sorafenib 
with TMZ in newly diagnosed GBM or recurrent GBM patients were discouraging (Table 2) 
(231, 232). Several phase I/II studies are being conducted using either in monotherapy or in 
combination with other treatment modalities (Table 2) (see http://clinicaltrials.gov/ for more 
information). 
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1.7.6 Pazopanib hydrochloride 
 
Pazopanib hydrochloride (Votrient or GW786034) is a multi-targeted inhibitor for PDGFRs, 
VEGFR1, 2, 3, and c-Kit (237). It has been approved for treatment of advanced or metastatic 
renal cell carcinomas (8). In recurrent GBMs, a phase II trial of single-agent pazopanib did not 
show a dramatic improvement in these patients, with a PFS-6 of only 3% (Table 2) (233). More 
studies are needed to test whether combination therapy using pazopanib can exert a better anti-
tumor effect. 
 
1.7.7 Tandutinib 
 
Tandutinib (formally MLN-518) is an orally active inhibitor of FLT3, PDGFRs, and c-Kit (244). 
Several phase I/II trials are being conducted using tandutinib mono- or combination therapy 
(Table 2) (see http://clinicaltrials.gov/ for more information). However, toxicity to the 
neuromuscular junctions has been reported and may discourage the use of this drug in certain 
patients (245).  
 
1.7.8 Other PDGF-targeted Agents 
 
There are numerous other tyrosine kinase inhibitors that are under development or in clinical 
trials to determine their efficacy against malignant brain cancers. Dasatinib (or Sprycel) is a 
potent multiple tyrosine kinase inhibitor that targets PDGFRs, c-Kit, Bcr-Abl, and SFKs (234). 
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Due to its potent activity against Src phosphorylation, it may be effective in treatment of patients 
with p-Src positive tumors (246). A novel multiple tyrosine kinase inhibitor, SU14813, inhibits 
phosphorylation of VEGFR-2, PDGFR?, and FLT3, and exerted a potent anti-tumor effect in a 
pre-clinical xenograft glioma model (247). Clinical evaluations of its efficacy in glioma patients 
are underway. SU6668 is an inhibitor of Flk-1, FGFR, and PDGFR?. Preclinical studies of 
SU6668 in human xenografts of gliomas yielded promising results, with significant inhibition of 
growth of C6 glioma cells and suppression of angiogenesis (248). It is currently under 
investigation for its clinical performance in various solid tumors. PDGF-targeted monoclonal 
antibodies have also been developed for treatment of various cancers including gliomas. One 
fully human neutralizing monoclonal antibody that targets specifically PDGFR? but not 
PDGFR? was developed and showed significant anti-tumor effect against human GBM cell line 
xenograft (249). A phase II trial using this antibody for treating patients with recurrent GBMs is 
being conducted to evaluate its clinical efficacy (250) (also see http://clinicaltrials.gov/ for more 
information). 
 
1.7.9 Lessons Learned From Clinical Trials 
 
Although PDGF targeted therapies using various tyrosine kinase inhibitors have been extensively 
studied over the past few years, the results were generally disappointing and have yet to shift the 
standard clinical treatment of GBMs, which encompasses maximal surgical resection, followed 
by TMZ and radiation (251). Several factors might be contributing to the failure of these PDGF-
targeted inhibitors in GBM treatment. First, delivery of drugs to the tumors in the brain was 
limited or insufficient to mount an effective anti-tumor response. The specialized structure of 
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BBB is one of the impediments that restrict the penetration of therapeutic drugs into the brain 
parenchyma (252). Second, brain tumor, especially malignant glioma, cells are highly infiltrative 
(2). Perhaps tumor cells were disseminated throughout the brain parenchyma prior to the 
administration of various PDGF inhibitors. Third, tumors in the patients of clinical studies might 
not respond to PDGF inhibition due to a lack of PDGFR expression/activation in the tumors. 
Thus, pre-selection of enrolled patients that will potentially benefit from anti-PDGF treatment 
should be performed in each clinical trial to more accurately determine the efficacy of anti-
PDGF treatments. A personalized treatment options should be provided for each individual in the 
future studies. Fourth, as suggested by its name, GBM is a disease of mixed cell types and 
genetic alterations. Heterogeneity of GBMs is another major factor that significantly decrease the 
efficacy of targeted therapies. Additionally, inhibition of one pathway may activate another one 
to either compensate (215) or substitute for (154, 253) the inhibited signaling molecules. The 
relapsed tumors are potentially more aggressive, resistant to the original therapies, and often lead 
to a rapid death of the patients. Fifth, the efficacy of PDGF-targeted therapies might also be 
reduced by multiple off-target effects of these agents on normal brain cells. One example is the 
intratumoral hemorrhage caused by off-target inhibition of PDGFR? expression in normal peri-
vascular cells observed in some of the glioma patients that received imatinib treatment (212). 
Lastly, the small population of CD133-positive CSC (254) identified in the brain tumor may 
represent another source of tumor recurrence after anti-PDGF treatment. Targeted therapies such 
as anti-PDGF inhibitors are expected to eliminate the tumor cells that are “addicted” to the 
targeted signaling pathways for survival and proliferation, but might leave the relatively dormant 
CSCs intact. These CSCs were later able to self-renew and differentiate into tumor cells that may 
acquire distinct properties and genetic aberrations from those of the primary tumors. All these 
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and other factors make the PDGF-targeted therapy an even more challenging issue than was 
previously thought. 
 
1.7.10 Future Directions 
 
Despite significant anti-tumor effect of various PDGF-targeted therapies in pre-clinical animal 
model testing, the results of subsequent clinical trails were often disappointing. In order to design 
therapeutic strategies that can benefit patients with brain tumors driven and maintained by PDGF 
signaling, more thorough pre-clinical studies are required. Various animal models that are 
candidates for this purpose have been proposed (255). Additionally, identification of new 
potential molecular targets in tumors induced by PDGF signaling is also important. The 
application of systems biology to the genomic data obtained from patient samples is expected to 
aid in this process (207). To generate a network of genes that share a regulatory program, the 
commonly altered genes in GBM were grouped into several functional “modules.” The 
interactions between each cancer-altered gene and other non-altered “linkers” can be identified 
within and among different modules (143). The SHP-2/PTPN11 was identified in this network 
approach as one of the six linkers, and was also shown to be important in the PDGF-driven 
gliomagenesis in our model (150). Molecules such as SHP-2/PTPN11 that are not commonly 
overexpressed or mutated in GBMs and are often understudied. However, several signaling 
pathways may converge on these molecules to exert downstream functions. Besides its 
involvement in regulating the PDGFR?/PI3K/Akt pathway in gliomas (150), SHP-2 has also 
been known to mediate EGFR/PI3K/Akt signaling (256) and downstream of Ras/MAPK 
pathway (257). Thus it represents one of the molecules loss of which may lead to disruption of 
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multiple signaling cascades involved in tumorigenesis. As tumors are now considered to be 
rather “network-addicted” than single “oncogene-addicted” (258), perhaps strategies targeting 
such a molecule in monotherapy or in combination with other cytotoxic drugs will prove more 
efficient than targeting multiple upstream RTKs. With the recent advances in the large-scale 
whole-genome profiling of GBMs, we expect that more promising targets like these can be 
uncovered. However, preclinical studies of various targeted pharmacological drugs require a 
more stringent selection of animal models that can most accurately re-capitulate the human 
tumors in every aspect. Additionally, personalized medicine should be given to each individual 
exploiting data gained from genomic profiling and systems biology. 
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2.0 PDGFRA OVEREXPRESSION COOPERATES WITH P16INK4A LOSS TO 
PROMOTE GLIOMA FORMATION FROM MOUSE ASTROCYTES OR HUMAN 
GLIOMA CELLS 
 
 
2.1 INTRODUCTION AND RATIONALE 
 
GBM is the most common and malignant tumor in the CNS. The prognosis of patients with this 
cancer remains dismal despite intensive treatments and care. A better understanding of the 
mechanisms of tumorigenesis is necessary to design more efficient therapeutic strategies. The 
recent advance in high-throughput genomic analysis technology has made possible to analyze 
GBM genomes in large scale (10). Although cancer genomics is still in its infancy and yet to 
impact the standard clinical treatments, studies have been underway to functionally validate the 
knowledge we gained from these genomic data in the hope that it will ultimately be routine to 
characterize the GBM genomes of each patient, and provide patients with personalized 
medications.  
Notably among the most frequently altered genes in GBMs, the gene encoding PDGFR? 
was amplified in ~13% of the total GBMs analyzed, and deletion of the tumor suppressor 
CDKN2A locus was frequently found in these PDGFR? amplified GBMs (10) (11). Most of the 
animal models of PDGF-induced gliomagenesis involve overexpression of PDGF-B chain in the 
mouse brain. The potential of PDGF-A chain, however, was relatively unexplored despite its 
  51 
frequent co-overexpression with the PDGFRA gene and important role in glial progenitor cell 
development. The PDGFR?-positive progenitor cells that respond to PDGF stimulation can be 
found in various parts of the adult brain (104, 162, 166). Exogenous PDGF-A infusion into the 
adult SVZ induces the PDGFR?-positive neural progenitor cells to generate glioma-like lesion in 
the mouse brain (104). Compared with PDGF-B homodimer, PDGF-A only binds to PDGFR? 
but not PDGFR?, making it a less potent tumor inducer than PDGF-B. Indeed, mouse 
transplanted with PDGF-B overexpressing Ink4a/Arf-null astrocytes developed tumors with 
shorter latency and increased malignancy (by our lab, unpublished data). These tumors also 
displayed high angiogenic characteristics with a high degree of microvascular proliferation, 
further demonstrating the role of PDGF-B/PDGFR? in tumor angiogenesis (66, 69), one 
mechanism of which may involve modulation of VEGF expression in the tumor 
microenvironment by PDGF-B in a paracrine manner (259). In order to determine which 
signaling pathway(s) downstream of PDGFR? is necessary for its oncogenic capacity, our lab 
chose PDGF-A instead of PDGF-B in that PDGF-A can only stimulate PDGFR? but not 
PDGFR?. To investigate how PDGF-A-mediated PDGFR? activation contributes to glioma 
formation, we utilized an orthotopic transplantation model, in which we implanted various PDGF 
receptor or ligand overexpressing human or mouse cells into the brain of mice to assess their 
tumorigenic potentials (150). Furthermore, we utilized cells harboring another frequently co-
altered genetic lesion, the Ink4a/Arf deletion, to demonstrate cooperation between this and the 
PDGFRA amplification during the glioma development. 
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2.2 MATERIALS AND METHODS 
 
2.2.1 Cell Lines and Reagents 
 
Primary Ink4a/Arf
-/- 
mAst were derived and propagated as previously described (45). Human 
glioma cell lines, LN444, LN443, LN-Z308, and LN319, were obtained from American Cell 
Type Culture Collection (Manassas, VA) or from our own collection (260). Unless otherwise 
mentioned, all glioma cell lines and primary mAst were routinely maintained in 5% CO2 at 37°C, 
in DMEM (Invitrogen) containing 10% FBS (Hyclone), 100 units/ml penicillin, and 100 μg/ml 
streptomycin (Invitrogen).  
The following antibodies and reagents were used in this study: rabbit anti-PDGFR? (sc-
338, 1:500 for IB; 1:50 for IHC), rabbit anti-PDGF-A (sc-128, 1:500 for IB; 1:50 for IHC), 
rabbit anti-p16 (sc-759, 1:500), and goat anti-?-actin (sc-1616, 1:500) antibodies were from 
Santa Cruz Biotechnology Inc., Santa Cruz, CA; a rabbit anti-phospho-RB (Ser807/811, #9308, 
1:1000) antibody was from Cell Signaling Technology, Danvers, MA; mouse anti-nestin 
(MAB353, 1:100), rabbit anti-GFAP (AB5804, 1:500), rabbit anti-NG2 (AB5320, 1:100), and 
mouse anti-phosphotyrosine (clone 4G10, #05-321, 1:1000) antibodies were from Millipore, 
Temecula, CA; a mouse anti-neuronal class III ?-tubulin (clone TUJ1, MMS-435P, 1:250) 
antibody was from Covance, Richmond, CA; a mouse anti-SHP-2 (610621) antibody was from 
BD Biosciences, San Jose, CA; a mouse anti-p14/ARF (P2610, 1:500) antibody was from 
Sigma-Aldrich, St. Louis, MO; a mouse anti-p53 (OP33, 1:500) antibody was from EMD 
Chemicals, Gibbstown, NJ; a rabbit anti-Ki67 antigen (NCL-Ki67p, IHC, 1:200) antibody was 
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from Leica Microsystems Inc., Bannockburn, IL; Matrigel
TM
 Basement Membrane Matrix, 
Growth Factor Reduced (GFR) (#356230) was obtained from BD Biosciences, San Jose, CA; 
CDK inhibitor PD0332991 (S1116) was from Selleck Chemicals, Houston, TX; Cisplatin 
(C3374) was from LKT Laboratories, Inc., St. Paul, MN. All secondary antibodies were from 
Vector Laboratories (Burlingame, CA) or Jackson ImmunoResearch Laboratories (West Grove, 
PA). All other reagents were from Invitrogen, Sigma-Aldrich, or Fisher Scientific. 
 
2.2.2 Retroviral and Lentiviral Constructs and Infections 
 
The retroviral vector pMXI-gfp was a gift from Dr. R. Pieper at the University of California, San 
Francisco (261). The cDNA insert encoding WT PDGFR? (a gift from Dr. Carl-Henrik Heldin at 
Uppsala University, Uppsala, Sweden) was excised from a pcDNA3 vector and subcloned into a 
BamHI site of the pMXI-gfp retroviral vector. To generate retroviral vectors encoding PDGF-A, 
cDNA insert encoding PDGF-A was excised from pcDNA3 vector and subcloned into a BamHI-
NotI site of pMXI-gfp or into an EcoRI site of a pMSCV (Murine Stem Cell Virus)-dsred2 
retroviral vector (a gift from Dr. T. Cheng at the University of Pittsburgh, Pittsburgh). For 
experiments of p16INK4a (a gift from Dr. L. Chin, Dana-Farbar Cancer Institute, Boston) and 
p19ARF (a gift from Dr. Y. Zheng, Cincinnati Children’s Hospital Medical Center, Cincinnati) 
re-expression, retroviral vectors pBabe-Puro-p16INK4a and pMIEG3-egfp-p19ARF were used. 
For shRNA experiments, the lentiviral vectors pLKO.1-shCDKN2A (6 clones) were purchased 
from Thermo Scientific, Huntsville, AL.  
Retroviruses and lentiviruses were produced by co-transfecting various cDNA and 
packaging plasmids (pKat and pVSV-g for retrovirus; pMDL-RRE, pRSV-REV, and pVSV-g 
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for lentivirus) into 293T or Phoenix
TM
 (Orbigen Inc., San Diego, CA) cells using Lipofectamine 
2000
TM
 reagent according to manufacturer’s instruction (#52758, Invitrogen). Forty-eight hours 
after transfection, the supernatants containing viruses were filtered by a 0.45-μm syringe filter 
(5) and added into the culture media supplemented with 8 μg/ml polybrene. Forty-eight hours 
after the infection, transduced human glioma cells or primary astrocytes were harvested and re-
plated in DMEM containing 10% FBS and 2 μg/ml puromycin or 300 μg/ml hygromycin for 
drug selection or sorted by Fluorescence-activated Cell Sorting (FACS) for GFP expression. 
Expression of exogenous PDGFR? in the resultant cell populations was validated by IB and GFP 
expression by FACS analysis. 
 
2.2.3 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)  
 
Total RNAs from various human glioma cell lines were extracted using RNeasy Mini Kit 
(Qiagen). Approximately 5 μg of total RNAs were used to synthesize the first strand cDNA by 
Superscript
TM
 II Reverse Transcriptase (Invitrogen).  The following primers were used for the 
PCR reactions: p16INK4a forward, 5’-CAA CGC ACC GAA TAG TTA-3’; reverse, 5’-AGC 
ACC ACC AGC GTG TC-3’; actin forward, 5’-CGG GAA ATC GTG CGT GAC AT-3’; 
reverse, 5’-GGA GTT GAA GGT AGT TTC GTG-3’. The resulting PCR products were then 
analyzed using 2% agarose gel electrophoresis. 
 
 
 
  55 
2.2.4 Mouse Glioma Transplantation/Xenograft 
 
Experiments of glioma xenografts were performed as previously described (262). For intracranial 
glioma xenograft experiments, human glioma cells or mAst were harvested and re-suspended at 
1?105 cells /μl in PBS solution and placed on ice until injection. Anesthetized 6-week-old female 
athymic nu/nu mice (Taconic Farms Inc., Hudson, NY) were placed on a stereotactic frame with 
ear bars. A burr hole was drilled 2 mm lateral and 1.5 mm anterior to the Bregma. 
Approximately 3?105 cells in a 3 μl volume (for mAst) or 5?105 cells in a 5 μl volume (for 
human glioma cells) were then injected 3 mm below the skull into the striatum of the brain. Mice 
were then monitored every 3 days. When neuropathological symptoms developed due to tumor 
burdens in the brain, the mice were euthanized. Brains of mice were then removed, embedded in 
Optimum Cutting Temperature (OCT) compound (Tissue-Tek) at -80°C, and cryo-sectioned at 
5-μm thickness. Sections of brains were stored at -80°C until histological analysis. For s.c. tumor 
xenograft experiments, 5 million of various types of cells in 100-μl PBS were mixed with equal 
volume of growth factor-reduced Matrigel
TM
 and injected into flanks of mice using a 1-ml 
syringe with a 30-gauge needle (Bekton Dickinson). Tumor volumes were measured every 3 
days with a caliper, estimated as (a
2 ? b) / 2, a < b (263), and analyzed with GraphPad Prism 
version 4.00 for Windows (GraphPad Software inc., La Jolla, CA). Mice were euthanized before 
s.c. tumors reached 2000 mm
3
 in volume or when pathological symptoms developed due to 
tumor burdens. All animal experiments were approved by Institutional Animal Care and Use 
Committee (IACUC) of University of Pittsburgh, Pittsburgh, PA. 
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2.2.5 Immunohistochemistry 
 
Thin sections of harvested mouse brains with various tumors were analyzed by IHC using 
indicated antibodies or a TUNEL staining kit as previously described (260, 262). Briefly, 5-?m 
frozen sections were fixed in pre-chilled acetone at -20°C for 5 min, rinsed with PBS, and 
blocked by AquaBlock (East Coast Biologics Inc.) for 1 hour at room temperature.  Afterwards, 
various tissue sections were then incubated with a primary antibody overnight at 4°C, and 
blocked by Peroxidase Blocking Reagent (DAKO) for 10 minutes, followed by incubation with a 
biotinylated secondary antibody for 30 min at room temperature. After washed in PBS, stained 
tissue sections were visualized by diaminobenzidine chromophore and H2O2 followed by 
hematoxylin counterstaining. Sections were then dehydrated by graded ethanol, and mounted 
with Permount Solution (5).  
 
2.2.6 Immunoblotting 
 
For IB analysis, total cell lysates containing ~30 μg of total proteins were separated in a SDS-
PAGE gel under a reducing condition. The separated proteins were then transferred to a 
polyvinylidene fluoride (PVDF) membrane (Bio-Rad), blocked by 5% (w/v) nonfat dry milk 
(Bio-Rad) in PBS, and probed with indicated primary antibodies at 4°C overnight. Proteins of 
interest were then visualized by incubating the membrane with indicated peroxidase-labeled 
secondary antibodies at room temperature for 30 min followed by detection with enhanced 
chemiluminescence (ECL, Amersham Bioscience) reaction following manufacturer’s 
instructions.  
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2.2.7 Soft Agar Colony Formation Assay 
 
Colony formation assay in soft agar was performed as previously described (264). Briefly, 
approximately 5000 cells were seeded in a 0.5% Noble Agar top layer with a bottom layer of 
0.8% Noble Agar in each of the triplicate wells of a 24-well plate. Growth factor-reduced 
Matrigel
TM 
(1 mg/ml) was added into the top layer with or without indicated inhibitors. PDGF-A-
expressing cells in 10% of total cells were included as a source of PDGF-AA. DMEM containing 
10% FBS was added 3 days after plating and changed every 3 days thereafter. Colonies were 
scored after 2-3 weeks using Olympus SZX12 stereomicroscope and data were analyzed using 
GraphPad Software.  
 
2.2.8 Cell Proliferation Assay 
 
Cell proliferation and viability were determined as previously described (45). Briefly, 50,000 
cells were seeded in 10% FBS / DMEM, split, counted, and re-seeded every 3 days in a 6-well 
plate. Population doubling was calculated by dividing the total cell number by the cells seeded 
(50,000 cells), using log2 versus the days in culture to determine the proliferation rate of each 
type of cells. 
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2.2.9 Cell Viability Assay 
 
Cell viability was assessed by a colorimetric assay using a tetrazolium salt WST-1 (4-[3-(4-
lodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) reagent (152) according 
to manufacturer’s instruction. Briefly, 3000 cells were seeded in triplicate wells of a 96-well 
microplate and incubated in a serum-free medium for 48 hours at 37°C and 5% CO2. A WST-1 
reagent was then added to the media (10 μl/well) and incubated for an additional 2 hours. Light 
absorption of samples in each well was measured at a wavelength of 450 nm in a ThermoMax 
microplate reader (Molecular Devices, Sunnyvale, CA). Wells containing only culture media 
were used as a background control for all the samples measured. Trypan Blue Exclusion assay 
was performed as previously described (265). Briefly, cells were harvested and mixed with an 
equal volume of Trypan Blue dye. The number of live (appearing bright under light microscope) 
cells was then estimated from a total number of 200 cells from the harvested cells. The data were 
then analyzed using GraphPad Software. 
 
2.2.10 Statistical Analyses 
 
One-way ANOVA or an unpaired, two-tailed Student’s t test followed by Newman-Keuls post-
test was performed using GraphPad Prism software. A P value of 0.05 or less was considered 
statistically significant. 
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2.3 RESULTS 
 
2.3.1 PDGFRA and Ink4a/Arf aberrations in mouse astrocytes in vitro 
 
To determine whether activation of PDGFR? signaling in Ink4a/Arf -/- mAst leads to increased 
proliferation and survival in vitro, we overexpressed PDGFR? and/or its ligand PDGF-A chain 
in a retroviral vector containing an IRES-GFP in Ink4a/Arf
 -/- 
mAst. The IB experiment showed 
that the parental mAst expressed very low endogenous PDGFR? and undetectable PDGF-A 
(Figure 6). Overexpression of the receptor or ligand greatly increased the expression in the cells. 
In vitro growth and survival were further analyzed by using hematocytometer and WST-1 assay 
(an MTT-like assay that measures the number of viable cells by detecting the activity of 
mitochondrial dehydrogenases in the sample), respectively. As shown, the impact of PDGFR?/-
A overexpression on the growth of these cells in vitro was moderate (Figure 7A and 7B). The 
time needed for one doubling of these cells is around 12 hours for PDGFR?/-A mAst, 15 hours 
for PDGF-A cells, and 20 hours for PDGFR? and GFP control cells. For survival assay, cells 
were plated in 96-well for 48 hours in serum-deprived medium. WST-1 survival assay was then 
performed on these cells. As shown, PDGFR?/-A mAst survived better than the other three cell 
lines in serum starvation, likely due to its capability to initiate survival pathways via PDGF 
autocrine signaling. Taken together, PDGFR? and/or PDGF-A overexpression exert moderate 
effect on Ink4a/Arf
 -/- 
mAst growth and survival only when both the receptor and ligand are co-
transfected into the cells, whereas overexpression of PDGFR? or PDGF-A alone did not 
markedly affect these processes. 
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Figure 6. The PDGFR?  and/or PDGF-A overexpression in Ink4a/Arf-/- mAst.  
IB analysis of exogenous expression of PDGFR?  and/or PDGF-A in mAst. Arrows, PDGFR?  and PDGF-A 
proteins run as doublet bands. ?-actin was used as a loading control. 
 
 
Figure 7. In vitro characterization of Ink4a/Arf
 -/-
 mouse astrocytes overexpressing PDGFR?  and/or PDGF-A. 
(A) Growth of Ink4a/Arf
 -/-
 mAsts in vitro. 50,000 of various cells with similar passage numbers were seeded in 
triplicate wells of 6-well plates, counted every three days, and re-seeded. Population doubling was calculated 
by dividing the total cell number by 50,000 and converting it to a log2 value. No significant difference in cell 
proliferation was found among these cells. (B) Viability of Ink4a/Arf
 -/-
 mAsts in vitro. 3,000 of various cells 
were seeded in triplicate wells of a 96-well plate, followed by a 48-hour serum starvation. The number of 
viable cells was estimated using the WST-1 reagent and presented as a percentage to the number of viable 
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PDGFR? /-A cells. Data are shown as mean ±  s.d. *, P < 0.001, one-way ANOVA followed by Newman-Keuls 
post hoc test. 
 
2.3.2 PDGFRA and Ink4a/Arf aberrations in transplanted mouse astrocytes in vivo 
 
To assess the effect of PDGF activation on in vivo tumor growth of Ink4a/Arf
 -/- 
mAst, we 
transplanted these cells into two different anatomic sites in the nude mice, the flanks and the 
brain. When mAsts expressing PDGFR? and/or PDGF-A were transplanted into the flanks of 
mice, significant s.c. tumor growth was evident in mice that separately received Ink4a/Arf
 -/- 
mAst expressing PDGFR?, PDGF-A, or PDGFR?/-A, whereas minimal or no tumor formation 
was seen in control mice that received Ink4a/Arf
 -/- 
mAst expressing GFP (Figure 8).  
 
 
 
Figure 8. In vivo growth of Ink4a/Arf
 -/-
 mouse astrocytes overexpressing PDGFR?  and/or PDGF-A. 
Subcutaneous tumor growth of various mAst. Tumor volumes were measured with a caliper, and estimated 
as (a
2 ?  b) / 2, a < b. n, the number of mice used for each group. Data are shown as mean ±  s.d. 
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To determine tumorigenicity of these cells in the brain, various mAst were separately 
implanted into the brain of mice. Notably, mice that received GFP mAst did not show active 
tumor growth up to 42 days post-implantation, while PDGFR?, PDGF-A, or PDGFR?/-A mAst 
started to form tumors in the brain as early as 8-11 days, majority of tumors reached a volume of 
~25 to 30 mm
3
 in 25 to 35 days. Moreover, mice that separately received PDGFR?- or PDGF-A-
expressing mAst survived up to 2 months post-implantation. On the other hand, all mice received 
autocrine PDGFR?/-A-expressing mAst developed large and invasive tumors by 20 days with an 
average survival time of 25 days post-implantation. As shown in Figure 9, significant larger and 
highly invasive gliomas formed in the brains of mice that received Ink4a/Arf
 -/- 
mAst 
overexpressing PDGFR?, PDGF-A, or PDGFR?/-A, whereas only small tumor lesions were 
found in the brain of mice that received control mAst (Figure 9A to 9J).  
 
 
Figure 9. Orthotopic growth in the mouse brain of Ink4a/Arf
 -/-
 mouse astrocytes overexpressing PDGFR?  
and/or PDGF-A. 
Representative H&E staining images of various brain sections from two independent experiments with at 
least 3-5 mice per group with similar results.  Brains were harvested 25-30 days post-transplantation for (A)-
(D), and 20 days for (E).  Bars, 1 mm for (A)-(E); 200 μm for (F)-(J). 
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Significantly, a ~10-fold increase in the cell proliferation index was found in gliomas 
derived from PDGFR?-activated mAst compared to control tumors (Figure 10A to F), whereas a 
~10-fold decrease of cell apoptosis was seen in PDGFR?/-A expressing tumors (Figure 10G). Of 
note, in established s.c. or brain tumors, exogenous expression of PDGFR? or PDGF-A was 
maintained at the end of the experiments (Figure 11 and data not shown). Taken together, these 
results indicate that expression of PDGFR? and/or PDGF-A confers tumorigenicity to Ink4a/Arf-
deficient mAst in the brain.  
 
 
Figure 10. In vivo proliferation and apoptosis of Ink4a/Arf
 -/-
 mouse astrocytes overexpressing PDGFR?  
and/or PDGF-A. 
(A)-(E) Ki-67 staining of the corresponding brain sections in Figure 10(A)-(E). Yellow arrows, tumor mass or 
invading tumor cells. Red arrows, Ki-67-positive cells. Bar, 50 μm. Quantification of (F) Ki-67 staining and 
(G) TUNEL staining of various brain sections. Data are presented as percentage to parental controls (mean ±  
s.d.). n, the number of mice used for each group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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Figure 11. Ink4a/Arf
 -/-
 mouse astrocytes overexpressing PDGFR?  and PDGF-A retained high expression of 
both the receptor and the ligand in vivo. 
(A) IB analysis of tissue lysates from s.c. tumors derived from Ink4a/Arf
 -/-
 GFP control, PDGFR? , and 
PDGFR? /-A mAst. Various s.c. tumors were snap-frozen, weighed, homogenized, and lysed in lysis buffer 
before IB analysis. Arrows, PDGFR?  and PDGF-A proteins run as doublet bands. ?-actin was used as a 
loading control. (B)-(I) Immunohistochemical (IHC) staining of brain tumors derived from Ink4a/Arf
 -/- 
GFP 
or PDGFR?  mAst using anti-PDGFR?  (panels B-E) and anti-PDGF-A (panels F-I) antibodies. PDGFR?  was 
weakly expressed (panels B and C) whereas PDGF-A proteins (panels F and G) were not detected in the 
Ink4a/Arf
 -/-
 GFP control tumor. In contrast, high levels of expression of PDGFR?  (panels D and E) and 
PDGF-A (panels H and I) were maintained in the Ink4a/Arf
 -/-
 PDGFR? /-A tumor in the brain of mice. 
Arrows in panels B and C, GFP control tumor lesions; the arrow in C indicates low level of endogenous 
PDGFR?  staining. Arrows in panels D, E, H, and I, positive staining of PDGFR?  (D and E) and PDGF-A (H 
and I) in tumor cell clusters invading the brain parenchyma. T, tumor mass; P, normal brain parenchyma. 
Scale bars represent 200 μm in panels B, D, F, and H; 50 μm in panels C, E, G, and I.   
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2.3.3 Mouse astrocytes with PDGFRA and Ink4a/Arf aberrations express markers of neural 
progenitor cells 
 
To further characterize the tumors derived from Ink4a/Arf
-/-
 PDGFR? mAst, we examined 
molecular markers of various cell lineages in the CNS development.  As shown in Figure 12, 
tumors derived from PDGFR?-expressing mAst were highly positive for the neural progenitor 
marker nestin which was distributed along the processes of individual cells (Figure 12A and B).  
As expected, most of tumor cells showed expression of the progenitor/mature astrocyte marker 
GFAP (Figure 12C and D) whereas they were negative for the neuronal marker class III ?-
tubulin (TUJ1) (Figure 12E and F). Significantly, NG2, an OPC marker (266), was expressed in 
a population of tumor cells that were actively invading the surrounding brain parenchyma, 
whereas the core of the tumor mass showed relatively low NG2 expression (Figure 12G and H). 
In contrast, control tumors derived from Ink4a/Arf 
-/-
 GFP mAst lacked nestin or NG2 expression 
(not shown). In addition, tumors derived from Ink4a/Arf
-/-
 PDGFR? mAst showed negative 
staining for O-2A progenitor marker A2B5 and an oligodendrocyte marker CNPase (data not 
shown). Notably, brain tumors derived from Ink4a/Arf
-/-
 PDGFR?/-A mAst (not shown) 
displayed similar IHC features to tumors derived from Ink4a/Arf
-/-
 PDGFR? mAst, suggesting 
that similar dedifferentiation events also occurred in autocrine PDGFR?/-A co-expressing 
tumors.  
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Figure 12. Ink4a/Arf
 -/-
 mouse astrocytes overexpressing PDGFR?  and PDGF-A retained high expression of 
both the receptor and the ligand in vivo. 
Tumors derived from Ink4a/Arf
 -/-
 PDGFR?  mAst express markers of neural progenitor cells. Representative 
images of IHC staining using antibodies against nestin (A and B), GFAP (C and D), ?III-tubulin (E and F), 
and NG2 (G and H). Arrows, positive staining of various markers. T, tumor mass; P, normal brain 
parenchyma. Bar, 100 μm for (A), (C), (E), and (G); 50 μm for (B), (D), (F), and (H). 
 
2.3.4 PDGFRA and Ink4a/Arf aberrations in human glioma cells in vitro 
 
Next, we utilized four human glioma cell lines that are either INK4A/ARF-null (LN444 and 
LN443) or INK4A/ARF-wt (LN-Z308 and LN319) (Table 3 and Figure 13A) (267) and 
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exogenously expressed PDGF-A in these glioma cells that express endogenous PDGFR? (Figure 
13B). As shown by RT-PCR analysis, expression of p16INK4A was evident in both LN-Z308 
and LN319 glioma cells, whereas LN444 and LN443 did not express any detectable p16INK4A 
mRNAs. IB using p16INK4A or p14ARF antibodies further confirmed that expression of both 
tumor suppressors is only present in LN-Z308 and LN319 but not in LN444 and LN443 cells. In 
order to create an autocrine stimulation loop in these cells, we overexpressed PDGF-A into each 
of these cells. We did not overexpress PDGFR? alone in these experiments since these cells 
express high level of PDGFR? endogenously. As shown in Figure 13B, exogenous PDGF-A 
overexpression increased the phosphorylation of the endogenous PDGFR? in these 4 cell lines.  
 
Table 3. Human Glioma Cell Lines Used in This Study 
 
Cell Line  Age / Sex Type Location PDGFRA INK4A ARF P53 PTEN 
                  
         
LN444 48 / F Recurrent GBM LP +++ Del Del WT Mut 
LN443 66 / M de novo GBM RFT ++ Del Del WT Mut 
LN-Z308 65 / M de novo GBM RPO ++ WT WT Null Mut 
LN319 67 / M de novo AA LPO ++ WT WT Mut Mut 
 
Abbreviations: F, female; M, male; AA, astrocytoma; LP, left parietal; RFT, right frontal temporal; RPO, right 
parietal occipital; LPO, left parietal occipital; Del, deletion; Mut, mutation. 
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Figure 13. PDGF-A overexpression in INK4A/ARF-deficeint and INK4A/ARF-wt human glioma cells. 
(A) RT-PCR (upper panels) and IB analyses (lower panels) of INK4A/ARF-deficient LN444 and LN443, and 
INK4A/ARF-wt LN-Z308 and LN319 human glioma cells. RT, reverse transcriptase. (B) IB analysis of PDGF-
A overexpression in glioma cells with endogenous PDGFR?  expression. PDGFR?  was phosphorylated at 
tyrosine residues in PDGF-A-expressing cells, but not in parental cells that have no detectable PDGF-A. 
Molecular weight for PDGFR? , 160-180 kD; PDGF-A, 16 and 30 kD. P, parental cells; A, PDGF-A 
overexpressing cells. ?-actin was used as a loading control in both (A) and (B). 
 
To assess the anchorage-independent growth of these cells in vitro, we utilized a soft agar 
colony formation assay, which can also serve as an in vitro cell transformation/tumorigenesis 
assay. As shown, expression of PDGF-A in INK4A/ARF-deficient LN444 cells significantly 
enhanced their capacity of anchorage-independent growth in soft agar, whereas a minimal effect 
was seen in INK4A/ARF-wt LN-Z308 and LN319 cells (Figure 14). Taken together from these 
preliminary in vitro analyses, PDGFR?/-A autocrine signaling was able to enhance the in vitro 
tumorigenic potential of INK4A/ARF- deficient LN444 but not INK4A/ARF-wt LN-Z308 and 
LN319 cells. 
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Figure 14. PDGF-A overexpression enhances anchorage-independent growth of INK4A/ARF-deficeint but not 
INK4A/ARF-wt human glioma cells in vitro. 
Representative images (Left) and quantification (Right) of anchorage-independent growth of various glioma 
cells in soft agar. Bar, 1 mm. Data are presented as percentage to the respective parental cells (mean ±  s.d.). 
*, P < 0.001, Student’s t test. 
 
 
 
2.3.5 Overexpression of PDGF-A conferred tumorigenicity to Ink4a/Arf-deficient but not -
wildtype human glioma cells 
 
When various glioma cells were separately implanted into the brain or the flanks of mice, PDGF-
A expression markedly enhanced tumor growth and invasion of INK4A/ARF-null LN444 and 
LN443 glioma cells while minimal impact of PDGF-A expression on tumorigenesis or invasion 
was seen in INK4A/ARF-wt LN-Z308 and LN319 cells in both anatomic sites (Figure 15 and 16). 
Mice that received LN444/PDGF-A cells in the brain had tumor onset as early as 35 days, while 
mice with LN443/PDGF-A cells developed invasive intracranial tumors on 25-30 days post-
implantation. In contrast, LN444 and LN443 parental cells only formed small tumor lesions in 
the brain up to 2 to 3 months post-implantation. Mice that received LN444/PDGF-A cells 
survived for 75 to 80 days, while most of the mice received LN443/PDGF-A cells lived up to 3 
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months post-implantation. On the other hand, no significant brain tumor growth in mice that 
received LN308/PDGF-A or LN319/PDGF-A cells was found 2-3 months post-implantation. 
Thus, consistent with our findings in the Ink4a/Arf
-/-
 mAst, these data indicate that PDGFR?/-A 
signaling enhances in vivo tumor growth and invasion of human glioma cells deficient in 
INK4A/ARF. 
 
 
Figure 15. Exogenous PDGF-A expression enhances growth of Ink4a/Arf-null LN444 but not Ink4a/Arf-WT 
LN-Z308 tumors in the flanks of mice. 
Parental human glioma cells were inoculated into the left flank of mice, whereas glioma cells expressing 
PDGF-A were implanted into the right flank of the same animals. Three to four mice were used in each 
group. Tumor volumes were estimated [volume = (a
2 ?  b) / 2, a < b] (263) at indicated times after 
implantation. Data are shown as mean ±  s.e.m. and representative from two independent experiments.  
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Figure 16. Exogenous PDGF-A expression enhances growth of Ink4a/Arf-null LN444 but not Ink4a/Arf-WT 
LN-Z308 tumors in the brain of mice. 
Representative H&E staining images of various brain sections from two independent experiments with 3-5 
mice per group with similar results.  Brains were harvested 50-55 days post-transplantation for A and E; 75-
80 days for B and F; 45-50 days for C, D, G, and H. Arrows, gliomas formed in the brain (bar, 1 mm). 
 
2.3.6 p16INK4a but not p19ARF attenuates PDGFR?-induced tumorigenesis of Ink4a/Arf-
deficient mouse astrocytes and human glioma cells. 
 
To investigate whether re-expression p16INK4a or p19ARF is able to abrogate the enhanced 
tumorigenicity in Ink4a/Arf
-/-
mAst, we separately expressed these two tumor suppressors in 
mAst (Figure 17A, upper and lower panels). Surprisingly, re-expression of p16INK4a but not 
p19ARF alone in Ink4a/Arf
-/- 
mAst suppressed soft agar growth of PDGFR?-expressing mAst 
stimulated by PDGF-A (Figure 17B).  Consistently, enforced restoration of p16INK4a in 
Ink4a/Arf
-/- 
mAst significantly inhibited tumorigenesis of PDGFR?/-A overexpressing mAst in 
the mouse brain (Figure 18).   
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Figure 17. Re-expression of p16INK4a but not p19ARF suppresses the anchorage-independent growth of 
mAst expressing PDGFR? /-A in vitro. 
(A) IB analyses of re-expression of p16INK4a or p19ARF in PDGFR?  or PDGF-A overexpressing Ink4a/Arf-/- 
mAst. (B) Anchorage-independent growth of p16INK4a or p19ARF expressing mAst. Bar, 1 mm. Bar graph 
in lower panel, quantification of soft agar assays. Data are presented as mean ±  s.d. *, P < 0.05. 
 
 
 
Figure 18. Re-expression of p16INK4a suppresses the in vivo tumor growth of mAst expressing PDGFR? /-A. 
Ink4a/Arf
-/-
 mAst expressing (A) PDGFR? /-A or (B) PDGFR?/-A and p16INK4a were separately injected 
into brain of nude mice. Representative H&E staining images of various brain sections from two independent 
experiments with 3-5 mice per group with similar results.  Brains were harvested 18-22 days post-
implantation.  Mice received either types of cells displayed similar tumor onset and survival time as described 
in text for mice in Figure 1.  Bar, 1 mm. 
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To further demonstrate the cooperative effect of PDGFR? activation and loss of Ink4a on 
tumorigenesis, we knocked down endogenous p16INK4a by shRNAs targeting CDKN2A in 
INK4A/ARF-wt LN319 cells.  As shown in Figure 19, significant inhibition of P16INK4A 
without affecting P14ARF expression by two separate shRNAs in LN319 cells (Figure 19A) 
resulted in a marked increase in colony formation in soft agar (Figure 19B).  Since p16INK4a 
inhibits CDK4/6 that inactivates RB by phosphorylation and p19ARF (or P14ARF) targets 
MDM2 that suppresses p53 (26), we thus examined responses of modulating CDK4/6 and p53 in 
these cells.  As shown in Figure 20, inhibition of phosphorylation of RB, the direct downstream 
target of CDK4/6 by a CDK4/6 inhibitor PD0332991 (268) (Figure 20A), markedly reduced 
PDGF-A-stimulated cell growth of Ink4a/Arf-deficient mAst and LN444 cells in soft agar 
(Figure 20B), suggesting that the tumorigenic effect of PDGFR? signaling is dependent on 
CDK4/6 inactivation of RB proteins (p-RB).  
 
 
Figure 19. P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-A- 
promoted anchorage-dependent growth in vitro. 
Anchorage-independent growth of INK4A/ARF-wt LN319 cells transfected with shCDKN2A in soft agar. (A) 
IB analysis. (B) Quantification of soft agar assays. Two stable cell clones with different efficiencies of 
P16INK4A knockdown were used. Data are mean ±  s.d. *, P < 0.05; **, P < 0.01. 
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Figure 20. P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-A- 
promoted anchorage-dependent growth in vitro. 
Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) 
Quantification of soft agar assays. ?-actin was used as a loading control in all IB experiments. Data are 
presented as mean ±  s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001 
 
Since we did not observe any tumor-suppressing effect of p19ARF on Ink4a/Arf
-/-
 
PDGFR?-expressing mAst (Figure 17B), we asked whether the downstream p53 protein was 
functional in these cells. When Ink4a/Arf
-/- 
and Ink4a/Arf
-/-
 p19ARF mAst were treated with 
cisplatin (269), p53 expression was strongly induced in Ink4a/Arf
-/-
 PDGFR?/p19ARF-
expressing mAst, but only at a moderate level in Ink4a/Arf
-/-
 PDGFR?-expressing mAst (Figure 
21A). The mAst expressing p19ARF were more sensitive to cisplatin inhibition of cell survival 
than those without p19ARF expression, indicating that p19ARF-upregulated p53 in Ink4a/Arf
-/-
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PDGFR?-expressing mAst rendered sensitivity to cisplatin inhibition (Figure 21B). Collectively, 
these data show that p16INK4a but not p19ARF suppresses the tumorigenesis promoted by 
PDGFR?/-A signaling, suggesting a cooperative effect of PDGFR? activation and p16INK4a 
inhibition during gliomagenesis. Additionally, p19ARF loss might be required for tumor survival 
in certain circumstances such as in the presence of DNA-damaging agents. 
 
 
Figure 21. Cisplatin induces p53 expression and cell death in Ink4a/Arf
-/-
 PDGFR?-expressing mAst in the 
presence of p19ARF. 
(A) U87MG or Ink4a/Arf
 -/-
 mAst expressing PDGFR?  or PDGFR? /p19ARF were serum-starved for 24 hours 
followed by incubation with cisplatin (CDDP) at indicated concentrations for an additional 24 hours. Cells 
were then lysed for IB analyses. Cisplatin was able to induce p53 expression at a concentration of 10 μg/ml 
for U87MG and 20 μg/ml for Ink4a/Arf -/- mAst expressing PDGFR? /p19ARF. ??actin proteins were used as 
loading control. (B) An equal number of PDGFR?  or PDGFR?/p19ARF-expressing Ink4a/Arf -/- mAst were 
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cultured in triplicate wells in the presence of DMSO, 10 μg/ml, or 20 μg/ml CDDP for 48 hours before 
Trypan Blue exclusion assay for cell viability.  *, P < 0.01; **, P < 0.0001, compared with DMSO control.  
Data are shown as mean ±  s.d. and representative of two independent experiments. 
 
 
2.4 SUMMARY AND CONCLUSION 
 
We have demonstrated that primary murine astrocytes or human glioma cells in the Ink4a/Arf-
null background retained the potential of responding to PDGF activation by generating gliomas, 
both in the brain and flanks of mice, which were significantly larger and more malignant than 
those formed by cells without PDGF stimulation. Moreover, we found that the PDGF-A-induced 
enhanced tumorigenicity only occurred in Ink4a/Arf-defcient but not Ink4a/Arf-wildtype human 
glioma cells. When we restored the expression of p16INK4a or p19ARF alone in the Ink4a/Arf
-/-
 
mAst, we found a dramatic decrease of tumorigenesis only in cells expressing p16INK4a but not 
in those expressing p19ARF. Furthermore, in our attempt to eliminate the endogenous expression 
of the P16INK4A in Ink4a/Arf-wildtype human glioma cells, we found that these cells showed a 
significant increase in anchorage-independent growth in soft agar. Thus we conclude that 
PDGFR?/PDGF-A is able to enhance gliomagenesis in cooperation with Ink4a/Arf deletion, and 
re-expression of p16INK4a is sufficient to abrogate this induced tumorigenicity. 
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3.0 PDGFRA-INDUCED GLIOMAGENESIS DEPENDS ON DOWNSTREAM PI3K 
PATHWAY THAT IS REGULATED BY SHP-2/PTPN11 ACTIVITY 
 
 
3.1 INTRODUCTION AND RATIONALE 
 
Changes in expression or copy number of the gene PDGFRA have been a key feature of GBMs 
(2, 4). The new genomic profiling has further identified PDGFRA overexpression as one of the 
key signature genetic alterations in the Proneural subtype of GBMs, together with TP53 and 
IDH1 mutations, among many others (11). Observations obtained from in vivo animal models 
have provided invaluable insights into how PDGF over-activity can cause glioma formation from 
different cell types in the brain (270). However, the molecular mechanisms behind which PDGF 
signaling induces glioma formation remain largely unknown. In the previous sections, we 
showed that PDGFRA overexpression cooperates with loss of p16INK4A to promote 
gliomagenesis. In order to dissect the downstream signaling cascades mediating the PDGF-
mediated enhanced tumorigenicity, we transfected a series of established PDGFR? mutants into 
the Ink4a/Arf
-/-
 mAst and assessed their tumorigenic potential by transplanting them into the 
mouse brain. These in vivo results were later confirmed by experiments using various 
pharmacological inhibitors that target specific signaling pathways downstream to the receptor. 
The subsequent biochemical studies further demonstrated how these downstream pathways 
interact to mediate tumor formation induced by PDGFR? overexpression. 
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3.2 MATERIALS AND METHODS 
 
3.2.1 Cell Lines and Reagents 
 
Primary Ink4a/Arf
-/- 
mAst were derived and propagated as previously described (45). Human 
glioma cell line LN444 was obtained from American Cell Type Culture Collection (Manassas, 
VA). Unless otherwise mentioned, LN444 and primary mAst were routinely maintained in 5% 
CO2 at 37°C, in DMEM (Invitrogen) containing 10% FBS (Hyclone), 100 units/ml penicillin, 
and 100 μg/ml streptomycin (Invitrogen).  
The following antibodies and reagents were used in this study: rabbit anti-PDGFR? (sc-
338, 1:500), rabbit anti-PDGF-A (sc-128, 1:500), and goat anti-?-actin (sc-1616, 1:500) 
antibodies were from Santa Cruz Biotechnology Inc., Santa Cruz, CA; rabbit anti-phospho-
p44/42 MAP Kinase (Thr202/Tyr204, #9101, 1:1000), rabbit anti-p44/42 MAP Kinase (#9102, 
1:1000), mouse anti-phospho-Akt (Ser473, #4051, 1:1000), rabbit anti-Akt (#9272, 1:1000), 
rabbit anti-phospho-p70 S6 Kinase (Thr389, #9205, 1:500), rabbit anti-p70 S6 Kinase (#9202, 
1:500), and mouse anti-Myc-Tag (#2276, 1:1000) antibodies were from Cell Signaling 
Technology, Danvers, MA; mouse anti-phosphotyrosine (clone 4G10, #05-321, 1:1000) and 
rabbit anti-PI3K p85 (#6-497, 1:500) antibodies were from Millipore, Temecula, CA; a rabbit 
anti-caspase-3 antibody was from Stressgen, Ann Arbor, MI; a rabbit anti-Ki67 antigen (NCL-
Ki67p, IHC, 1:200) antibody was from Leica Microsystems Inc., Bannockburn, IL; Matrigel
TM
 
Basement Membrane Matrix, Growth Factor Reduced (GFR) (#356230) was obtained from BD 
Biosciences, San Jose, CA; LY294002 (#440202), Insolution
TM
 SU6656 (#572636), PP2 
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(#529573), SHP1/2 PTPase Inhibitor NSC87877 (#565851) and MEK inhibitor PD98059 were 
from EMD Chemicals, Gibbstown, NJ; PHPS-1 sodium salt hydrate (P0039) was from Sigma-
Aldrich, St. Louis, MO. Rapamycin/Sirolimus (NSC-226080) was from NCI Developmental 
Therapeutic Program, National Institute of Health, Bethesda, MD. All secondary antibodies were 
from Vector Laboratories (Burlingame, CA) or Jackson ImmunoResearch Laboratories (West 
Grove, PA). All other reagents were from Invitrogen, Sigma-Aldrich, or Fisher Scientific. 
 
3.2.2 Retroviral and Lentiviral Constructs and Infections 
 
The cDNA’s of various PDGFR? mutants were described previously (271, 272). To generate 
retroviral vectors encoding various PDGFR? mutants, cDNA inserts were subcloned from either 
pLNCX2 (for R627, F731/42, F572/74, F988, F1018, and Y720 PDGFR? mutants, gifts from 
Dr. Andrius Kazlauskas at Harvard Medical School, Boston) or pCS2 (for F720 and Y731/42 
PDGFR? mutants, gifts from Dr. Karen Symes at Boston University School of Medicine, 
Boston) vectors into the NotI-SnaBI sites of the pMXI-gfp retroviral vector. For shRNA 
experiments, the lentiviral vectors pLKO.1-shPTPN11 (5 clones) were purchased from Thermo 
Scientific, Huntsville, AL.  
Retroviruses and lentiviruses were produced and the mAst or LN444 cells were 
transduced as described in 2.2.2 (Page 51) of this dissertation. 
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3.2.3 Immunoprecipitation and Immunoblotting 
 
For IP experiments, cells were serum-starved for 24-48 hours and lysed in a lysis solution 
(20mM Tris-HCl pH 7.4, 50mM NaCl, 0.5% Triton X-100, 2% NP-40, 1mM CaCl2, 1mM 
MgCl2, and Complete
TM
 EDTA-free protease inhibitor cocktail, cat# 11836170001, Roche). In 
some experiments, cells were pre-incubated with or without indicated inhibitors for 24 hours and 
then stimulated by 50 ng/ml PDGF-A for 5 min prior to lysis. The cell extracts were then 
centrifuged, and proteins in the supernatants were quantified. Approximately 1 μg of indicated 
primary antibody was added to a lysate preparation containing 1 mg total protein. The mixtures 
were then incubated at 4°C overnight on a rotator. The protein-antibody complex was pulled 
down by rProtein G Agarose beads (15920-010, Invitrogen), washed 3 times with the lysis 
solution, and analyzed in a SDS-PAGE. For IB analysis, immunoprecipitated proteins or total 
cell lysates containing ~30 μg of total proteins were separated in a SDS-PAGE gel under a 
reducing condition. The separated proteins were then transferred to a polyvinylidene fluoride 
(PVDF) membrane (Bio-Rad), blocked by 5% (w/v) nonfat dry milk (Bio-Rad) in PBS, and 
probed with indicated primary antibodies at 4°C overnight. Proteins of interest were then 
visualized by incubating the membrane with indicated peroxidase-labeled secondary antibodies 
at room temperature for 30 min followed by detection with enhanced chemiluminescence (ECL, 
Amersham Bioscience) reaction following manufacturer’s instructions.  
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3.2.4 RNA Interference 
 
SHP-2 specific siRNA (5’-AAG GAC AUG AAU AUA CCA AUA-3’) (273) and a scrambled 
siRNA control were obtained from Dharmacon (Lafayette, CO). Transient transfection of 
siRNAs was performed using Effectene? Reagent (Qiagen) according to manufacturer’s 
instructions. Cells were transfected with 100 nM siRNAs for 24 hours, recovered in 10% FBS / 
DMEM for 48 hours prior to further analyses. Knockdown of SHP-2 was validated by IB using a 
mouse anti-SHP-2 antibody. 
 
3.2.5 Other Experiments 
 
Experiments of glioma transplantation, IHC, soft agar assay, and cell viability assay were 
performed as described in sections 2.2.4 (Page 53), 2.2.5 (Page 54), 2.2.7 (Page 55), and 2.2.9 
(Page 56) of this dissertation. 
 
3.2.6 Statistical Analyses 
 
One-way ANOVA or an unpaired, two-tailed Student’s t test followed by Newman-Keuls post-
test was performed using GraphPad Prism software. A P value of 0.05 or less was considered 
statistically significant. 
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3.3 RESULTS 
 
3.3.1 Generation of Ink4a/Arf
-/-
 mouse astrocytes overexpressing various PDGFR?  
mutants that are not able to activate specific downstream pathways 
 
Previous studies using genetic and biochemical approaches have defined the roles of signaling 
molecules in PDGFR?-mediated cellular functions by specific tyrosine-to-phenylalanine 
mutations (Y to F) (Figure 22A) (70, 74, 75). To investigate the impact of these PDGFR? 
mutations on tumorigenesis, we separately expressed wild-type (PDGFR?-wt) or various 
PDGFR? mutants in Ink4a/Arf-/- mAst.  A PDGFR? mutant R627 (PDGFR?-R627) that harbors 
a lysine-to-arginine (K-to-R) mutation was included as a “receptor kinase-dead” control. As 
shown in Figure 22B, stimulation of PDGFR?-wt by PDGF-A resulted in autophosphorylation 
of the receptor and promoted phosphorylation of downstream signaling molecules Erk1/2 and 
Akt, whereas there was an undetectable receptor tyrosine autophosphorylation in PDGFR?-R627 
(Figure 22B). PDGFR? Y-to-F mutations at Y572 and Y574 (PDGFR?-F572/74; for SFK 
binding), Y1018 (PDGFR?-F1018; for PLC? binding), and Y988 (PDGFR?-F988) did not result 
in a significant decrease in p-Akt and p-Erk levels in response to PDGF-A stimulation (Figure 
22B). Moreover, the mutation at Y731 and Y742 (PDGFR?-F731/42; for PI3K binding) led to a 
marked decrease in PDGF-A-stimulated p-Akt and p-Erk1/2 levels (Figure 22B).  In agreement 
with a previous report (274), p-Erk1/2 was markedly reduced in PDGF-A-stimulated mAst 
expressing PDGFR?-F720 (Y-to-F mutation at Y720; for SHP-2 binding), compared to 
PDGFR?-wt mAst (Figure 22B). Interestingly, p-Akt level was also attenuated in PDGFR?-
F720 cells. 
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Figure 22. Impacts of PDGFR?  mutations on downstream signaling of PDGFR? . 
(A) Schematics of various PDGFR?  mutants. (B) IB analyses of PDGF-A-stimulated Ink4a/Arf-/- mAst 
overexpressing individual PDGFR?  mutants. Various mAst cells were serum-starved for 48 hours before 
stimulation by 50 ng/ml PDGF-A for 5 min. Total cell lysates were then collected for IB experiments. 
Corresponding total proteins or ?-actin were used as loading controls.   
 
3.3.2 Disruption of SHP-2 and PI3K pathways downstream to PDGFR?  suppresses tumor 
growth of Ink4a/Arf
-/-
 mouse astrocytes 
 
Next, we determined the impact of these Y-to-F mutations on PDGFR?-promoted cell 
transformation of Ink4a/Arf
-/- 
mAst in vitro.  As shown in Figure 23A, mAst expressing 
PDGFR?-wt, PDGFR?-F572/74, PDGFR?-F988, and PDGFR?-F1018 PDGFR? mutants 
showed similar capability of anchorage-independent growth in soft agar. In contrast, expression 
of PDGFR?-R627, PDGFR?-F731/42, or PDGFR?-F720 instead of PDGFR?-wt significantly 
abrogated the capacity of mAst to form colonies in soft agar (Figure 23A and B), indicating that 
PI3K and SHP-2 signaling were critical for cell transformation in vitro.   
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Figure 23. Impacts of PDGFR?  mutations on downstream signaling of PDGFR?  and anchorage-independent 
growth in soft agar of Ink4a/Arf
-/- 
mAst. 
(A) Representative images of soft agar colonies. (B) Quantification of soft agar assays. Data are presented as 
mean ±  s.d. and representative of two independent experiments. *, P < 0.01. Bar, 1 mm. 
 
 
When various Ink4a/Arf
-/- 
mAst were separately implanted into the brains of mice, 
compared to PDGFR?-wt (Figure 24A), PDGFR?-R627, PDGFR?-F731/42, PDGFR?-F720, 
and PDGFR?-F988 significantly impaired PDGFR?-promoted tumorigenesis and invasion 
(Figure 24B, C, E and F). However, mAst expressing PDGFR?-F572/74 or PDGFR?-F1018 
displayed comparable tumorigenicity to PDGFR?-wt tumors (Figure 24D and G, compared to 
24A), but with markedly reduced tumor invasion compared to the tumors derived from mAst 
expressing PDGFR?-wt (Figure 24K and N, compared to H). Higher magnification images of 
PDGFR?-R627, PDGFR?-F731/42, and PDGFR?-F720 mutants (Figure 24I, J and L) further 
illustrated that these mutations significantly negated the enhanced tumorigenicity conferred by 
PDGFR? activation, leading to the formation of tumors similar in volume and invasiveness to 
those seen in GFP-expressing mAst tumors (Figure 9B and G).  
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Figure 24. Impacts of individual mutations of PDGFR?  in mAst on brain tumorigenesis. 
(A) to (N), Representative H&E staining images of various brain sections from two independent experiments 
with at least 5 mice per group with similar results. Mice received either types of cells displayed similar tumor 
onset and survival time as described in text for mice in Figure 1. Brains were harvested 25-30 days post-
transplantation for A ; 30-35 days for B, C, D and G; and 35-40 days for E and F.  Bar, A to G, 1 mm, H to N 
200 μm.  Arrows, tumors or invading cells. 
 
Moreover, PDGFR?-F731/42 and PDGFR?-F720 tumors showed a significantly 
decreased cell proliferation (Figure 25A and B) and increased apoptosis (Figure 26A and B), 
whereas PDGFR?-F572/74, PDGFR?-F988, and PDGFR?-F1018 tumors exhibited moderate or 
minimal impacts on cell proliferation and survival compared to PDGFR?-wt tumors. 
Conversely, retention of any one of the five signaling modules (Y731/42, Y572/74, Y720, Y988, 
and Y1018 PDGFR? mutants) (74) was insufficient to rescue the abolished tumorigenesis in the 
brain (data not shown).  Taken together, these data indicate that ablation of PDGFR? association 
with SHP-2 or PI3K abrogates tumorigenicity of Ink4a/Arf
-/- 
mAst expressing PDGFR?, whereas 
individual association of PI3K, SHP-2, SFK, or PLC? with the RTK was insufficient to elicit the 
full spectrum of tumor-promoting effects of PDGFR?. 
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Figure 25. Impacts of individual mutations of PDGFR?  in mAst on in vivo proliferation in the mouse brain. 
(A) Ki-67 staining of brain sections, bar, 50 μm. Red arrows, Ki-67-positive cells. (B) Quantification of Ki-67 
staining. Data are presented as mean ±  s.d. *, P < 0.01; **, P < 0.001. 
 
 
 
 
 
Figure 26. Impacts of individual mutations of PDGFR?  in mAst on in vivo apoptosis in the mouse brain. 
(A) (TUNEL staining images, bar, 100 μm. (B) Quantification of TUNEL staining.  Data are presented as 
mean ±  s.d. **, P < 0.001. 
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3.3.3 Pharmacological inhibition of SHP-2 or PI3K abrogates PDGF-promoted 
tumorigenesis of Ink4a/Arf
-/-
 mouse astrocytes or human glioma cells 
 
We further investigated whether inhibition of SHP-2 and PI3K activities by pharmacological 
approaches suppresses tumorigenicity of PDGFR?/-A expressing Ink4a/Arf-/- mAst and LN444 
cells.  To this end, we exploited several pharmacological inhibitors against PI3K (LY294002), 
SHP-2 (PHPS-1 and NSC87877) (275), and SFK (SU6656 and PP2). As shown in Figure 7, 
LY294002 inhibits PDGF-A-induced phosphorylation of Akt at 10 μM in mAst and 5 μM in 
LN444 glioma cells, whereas Erk1/2 phosphorylation was unaffected by LY294002 treatment in 
both types of cells (Figure 27A and 28A). Of note, a modest decrease in p-Erk1/2 level in mAst 
treated with 20 μM LY294002 was observed (Figure 27A). At a concentration of 100 μM (275), 
both PHPS-1 and NSC87877 significantly inhibited p-Erk1/2, a direct downstream target of 
SHP-2, in mAst and LN444 cells (Figure 27B and 28B). Next, we examined the impact of the 
pharmacological interventions of these signaling enzymes on in-vitro cell transformation and 
found that 10 μM LY294002 that had no effect on Erk1/2 activation suppressed soft agar growth 
of PDGFR?-expressing mAst stimulated by PDGF-A (Figure 27D) and PDGF-A-expressing 
LN444 cells (Figure 28C). Similarly, 100 μM of either PHPS-1 or NSC87877 ablated PDGFR?-
stimulated anchorage-independent growth in soft agar, but only had minimal effect on the cell 
survival and caspase-3 activation of both PDGFR?/-A-expressing mAst and LN444 cells in 
culture (Figure 29). Additionally, the MEK inhibitor PD98059 at 10 μM that suppressed PDGF-
A-induced p-Erk1/2 in mAst (Figure 27C) also inhibited soft agar growth of these cells (Figure 
27D), validating Erk1/2 as a mediator of PDGFR?-SHP-2 signaling. In contrast, two SFK 
inhibitors, 5 μM SU6656 and PP2, also showed a modest impact on tumorigenesis of these cells 
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(Figure 27D and 28C). Taken together, these data demonstrate that the PDGFR?/-A-enhanced 
tumorigenicity of Ink4a/Arf-deficient mAst and human glioma cells requires intact SHP-2 and 
PI3K enzymatic activities. 
 
 
Figure 27. Inhibition of PI3K or SHP-2 activity suppresses PDGFR?-stimulated signaling and cell 
transformation in Ink4a/Arf
-/- 
mAst. 
Inhibitors of PI3K (LY294002), SHP-2 (PHPS-1 and NSC87877), and MEK (PD98059), but not SFK (SU6656 
and PP2) abrogate cell transformation of PDGFR?-overexpressing Ink4a/Arf-/- mAst. (A) to (C) Ink4a/Arf -/- 
mAst expressing PDGFR?  were serum-starved for 24 hours followed by incubation with various inhibitors at 
indicated concentrations for an additional 24 hours. Cells were then stimulated with 50 ng/ml PDGF-A for 5 
min before IB analyses. Total Erk1/2 or Akt and ?-actin proteins were used as loading controls. (D) 
Quantification of soft agar assays. Cells were grown in triplicates in soft agar with or without LY294002 (10 
μM), PHPS-1 (100 μM), NSC87877 (100 μM), PP2 (5 μM), SU6656 (5 μM), or PD98059 (10 μM). Data are 
presented as mean ±  s.d. *, P < 0.001; **, P < 0.0001. 
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Figure 28. Inhibition of PI3K or SHP-2 activities suppresses PDGFR?-stimulated signaling and cell 
transformation in LN444 cells. 
PI3K and SHP-2 inhibitors suppress PDGF-A-promoted soft agar growth of INK4A/ARF-deficient LN444 
glioma cells. (A) and (B) IB analysis. Corresponding total proteins or ?-actin were used as loading controls. 
(C) Soft agar assays. Concentrations of the inhibitors and experimental conditions were identical to those in 
Figure 29D.  Data are presented as mean ±  s.d. *, P < 0.01.  
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Figure 29. Effects of SHP-2 inhibitors on Ink4a/Arf
 -/-
 mAst and LN444 cell viability 
 (A) The same number of PDGFR? /PDGF-A-coexpressing Ink4a/Arf-/- mAst or LN444 cells was separately 
cultured in the presence of DMSO, 100 μM PHPS-1 or NSC87877 for 48 hours. Trypan Blue exclusion assay 
was then performed to determined cell viability. No significant difference was found between inhibitors- and 
DMSO-treated groups of both types of cells.  Data are presented as mean ±  s.d. (B) PDGFR? /PDGF-A-
coexpressing Ink4a/Arf
-/-
 mAst or LN444 cells were separately cultured in the presence or absence of 100 μM 
PHPS-1 or NSC87877 for 48 hours. Cells were then lysed for IB analysis using an anti-caspase-3 antibody. No 
detectable caspase-3 cleavage was seen in both types of cells. ?-actin was used as a loading control. 
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3.3.4 SHP-2 ablation disrupts PI3K/AKT activation by interfering with PI3K association 
with PDGFR?  
 
We then examined the impact of SHP-2 inhibitors, PHPS-1 and NSC87877, and PDGFR?-F720 
on the PI3K-signaling.  As shown in Figure 23B and 30A, PDGFR?-F720 mutant and SHP-2 
inhibitors significantly decreased PDGF-A-stimulated p-Akt in PDGFR?-expressing mAst. A 
near complete knockdown of SHP-2 by siRNAs markedly reduced the stimulated p-Akt levels in 
these cells, possibly through interruption of the association between PI3K (p85 subunit) and 
PDGFR? (Figure 30B).  
 
 
Figure 30. SHP-2 recruits PI3K to activate AKT pathway and is important for PDGF-A-stimulated growth. 
(A) IB analyses of serum-starved Ink4a/Arf
-/- 
PDGFR?-expressing mAst were treated with SHP-2 inhibitors 
PHPS-1 or NSC87877 for 24 hours followed by 50 ng/ml PDGF-A for 5 min. (B) IP-IB analysis of PDGFR?-
overexpressing mAst that were transfected with SHP-2 siRNA for 48 hours, serum-starved for an additional 
24 hours followed by PDGF-A stimulation. Corresponding total proteins, ?-actin, or total pulled-down IgG 
were used as loading controls. 
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However, a previous study showed that PDGFR?-F720 mutation did not result in a 
decrease in PI3K association with the RTK in mouse fibroblasts (74). Similarly, when SHP-2 
was knocked down in NIH3T3 cells, a minimal impact of SHP-2 inhibition on PDGF-A-induced 
PI3K association and Akt phosphorylation was observed in these fibroblasts (Figure 31A), 
suggesting that the impact of SHP-2 on PI3K association with the RTK and p-Akt in astrocytes 
and glioma cells was specific. To examine whether the effect of SHP-2 knockdown on p-Akt 
signaling was specific to PDGFR? signaling, we knocked down SHP-2 by siRNAs in EGFRvIII-
expressing Ink4a/Arf
-/-
 mAst (PTEN wt), LN444, and U87MG (both PTEN mutant) cells.  We 
observed a reduction or a modest impact of p-AKT level in LN444/EGFRvIII and 
U87MG/EGFRvIII cells, respectively (Figure 31B), suggesting that SHP-2 also regulates 
PI3K/AKT activation in other RTK signaling.  However, Akt phosphorylation was absent in 
Ink4a/Arf
-/-
 EGFRvIII mAst, possibly due to the presence of WT Pten in these cells. Together, 
we have demonstrated that SHP-2 regulates PI3K binding to the PDGFRa and the downstream 
AKT phosphorylation, and this regulation is likely also present in other RTK signaling such as 
EGFR signaling but is cell type-specific. 
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Figure 31. The impacts of SHP-2 knockdown in NIH3T3, Ink4a/Arf
 -/-
 EGFRvIII mAst, LN444/EGFRvIII, 
and U87MG/EGFRvIII cells. 
(A) Association of PI3K to PDGFR?  and downstream Akt phosphorylation in NIH3T3 cells were only 
moderately affected by SHP-2 knockdown. IB analysis of NIH3T3 mouse fibroblasts that were transfected 
with control or SHP-2 siRNA for 48 hours, serum-starved for an additional 24 hours followed by 50 ng/ml 
PDGF-A stimulation. Various whole-cell lysates or immunoprecipitates pulled down by an anti-PDGFR?  
antibody were subjected to IB analysis using indicated antibodies. Corresponding total proteins, ?-actin, or 
total pulled-down IgG were used as loading controls for induced protein phosphorylation (272) or 
associations (IP followed by IB). (B) Ink4a/Arf
 -/-
 EGFRvIII mAst, LN444/EGFRvIII, and U87MG/EGFRvIII 
cells were transfected with control or SHP-2 siRNA for 48 hours, and then lysed for IB analysis using 
indicated antibodies. ?-actin was used as a loading control. 
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3.3.5 SHP-2 ablation attenuates the enhanced anchorage-independent growth of PDGFR?-
overexpressing cells which can be rescued by constitutively active PI3K signaling 
 
We further determined the impact of the ablation of SHP-2 on cell transformation. Strikingly, 
stable knockdown of SHP-2 by shRNAs markedly reduced PDGFR?-promoted soft agar growth 
of mAst (Figure 32).  
 
 
Figure 32. SHP-2 knockdown suppresses PDGF-A-stimulated soft agar growth of Ink4a/Arf
-/-
 mAst 
overexpressing PDGFR? . 
(A) IB analysis showing SHP-2 knockdown by different shRNA clones with distinct knockdown efficiencies. 
(B) Clones that induce significant reduction in SHP-2 expression (clones 1 and 3) lead to decreased tumor cell 
growth in soft agar. Data are presented as mean ±  s.d. *, P < 0.01, Student’s t test. 
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Since in clinical glioblastomas, activating PI3K mutations are mostly observed in 
specimens with no PDGFRA aberrations (10, 11), we introduced a constitutively active PI3K 
p110 subunit (p110?-CAAX) into Ink4a/Arf-/- mAst that either expressed PDGFR?-F720 or a 
SHP-2 shRNA (Figure 33A).  In both cell lines, we observed a rescue effect of p110?-CAAX in 
soft agar colony formation (Figure 33B), suggesting that PI3K/AKT acts downstream to SHP-2 
in PDGFR?-overexpressing gliomas, and that activating PI3K mutations in clinical gliomas 
might be able to bypass SHP-2 activation to promote tumorigenesis.  Taken together, our results 
suggest that SHP-2 regulates the PI3K/AKT/mTOR-signaling emanating from PDGFR? 
activation and this regulation is important for PDGF-A-stimulated cell transformation. 
 
 
Figure 33. Constitutively activated PI3K rescued the inhibitory effect of SHP-2 inhibition on blocking 
PDGFR?-mediated cell transformation. 
(A) IB analysis of expression of p110?-CAAX. (B) Soft agar assays. Data are presented as mean ±  SEM. *, P 
< 0.0001. For IB analysis,  ?-actin was used as a loading control.  
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3.3.6 SHP-2 ablation disrupts mTORC1/S6K activation and mTOR inhibitor rapamycin 
treatment suppresses growth of PDGFR?- or EGFRvIII-overexpressing cells 
 
Next, we tested whether signaling downstream to Akt was affected by SHP-2 inhibition.  We 
found that SHP-2 inhibitors (Figure 34A), PDGFR?-F720 mutations (Figure 34B), or SHP-2 
siRNA knockdown (Figure 34C) significantly impaired PDGF-A-stimulated phosphorylation of 
S6 kinase (p-S6K) downstream to the mTOR pathway. These results suggest that PDGFR?-
promoted tumorigenesis necessitates an intact SHP-2 activity that regulates the 
PI3K/AKT/mTOR/S6K pathway. 
 
 
Figure 34. SHP-2 is required for activation of mTOR/S6K pathway stimulated by PDGF-A in PDGFR?-
overexpressing mAst. 
(A) IB analyses of serum-starved Ink4a/Arf
-/- 
PDGFR?-expressing mAst that were treated with SHP-2 
inhibitors PHPS-1 or NSC87877 for 24 hours followed by 50 ng/ml PDGF-A for 5 min. (B) IB analysis of 
phospho-S6 kinase levels of various mAst stimulated by PDGF-A. (C) IB analysis of PDGFR?-overexpressing 
mAst that were transfected with SHP-2 siRNA for 48 hours, serum-starved for an additional 24 hours 
followed by PDGF-A stimulation.   
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Since PDGF-A-induced cell transformation requires an intact SHP-2 to activate 
PI3K/AKT/mTOR/S6K pathway, it was of interest to examine whether mTOR inhibitors under 
intensive clinical testing were able to suppress the PDGF-promoted tumorigenesis. As shown in 
Figure 36, treatment with a mTOR complex 1 (mTORC1) inhibitor rapamycin led to a dose-
dependent decrease in soft agar colonies formed by PDGF-A-stimulated Ink4a/Arf
-/-
 mAst 
expressing PDGFR? or LN444 cells (Figure 35A and B), compared to their respective DMSO-
treated controls. Similarly, rapamycin was able to effectively suppress the cell transformation 
capacity conferred by EGFRvIII expression in these cells (Figure 36), further suggesting the 
importance of downstream mTOR/S6K pathway in PDGF- or EGFR-mediated tumorigenesis. 
 
 
Figure 35. Rapamycin inhibits PDGFR?-promoted cell transformation. 
(A) Upper panel, IB analysis of whole-cell lysates from serum-starved PDGFR?-expressing Ink4a/Arf -/- mAst 
that were pre-incubated in the presence or absence of rapamycin at indicated concentrations for 24 hours 
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followed by stimulation with or without PDGF-A for 5 min. Corresponding total proteins or ?-actin were 
used as loading controls for induced protein phosphorylation. Lower panel, bar graph, quantification of soft 
agar assays. Cells were grown in triplicates in soft agar with or without rapamycin at indicated 
concentrations. PDGF-A-expressing mAst in 10% of total cells were included as a source of PDGF-AA in 
these experiments. (B) Soft agar assay of LN444 and LN444/PDGF-A glioma cells treated with indicated 
concentration of rapamycin. Upper panel, bar graph, quantification of the soft agar assay. Lower panel, 
representative images of LN444/PDGF-A cells treated with DMSO control or 100 nM rapamycin. Data are 
presented as percentage to the controls in mean ±  s.d. and are representative of two independent 
experiments. *, P < 0.05; **, P < 0.01, Student’s t test. 
 
 
 
Figure 36. Rapamycin inhibits EGFRvIII-promoted cell transformation. 
Soft agar assay of PDGFR? /PDGF-A- or EGFRvIII-expressing Ink4a/Arf -/- mAst or LN444 cells treated with 
100 nM rapamycin. Cells were grown in triplicates in soft agar with or without rapamycin at indicated 
concentrations. Data are presented as percentage to the controls in mean ±  s.d. and are representative of two 
independent experiments. *, P < 0.005; **, P < 0.001, Student’s t test. 
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Previous studies suggested that the limited efficacy of rapamycin in clinical use was due 
to the capacity of rapamycin to potentiate PI3K/Akt signaling (276). However, we did not 
observe an increase of p-Akt level in both Ink4a/Arf-deficient mAst and LN444 cells treated with 
rapamycin up to 72 hours (Figure 37). 
 
 
Figure 37. Rapamycin treatment does not lead to feedback AKT activation in PDGF-A-stimulated cells. 
IB analysis of whole-cell lysates from serum-starved PDGFR?-expressing Ink4a/Arf -/- mAst that were pre-
incubated in the presence or absence of 100nM rapamycin for 24 hours followed by stimulation with PDGF-A 
for the indicated times. Total Akt or ?-actin was used as loading controls for induced protein 
phosphorylation. 
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3.4 SUMMARY AND CONCLUSION 
 
In summary, we have defined the key signaling pathways that are required for PDGFR?-
mediated gliomagenesis in the background of Ink4a/Arf deletion (Figure 38). When the tyrosine 
phosphorylation sites for PI3K binding were mutated to phenylalanine, PDGFR? lost the 
capacity to transform mAsts, both in vitro in soft agar and in vivo in the mouse brain. 
Unexpectedly, association between PDGFR? and one of the downstream effecter 
phosphotyrosine phosphatase SHP-2 was also required for maximal tumorigenic potential seen in 
cells overexpressing the WT receptor. Soft agar colony formation experiments using various 
pharmacological inhibitors further confirmed the importance of PI3K and SHP-2 activities in 
PDGF-induced growth. IP/IB experiments showed that SHP-2 association with PDGFR? is 
required for PI3K/Akt/mTOR pathway activation, further demonstrating a mechanism that SHP-
2 can modulate the PDGFR? signaling during the formation of gliomas (Figure 38). As in the 
PDGFR?-expressing cells, SHP-2 also regulated Akt activation in some EGFRvIII-expressing 
human glioma cells, suggesting that SHP-2 may be an important signaling molecule where 
different RTKs signaling pathways converge. Thus we identified SHP-2 to be a potential target 
for therapeutic intervention for patients with malignant gliomas. 
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Figure 38. SHP-2-regulated PI3K/AKT/mTOR pathway in the PDGFR?/PDGF-A-mediated gliomagenesis. 
PDGF-AA homodimer binding triggers PDGFR?  dimerization and autophosphorylation in the cytoplasmic 
domain. Recruitment of downstream signaling effectors PI3K and SHP-2 is mediated by phosphorylated Tyr 
731/742 and Tyr 720, respectively. In addition, in this study we demonstrate that SHP-2 activity is required 
for the binding between PI3K and pTyr 731/742 of the receptor, and the downstream AKT and 
mTOR/p70S6K phosphorylation/activation. Inhibitors that suppress SHP-2 phosphatase activity (PHPS-1 
and NSC87877) or SHP-2 downstream MEK/MAPK pathway (PD98059) were able to impact on the 
activation of PI3K pathway as well, indicating SHP-2 activity is important for this regulation. Finally, the 
SHP-2 inhibitors, MEK inhibitor, PI3K inhibitor LY294002, and mTORC1 inhibitor rapamycin were shown 
to suppress PDGF-induced tumorigenesis, and the constitutively active PI3K was capable of rescuing the 
anti-tumor effect of SHP-2 ablation, suggesting this network of signaling interactions are crucial to 
gliomagenesis promoted by PDGF over-activation. 
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4.0 PDGFRA/PDGF-A EXPRESSION IN CLINICAL GLIOMA TISSUES IS 
CONCOMITANT WITH ACTIVATION OF SHP-2 AND PI3K/AKT/MTOR 
SIGNALING PATHWAYS 
 
 
4.1 INTRODUCTION AND RATIONALE 
 
We have identified in our mouse model that SHP-2 is required for optimal PI3K/Akt/mTOR 
activation downstream to PDGFR?, and activation of both SHP-2 and PI3K was required for 
maximal tumorigenesis induced by PDGFR? overexpression. To further demonstrate that SHP-2 
and PI3K activation is present in the PDGFR?/PDGF-A-expressing clinical glioma specimens, 
we attempted to exploit IHC and IB analyses to characterize the glioma tissues of two separate 
cohorts. 
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4.2 MATERIALS AND METHODS 
 
4.2.1 Antibodies 
 
The following antibodies were used in this study: rabbit anti-PDGFR? (sc-338, IHC, 1:50), 
rabbit anti-PDGF-A (sc-128, IHC, 1:50), and goat anti-?-actin (sc-1616, 1:500) antibodies were 
from Santa Cruz Biotechnology Inc., Santa Cruz, CA; mouse anti-phospho-Akt (Ser473, #4051, 
1:1000), rabbit anti-phospho-Akt (Ser473, #4060, IHC, 1:50), rabbit anti-phospho-S6 
(Ser235/236, #4858, 1:2000 for IB; 1:50 for IHC), and rabbit anti-phopho-SHP-2 (Tyr542, 
#3751, 1:1000 for IB; 1:50 for IHC) antibodies were from Cell Signaling Technology, Danvers, 
MA; All secondary antibodies were from Vector Laboratories (Burlingame, CA) or Jackson 
ImmunoResearch Laboratories (West Grove, PA). All other reagents were from Invitrogen, 
Sigma-Aldrich, or Fisher Scientific. 
 
4.2.2 Histology and IHC of Clinical Human Glioma Tissues 
 
Studies using human tissues were reviewed and approved by the Institutional Review Board 
involving Human Subjects of the University of Pittsburgh (Pittsburgh, PA, USA).  The 
specimens were de-identified human tissues thus no informed consent was required.  A total of 
158 paraffin-embedded thin sections of primary human glioma specimens were utilized 
including 87 WHO grade IV GBM, 34 grade III anaplastic astrocytoma (AA), 
oligodendroglioma (AO) or oligoastrocytoma (AOA) and 37 grade II oligodendroglioma (OD) 
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and diffuse astrocytoma (DA).  Thin sections of human glioma specimens were analyzed by IHC 
using indicated antibodies. Briefly, the 5-?m human tissue sections were deparaffinized in 
xylene followed by rehydration in graded ethanol. After washing with Tris-buffered saline 
(TBS), the antigen was retrieved by boiling the sections in a citrate buffer (pH 6.0) twice for 5 
min. Tissues were blocked by AquaBlock (East Coast Biologics Inc.) for 1 hour at room 
temperature.  Afterwards, tissue sections were then incubated with a primary antibody overnight 
at 4°C, and blocked by Peroxidase Blocking Reagent (DAKO) for 10 minutes, followed by 
incubation with a biotinylated secondary antibody for 30 min at room temperature. After washed 
in PBS, stained tissue sections were visualized by diaminobenzidine chromophore and H2O2 
followed by hematoxylin counterstaining. Sections were then dehydrated by graded ethanol, and 
mounted with Permount Solution (5).  
 
4.2.3 Immunoblotting 
 
The IB analysis on the lysates of snap-frozen human GBM tissues was performed as described in 
2.2.6 (Page 54) of this dissertation. 
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4.3 RESULTS 
 
4.3.1 Analysis of PDGFR?/PDGF-A, SHP-2, and PI3K/AKT/mTOR pathway activation 
status by immunohistochemistry on paraffin-embedded human glioma tissues. 
 
To determine whether PDGF-A and PDGFR? are co-expressed and whether there is a link of 
overexpression of PDGF-A and PDGFR? and activation of the SHP-2 and the 
PI3K/AKT/mTOR signaling in clinical glioma specimens, we performed IHC staining on a total 
of 158 paraffin-embedded primary human glioma specimens using anti-PDGFR?, anti-PDGF-A, 
anti-p-SHP-2 Tyr542, anti-p-AKT Ser473, and anti-p-S6 Ser235/236 antibodies.  PDGFR? 
proteins were detected at medium to high levels in 17 out of 87 GBMs (WHO grade IV tumors) 
and 9 out of 71 grade II and III tumors. Among these PDGFR?-positive gliomas, PDGF-A is 
often co-expressed in the same population of tumor cells (Figure 39B and C, and Table 4).  
Significantly, phosphorylation of SHP-2 Y542 (p-SHP-2, required for its activation) (277), AKT 
(p-AKT), and ribosomal S6 subunit (p-S6) was also often detected on sister sections of the same 
tumor in many of the PDGF-A/PDGFR?-positive glioma specimens (Figure 39 B to F, and 
Table 4), suggesting a link of activation of PDGF-A/PDGFR? to stimulation of SHP-2, AKT, 
and mTOR in clinical glioblastoma specimens. 
To evaluate the expression of various proteins in the clinical glioma specimens, we 
employed a set of grading criteria for IHC analysis. As shown in Table 4, in all IHC analyses, 
tumors that harbor low or no signals in less than 1% of tumor cells were graded as “+ / -”; low 
signals in around 1-10% of tumor cells as “+”; moderate signals in less than 10-25% as “++”; 
moderate signals in around 25-50% of the tumor cells as “+++”; and strong signals in 50-75% of 
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the tumor cells as “++++.” Representative images for each of these categories are shown in 
Figure 40. Grading of all IHC-stained tumor specimens was independently assessed by two 
different individuals in the laboratory. The final grading was then determined by comparison and 
discussion of the scores evaluated by these individuals.  
 
 
Figure 39. PDGFR?  and PDGF-A are co-expressed in clinical glioma specimens with activated SHP-2 and 
PI3K/AKT/mTOR pathways. 
(A) to (F), Images of IHC staining on a representative human GBM specimens, J212 (sister sections), using 
anti-PDGFR?  (B), anti-PDGF-A (C), anti-p-SHP-2 (Y542) (D), anti-p-AKT (E), and anti-p-S6 (F) antibodies.  
(A) No primary antibody. Arrows, positive staining of indicated proteins. Bars, 50 μm. 
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Table 4. Summary of Immunohistochemical Analyses on Clinical Human Glioma Tissues 
 
                
Number Grade Histology PDGFR? PDGF-A p-Akt p-S6 p-SHP-2 
                
        
J7 4 Glioblastoma  ++  ++  -  -  - 
J10 3 Anaplastic Astrocytoma  ++  ++  +  +  + 
J16 3 Anaplastic Oligodendroglioma  +++  +++  ++  +  + 
J44 2 Diffuse Astrocytoma  +++  ++++  ++++  +++  ++ 
J57 2 Diffuse Astrocytoma  ++  ++  +  +  + 
J69 4 Glioblastoma  +++  +++  +  ++  ++ 
J72 4 Glioblastoma  ++  +++  +++  +++  +++ 
J80 4 Glioblastoma  ++  ++  +  ++  - 
J84 4 Glioblastoma  +++  +++  +  +  + 
J94 2 Oligodendroglioma  ++  ++  ++  -  - 
J152 4 Glioblastoma  +  ++  +  + / -  ++ 
J156 4 Glioblastoma  +  +  +  ++  + 
J158 4 Glioblastoma  +++  ++  +++  +  ++ 
J159 4 Glioblastoma  +++  + / -  +++  +  ++ 
J161 4 Glioblastoma  ++  +  ++  ++  ++ 
J163 4 Glioblastoma  ++  +++  ++  +++  + 
J165 3 Anaplastic Astrocytoma  ++  ++  ++  ++  - 
J171 3 Anaplastic Oligodendroglioma  +++  ++  ++  ++  ++++ 
J182 1 Pilocytic Astrocytoma  + / -  + / -  -  -  + 
J183 1 Pilocytic Astrocytoma  + / -  + / -  +  ++  + 
J196 3 Anaplastic Astrocytoma  +++  ++  +++  ++  ++++ 
J200 3 Anaplastic Oligodendroglioma  ++  + / -  ++  +  - 
J211 4 Glioblastoma  +  +  +  +  + 
J212 4 Glioblastoma  +++  ++  ++  +++  + 
J216 4 Glioblastoma  +  ++  ++  ++  ++ 
J233 4 Glioblastoma  +  + / -  -  -  - 
J235 4 Glioblastoma  +  ++  +  ++  + 
JKU01 4 Glioblastoma  + / -  ++  + / -  +  + 
JKU02 4 Glioblastoma  ++  + / -  + / -  + / -  + / - 
JKU03 4 Glioblastoma  ++  + / -  +  +  + 
JKU04 4 Glioblastoma  ++  +  +  +  ++ 
JKU05 4 Glioblastoma  ++  ++  ++  +  + 
JKU06 3 Anaplastic Astrocytoma  +++  ++++  +  + / -  ++ 
JKU07 4 Glioblastoma  ++  ++  +  + / -  ++ 
JKU08 4 Glioblastoma  +++  ++  +  +  + 
JKU09 4 Glioblastoma  +  +++  +  +  + 
JKU10 4 Glioblastoma  ++  +++  ++  +  + 
        
        
   ++++ Strong signals in most tumor cells (50~75%) 
   +++ Moderate signals in most tumor cells (25~50%) 
   ++ Moderate signals in some tumor cells (10~25%) 
   + Low signals in few tumor cells (1~10%) 
   + / - Low or no signals in few tumor cells (<1%) 
     - No detectable signals in all tumor cells (0%) 
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Figure 40. Representative images of PDGF-A IHC staining showing grading of clinical glioma tissues 
according to PDGF-A positivity. 
Images of IHC staining on representative human GBM specimens graded as (A) “+ / -”: Low or no signals in 
few tumor cells (< 1%); (B) “+”: Low signals in few tumor cells (1~10%); (C) “++”: Moderate signals in some 
tumor cells (10~25%); (D) “+++”: Moderate signals in most tumor cells (25~50%); (E) “++++”: Strong 
signals in most tumor cells (50~75%). Arrows, positive staining of PDGF-A proteins. Bars, 50 μm. 
 
4.3.2 Analysis of PDGFR?/PDGF-A, SHP-2, and PI3K/AKT/mTOR pathway activation 
status by immunoblotting using snap-frozen human glioma tissues. 
 
To validate these IHC data, we performed IB analyses on a separate cohort of a total of 20 snap-
frozen clinical GBM specimens.  As shown in Figure 41, PDGFR? is expressed at high levels in 
7 out of 20 GBM samples, 5 of which expressed PDGF-A proteins, suggesting an autocrine 
PDGFR? signaling in these tumors.  In 4 out of these 5 PDGF-A/PDGFR?-positive tumors, p-
AKT, p-SHP-2 and p-S6 were also detected.  Of note, expression of PDGF-A, p-AKT, p-SHP-2 
and p-S6 at various levels in other tumor samples likely reflects the impact of heterogeneous 
gene alterations such as mutations of PTEN, TP53 and overexpression of EGFR/EGFRvIII and 
c-MET that affect the expression or activation (phosphorylation) of these proteins in clinical 
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glioblastomas.  Taken together, these results establish a link of PDGF-A/PDGFR? expression 
with activation of SHP-2, PI3K/AKT/mTOR signaling in clinical glioblastoma samples. 
 
 
Figure 41. PDGFR?  and PDGF-A are co-expressed in clinical glioma specimens with activated SHP-2 and 
PI3K/AKT/mTOR pathways. 
IB analysis of tissue lysates of a separate cohort of 20 human GBM snap-frozen specimens using indicated 
antibodies. ?-actin was used as a loading control. The band intensity was determined by Adobe Photoshop 
CS3 Version 10.0.1 software. The mean intensity of each tumor sample was then normalized according to the 
corresponding ?-actin levels and compared to that of GBM #10.  
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4.4 SUMMARY AND CONCLUSION 
 
We have characterized PDGFR? expression and its downstream pathway activation using IHC 
staining in a cohort of 158 grade II-IV human glioma specimens. We found that around 15% of 
the samples in our collection show medium to high expression of the receptor, many of which 
also concomitantly express PDGF-A chain. Interestingly, 90% of the PDGFR?-positive tumors 
also harbor activation of PI3K/Akt pathway as determined by p-Akt expression, while 80% show 
phosphorylation of p70 S6 ribosomal subunit downstream to the mTOR pathway. Our IB 
analyses on a separate cohort of 20 human GBM samples further confirmed these results. 
Although a causal link between activation of PI3K/Akt/mTOR and PDGF-induced glioma 
formation requires the use of animal models or in vitro cultured tumor-derived cell lines, we 
provide evidence that there is co-occurrence of PI3K/Akt/mTOR activation and PDGFR/PDGF-
A autocrine in human glioma tissues. 
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5.0 GENERATION OF GENETICALLY MODIFIED MICE USING THE SLEEPING 
BEAUTY TRANSPOSON SYSTEM—A POTENTIAL PLATFORM FOR PRE-
CLINICAL TESTING OF PDGF/SHP-2 TARGETED THERAPIES 
 
 
5.1 INTRODUCTION AND RATIONALE 
 
5.1.1 Animal Model Systems For Malignant Gliomas 
 
Since PDGF-targeted therapies have been largely disappointing to date, development of animal 
models of malignant gliomas that can re-capitulate the human tumor progression, histology, and 
genetic alterations is urgent. Most of the current mouse models of spontaneous gliomas involve 
generation of germ-line transgenic GEMs (162) or the use of viral vectors delivering genes of 
interest into the mouse brain (164-167). However, the production and the subsequent 
characterization of GEMs or viral vectors can take a long time and is often expensive. Moreover, 
the viral capacity for DNA cargos is limited; the stability of the vectors may be compromised by 
reverse transcription; and the preferential insertion of viral vectors into actively transcribed 
sequences may increase the chance of undesired mutagenesis.  
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5.1.2 Sleeping Beauty Awakens! 
 
In an effort to develop a non-viral, time- and cost-efficient method to generate spontaneous 
mouse models of malignant gliomas, Dr. John R. Ohlfest at University of Minnesota 
(Minneapolis, MN) has exploited an ancient transposon system to deliver various oncogenes into 
the mouse brain, and successfully generated de novo brain tumor GEM models by using several 
different combinations of oncogene/shRNA expression (174). This ancient transposon system, 
called Sleeping Beauty (SB), was so-named since it was first isolated from salmonid fish as a 
dormant “junk DNA” with accumulated mutations. The SB transposon, together with the 
transposase gene that is responsible for its transposition in the genome, was later “resurrected” 
by site-directed mutagenesis to remove the inactivating mutations, and was shown to be capable 
of jumping via cut-and-paste in fish, mouse, and human cells (175). It thus represents the first 
transposon system isolated from the vertebrate animals. Since its discovery, the SB system has 
been developed as a novel tool both in cancer gene discovery (278, 279) and in gene therapy 
(280, 281), for SB is able to transpose randomly throughout the genome by insertional 
mutagenesis and its expression is relatively stable compared with traditional non-viral, episomal 
DNA plasmids used for gene therapies.  
The SB transposase recognizes and binds the inverted direct repeats flanking the DNA 
sequence of interest, excises and inserts it into a new location within a TA dinucleotide in the 
targeted genomic sequence. The long-term stable in vivo expression of the SB-mediated 
transposons in the genome suggests that SB system is a candidate for generating animal models 
of various cancers. Combined with transgenic or knockout mice, SB system can be used to study 
the cooperation between different oncogene expression and loss of tumor suppressors in cancers. 
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For example, SB transposase-mediated expression of an activated NRAS can cooperate with loss 
of Arf to generate liver cancers (282). Additionally, the use of tissue-specific promoter-driven 
expression of the SB transposase can restrict the transposition in specific types of cells, further 
improving the power of this system to model various human diseases including cancers (176). 
We have here recently established the SB system in our lab. We plan to exploit this system to 
model PDGF-driven gliomagenesis in various types of mice including BALB/c, C57BL/6, p53
-/-
, 
and likely the Ink4a/Arf
-/-
 mice. We expect that a combinational use of this system with various 
existing knockout/transgenic mice will elucidate the pathogenesis of gliomas and facilitate pre-
clinical assessments of various targeted therapies for this cancer. Therefore the ancient Sleeping 
Beauty transposon system has awakened in the field of cancer research. 
 
 
5.2 MATERIALS AND METHODS 
 
5.2.1 Animal Care and Mating 
 
All animal experiments were approved by Institutional Animal Care and Use Committee 
(IACUC) of University of Pittsburgh, Pittsburgh, PA. C57BL/6 mice were purchased from The 
Jackson Laboratory. Breeding pairs were setup in one pair per cage and females checked for their 
pregnancy everyday until they gave birth. Neonates with ages < 48 hours were used for 
experiments. 
 
 
  114 
5.2.2 SB DNA Plasmid Vectors 
 
The generation of pT2/Luc//PGK-SB13, pT/CMV-SV40-LgT, pT/CAGGS-NRAS-V12 vectors 
were described previously (174). PT2/CMV-PDGFR? was created by excising the CMV- 
PDGFR? from pcDNA3/PDGFRa as an Nru I/Not I fragment and ligating into the pT2 vector 
between the Bgl II and Not I sites as a blunt end/Not I fragment. PT2/MSCV was created by 
excising the MSCV 5’-LTR and 3’-LTR from pMSCV-PGK-GFP vector (a kind gift from Dr. 
Tao Cheng at University of Pittsburgh, Pittsburgh, PA) as a Bgl II/Not I and Nco I/Hind III 
fragments, respectively, and ligating them into the pT2 vector between the same restriction sites. 
The pT2/MSCV/PDGF-A vector was then generated by excising the PDGF-A cDNA from 
pMXI-PDGF-A vector as an Eco RI fragment and ligating into the Eco RI site of the pT2/MSCV 
vector. Plasmids were purified using EndoFree Plasmid Maxi Kit (Qiagen, cat#: 12362) and 
stored in 0.1% TE buffer (pH8.0) at -80 °C. 
 
5.2.3 Intracranial SB DNA Injection Using Polyethylenimine (PEI) In-vivo Transfection 
 
The DNA plasmids used for stereotactic injection were prepared using an in vivo-jetPEI reagent 
(Polyplus Transfection) according to manufacturer’s instructions. Briefly, SB plasmids 
pT2/Luc//PGK-SB13, pT/CMV-SV40-LgT, and pT/CAGGS-NRASV12 (0.1, 0.2, and 0.2 μg per 
mouse) were diluted in half the volume of the total to be injected (1 μl per mouse) in 5% 
dextrose. The in vivo-jetPEI reagent was diluted in a separate half volume of the total in 5% 
dextrose. After 5 min incubation of both mixtures, PEI reagent was added into the DNA solution. 
The cocktail was then incubated at room temperature for another 15 min before used directly for 
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intracranial injection. The amount of PEI reagent to be used was calculated as μl of PEI 
(150mM) used = 
μgDNA ? 3( ) ? N /P
150
. To achieve an N/P ratio of 7, 0.21 μl of PEI was used 
with 0.5 μg of DNA plasmids per neonate. The final DNA concentration in the DNA/PEI 
mixture to be injected was 0.5 μg/μl. 
Stereotactic injection of SB DNA/PEI mixtures into neonatal mice was performed as 
previously described (174). Briefly, neonatal C57BL/6 mice (24~48 hours after birth) were 
placed on ice for 3-5 min to induce hypothermia anesthesia. Mice were then secured on a dry 
ice/ethanol-cooled neonatal mouse adaptor (Stoelting, cat. #51625). A 10 μl syringe with a 30-
gauge needle (Hamilton) attached to the Quintessential Stereotactic Injector system (Stoelting, 
cat. #53311) and a Digital Three Axis Manipulator Arm (Stoelting, cat. #51904) were used to 
inject the DNA/PEI mixtures at a flow rate of 0.5 μl/min for 2 min into the right lateral ventricle 
at a coordinate of 0.8 mm lateral, 1.5 mm anterior to the lambda, and 1.5 mm under the dura. 
After the injection, the needle was gently pulled out 0.5 mm and left for an extra 1 min before 
gently pulled out of the brain. The neonates were then placed under a heat lamp to recover from 
anesthesia and transferred back into the cage with the female mouse before returned to their 
housing area.  
 
5.2.4 Bioluminescence Detection and Histology 
 
In vivo luciferase detection was performed as previously described (174). Briefly, 48 hours after 
the injection, neonatal mice were placed in a 6-well plate and transferred to the bioluminescence 
facility. Mice were then injected i.p. with 50 μl of D-Luciferin Firefly (33 mg/ml; Caliper Life 
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Sciences, cat. #XR-1001) per mouse. Neonates were then imaged using Xenogen IVIS-200 
Optical In vivo Imaging System (Xenogen corp., Alameda, CA) and analyzed using Living 
Imaging Software Version 4.1 (Caliper Life Sciences, Hopkinton, MA). Adult mice of age of 20 
days were weaned and monitored for luciferase expression 1-2 times every 10 days until signs of 
tumor burdens. For luciferase imaging in the adult mice, mice were placed in an isoflurane 
chamber to induce anesthesia, and were then injected i.p. with 150 μl of D-Luciferin. After 5 
min, mice were imaged using the Xenogen IVIS-200 Imaging System. When neuropathological 
symptoms developed due to tumor burdens in the brain, the mice were euthanized. Brains of 
mice were then removed, embedded in Optimum Cutting Temperature (OCT) compound 
(Tissue-Tek) at -80°C, and cryo-sectioned at 5-μm thickness. Sections of brains were stored at -
80°C until histological analysis. The following antibodies were used in IHC of this study: a rat 
anti-mouse CD31 (#550274, IHC, 1:1000) antibody was from BD Biosciences, San Jose, CA; a 
rabbit anti-Ki67 antigen (NCL-Ki67p, IHC, 1:200) antibody was from Leica Microsystems Inc., 
Bannockburn, IL. 
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5.3 RESULTS 
 
5.3.1 Monitoring real-time tumor growth by luciferase bioluminescence 
 
In order to establish a time- and cost-efficient glioma model that can more accurately re-
capitulate human tumors in our lab, in collaboration with Dr. Hideho Okada at University of 
Pittsburgh Cancer Institute (Pittsburgh, PA), we have established the SB-mediated spontaneous 
glioma formation model in our lab. It has been reported previously that spontaneous gliomas 
formed near the ventricles after the mice were injected with vectors encoding SB transposase and 
transposons carrying SV40-LgT and hyper-active human NRAS-G12V (G-to-V mutation in 
glycine residue 12 of the NRAS gene) expression (174). We thus first utilized this combination of 
oncogenes in our preliminary testing of the SB model. As shown in Figure 42, representative of 
two of the experiments using NRAS-G12V and SV40-LgT combination, we showed that median 
survival of mice is around 65 days, with some mice dying as early as 30-40 days and the others 
up to 80-90 days post-injection. Since the co-injected SB transposase vector contains a firefly 
luciferase gene, we can monitor the real-time tumor development by using bioluminescence 
imaging. We first confirmed whether the in vivo transfection of SB vectors was successful by 
imaging the neonatal mice 48 hours post-injection. As shown in Figure 43A, successful 
transfection is evident with strong luciferase signals in the brain of mice. All the luciferase-
negative neonates (less than 10%) were euthanized and excluded from the study. The remaining 
neonates were kept in the same cage with the mother until around 20 days of age. After weaning, 
the mice were monitored closely for tumor formation by luciferase imaging 1-2 times every 10 
days. As shown in Figure 43B, Mouse 2 represents one of the mice that developed luciferase-
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positive tumors as early as 30 days (“early-progression” tumor). They often showed high 
morbidity by day 40 and prompted us to sacrifice them. Some of the mice, however, did not 
develop detectable luciferase expression until 40-50 days post-injection (“late-progression” 
tumors). As shown in Figure 43B, Mouse 1 showed luciferase expression around 46 days and 
Mouse 3 around 54 days post-injection, both of which did not show apparent neuropathological 
symptoms by the time of tumor development.  
 
 
 
Figure 42.  Kaplan-Meier survival curve for mice injected with SB transposase and NRAS/SV40-LgT-
encoding transposons.  
Survival analyses were performed on 7 SB-injected mice from two independent experiments. The median 
survival time was 65 days post-injection. Two mice survived up to 90 days with no signs of tumor burden 
prior to sacrifice. 
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Figure 43. Luciferase imaging for mice injected with SB transposase and NRAS/SV40-LgT-encoding 
transposons.  
(A) On day 2 post-injection, neonates were placed in a 6-well tissue culture plate and subjected to luciferase 
imaging as described in the Materials and Methods section. Mice with low or undetectable bioluminescence 
signals were euthanized and excluded from the study. (B) Luciferase images of representative SB-induced 
mice at different time points were shown. In some mice, the tumor progressed faster (Mouse 2; “early-
progression” group) than the others (Mouse 1 and 3; “late-progression” group). 
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It has been noted that a higher injection volume (2 μl) resulted in development of 
hydrocephalus, which is evident with an enlarged skull and accumulation of cerebrospinal fluid 
in the ventricular space (174). This complication seemed to occur more frequently in C57BL/6 
mice than other strains of mice due to different genetic susceptibility (174). We constantly 
observed hydrocephalus in over 70% of the mice that were injected with 2 μl of the DNA/PEI 
mixture, as early as 25 days post-injection. These mice often presented with neuropathological 
symptoms followed by death within 1-2 weeks and thus were excluded from the survival 
analyses. In order to avoid this complication, we reduced the injection volume but kept the same 
DNA concentration by injecting a total volume of 1 μl with 0.5 μg DNA per mouse. In these 
experiments, hydrocephalus became less prevalent and occurred only in < 25% of the cases. In 
one of the experiments, among the five mice that received 1 μl of DNA/PEI mixtures, one died 3 
days after weaning with no signs of tumor or hydrocephalus development. One developed mild 
hydrocephalus with high luciferase signal in the brain (Mouse 6) (Table 5). Subsequent 
histological analysis revealed that a grade III/IV tumor formed in the left ventricle, reminiscent 
of the observation in the previous report showing that hydrocephalic brain frequently harbored 
multifocal tumors in both lateral ventricles (174). Of the three remaining mice, one started to 
show luciferase expression in the brain 50 days post-injection and developed a grade III/IV 
tumor 60 days confirmed by histological assessment (Mouse 3). The other two mice showed no 
signs of tumor up to 90 days and were thus excluded from the study (Mouse 4 and 5). Overall, 
injection with 1 μl of the DNA/PEI complex gave a significantly lower incidence of developing 
hydrocephalus but also came with a price of reduced tumor penetrance in C57BL/6 mice. Taken 
together, we have successfully generated SB-induced spontaneous glioma mouse models with 
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around 60% penetrance and were able to monitor real-time tumor progression through 
bioluminescence imaging.  
 
5.3.2 Histological analyses of SB tumors reveal characteristics corresponding to those 
observed in human gliomas 
 
Previous report showed that mice that received SB transposase-mediated NRAS and SV40-LgT 
expression developed spontaneous gliomas after 3-4 weeks and the tumor diagnosis often 
corresponds to WHO grade III and IV (174). A subsequent report using SB-induced expression 
of NRASV12 and shp53 also showed tumor histology corresponding to different grades of human 
gliomas (283). In this experiment, Fujita and colleagues demonstrated that SB-induced gliomas 
at 21 days post-injection resembled human grade II diffuse fibrillary astrocytomas, while 60-day 
tumors showed additional features such as pleomorphic nuclei and active mitoses, thus 
resembling WHO grade III gliomas (283). We observed differential tumor progression rates 
among SB-induced gliomas. As shown in Figure 43B, some of the mice developed tumors as 
early as 30 days whereas the others did not show detectable luciferase signal until 50 days post-
injection. The mice with “early-progression” tumors often developed hydrocephalus around 30-
40 days post-injection. This observation was reminiscent of a previous report, in which 
researchers generated spontaneous gliomas by injecting PDGF-B-encoding retrovirus into lateral 
ventricle of E14 mice and observed a group of “early-affected” mice showed high incidence of 
hydrocephalus and differential tumor histology, as compared to “late-affected” mice (167).  
When the brains with SB-induced tumors were harvested and assessed for the presence of 
features of human tumors, both early- and late-progression tumors showed neuro-pathological 
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characteristics of high-grade gliomas, including high cellularity, cell infiltration into normal 
brain parenchyma, nuclear atypia, brisk mitotic activity, focal necrosis, and high Ki67 positivity 
(Figure 44, 45 and Table 5). We also found that one of the “early-progression” tumors (Mouse 6) 
contained multi-nuclear tumor cells characteristic of giant cell GBMs in humans (3).  However, 
we were not able to confirm the presence of microvascular proliferation in all tumor specimens 
analyzed. In order to assess the endothelial cell proliferation of the SB-induced tumors, we 
performed IHC staining with an anti-platelet endothelial cell adhesion molecule 1 (PECAM-
1/CD31) antibody on tumor sections from different mice. The intensity of CD31 staining in 
glioma tissues has been linked to degree of angiogenesis (259) and glioma tumor grades (284). 
As shown in Figure 45, both “early-“ and “late-progression” SB-induced tumors displayed active 
endothelial proliferation (Figure 45E-G), as compared to normal brain control (Figure 45A). 
Based on the histological and immunological features of these SB-induced tumors, we concluded 
that these spontaneous mouse gliomas resemble WHO grade III/IV gliomas in humans (Table 5). 
Taken together, we have demonstrated that SB-induced spontaneous gliomas displayed similar 
characteristics to human gliomas both histologically and immunohistochemically and thus this 
model is a promising tool for pre-clinical testing of various standard or targeted therapies, 
including the development of anti-PDGFR?/SHP-2 treatments. 
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Figure 44. SB-induced spontaneous gliomas exhibit characteristics of human gliomas.  
Representative H&E staining images were shown for Mouse 1 (A), 3 (B), and 6 (C). Yellow arrows demarcate 
the tumors of each mouse. Detailed histological characteristics of SB-induced mice are summarized in Table 
5. (D), (E), (F) are enlarged images of the boxed regions indicated in (A), (B), and (C), respectively. Tumor 
cells in (D) show high anaplasia, pleomorphic nuclei (arrows), active mitotic activity (arrowheads), and 
poorly differentiated glial cells. (E) shows infiltration of tumor cells into the surrounding brain parenchyma 
(arrows). (F) Prominent pseudopalisading cells (arrows) surrounding an area of focal necrosis (arrowhead), a 
typical feature of human GBMs. Scale bars, 1 mm for panels A-C; 100 μm for D-F. 
 
 
 
 
 
  124 
 
 
Figure 45. SB-induced spontaneous gliomas showed high positivity for Ki67 and CD31 staining. 
(A) CD31 staining of normal mouse brain. (B)-(D) Representative Ki67 IHC staining images on frozen 
sections of Mouse 1 (B), 3 (C), and 6 (D). Representative CD31 IHC staining images on frozen sections of 
Mouse 1 (E), 3 (F), and 6 (G). Insets, corresponding negative controls for each image. Scale bars, 50 μm. 
 
Table 5. Histological and immunohistochemical analyses of SB-induced gliomas. 
Mouse# Surv Size Ki67 CD31 CD DI PN MT FN Grade 
                      
           
1 75 L  +++  +++  +++  +++  +++  +++  ++ III / IV 
2 43 M ND ND  +  +  +  + / - - II 
3 65 M  +++  +++  +++  ++  +++  +++  + III / IV 
4 90 N NA NA NA NA NA NA NA NA 
5 90 N NA NA NA NA NA NA NA NA 
6 33 M  ++  +++  ++  ++  +++  ++  ++ III / IV 
 
Abbreviations: Surv: survival time (days post-injection); L, large; M, medium; S, small; N, no tumor found; ND, not 
determined; NA, non-applicable; CD, cell density; DI diffuse infiltration; PN, pleomorphic nuclei; MT, mitosis; FN, 
focal necrosis. The sizes of tumors were estimated using these criteria: small, < 1 mm in diameter; medium, 1-3 mm; 
large, > 3 mm. The tumors were graded based on the presence of histological features found in human gliomas. 
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5.4 SUMMARY AND CONCLUSION 
 
By using the SB transposon system, we have successfully generated NRAS- and SV40-LgT-
mediated spontaneous glioma mouse model. We were able to track the in vivo tumor growth via 
bioluminescence imaging, and to assess the resulted tumors based on their resemblance to the 
neuro-pathological features of clinical human gliomas. With the pT2/CMV-PDGFR? and 
pT2/MSCV/PDGF-A vectors now available in our lab, generation of SB-mediated, PDGF-
induced spontaneous gliomas and the subsequent pre-clinical testing of various targeted therapies 
on these mice will ensue. 
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6.0 DISCUSSION AND FUTURE DIRECTIONS 
 
 
6.1 DISCUSSION 
 
In this dissertation, we report that PDGFR? and/or PDGF-A overexpression is able to drive 
gliomagenesis of Ink4a/Arf-deficient mAst and human glioma LN444 and LN443 cells. Re-
introduction of p16INK4a but not p19ARF into Ink4a/Arf-null mAst suppresses PDGFR?-
promoted tumor growth. In the absence of PI3K or SHP-2 signaling, PDGFR? fails to enhance 
tumorigenesis in the brain of mice. Additionally, we establish a link between activation of SHP-2 
and the PI3K/AKT/mTOR signaling in PDGFR?-stimulated tumorigenesis in vitro, in mice, and 
in clinical glioblastoma specimens.  Therefore, our data demonstrate that co-alteration of the 
RTK PDGFR? and tumor suppressor p16INK4a is required for gliomagenesis and that SHP-2 is 
a critical linker between the PI3K/ AKT /mTOR pathway and PDGFR? in the formation of 
gliomas. 
A unique feature of this study is that specific activation of PDGFR? signaling in vivo by 
PDGF-A, a ligand that only binds to PDGFR? but not PDGFR?? (71) as an autocrine loop 
significantly enhanced the tumorigenesis of Ink4a/Arf-deficient mAst and human glioma cells in 
the brain.  Early studies of clinical glioma specimens showed that PDGF-A and PDGFR? are 
overexpressed in tumor cells while PDGF-B and PDGFR? are expressed in hyperplastic 
capillaries, suggesting both autocrine and paracrine loops for PDGF/PDGFR activation in 
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gliomas (127). In neonate and adult mice, expression of PDGF-B induces de novo gliomas from 
GFAP-positive astrocytes and nestin-expressing glial progenitor cells through activation of 
PDGFR? and PDGFR? in the brain of both WT and Ink4a/Arf-deficient animals (165, 270).  
Moreover, in WT Ink4a/Arf mice, infusion of PGFD-A proteins into the lateral ventricle 
stimulated tumor-like growth of PDGFR?-positive NSC in the SVZ in the brain (104). 
Importantly, data of the cancer genome atlas (10) and other studies revealed that PDGFR? is 
overexpressed and amplified, and often co-expressed with PDGF-A in clinical glioblastoma 
samples (10, 12, 130).  Our results not only functionally validated these studies but also further 
demonstrated the significance of specific activation of PDGFR? signaling by PDGF-A in 
cooperation with loss of p16INK4a but not p19ARF in promoting gliomagenesis.  We found that 
when PDGFR? signaling is activated in Ink4a/Arf-/- mAst or human glioma cells, mice that 
received these cells developed significantly larger and highly invasive tumors in the brain.  In 
contrast, no enhancement of tumorigenesis was found in mice that received glioma cells with 
PDGFR? and an intact CDKN2A locus (267). Together, our studies indicate that PDGFR? 
activation together with Ink4a/Arf loss results in enhanced tumor growth of both mAst and 
human glioma cells in the brain. 
Tumor suppressor P16INK4A is frequently mutated in clinical glioblastomas (11, 12, 
245).  In mice, loss of p16INK4a and p19ARF was shown to be indispensable in facilitating 
tumorigenesis (42).  Ink4a/Arf-deficient mice were viable and developed spontaneous tumors at 
early ages, but without detectable tumors in the brain (42, 45).  Further studies showed that 
Ink4a/Arf loss cooperates with oncogenic K-Ras, EGFRvIII or PDGF-B expression in promoting 
gliomagenesis in the brain (45, 164, 165, 255, 270).  However, compared to p16INK4a loss that 
contributes to tumor initiation from mAst, p19ARF deficiency was shown to display a more 
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pronounced impact on cell transformation and gliomagenesis (44, 168). Our data corroborates 
and also differs with these studies. We showed that re-expression of p16INK4a but not p19ARF 
in PDGFR?-expressing Ink4a/Arf-/- mAst inhibited tumorigenesis.  Inhibition of CDK4/6, the 
direct target of p16INKa by a specific inhibitor (268) in Ink4a/Arf
-/- 
mAst and glioma cells 
attenuated PDGF-A stimulation of soft agar growth, suggesting CDK4/6/p-RB signaling is 
required for PDGFR?-induced tumorigenesis. On the contrary, although p53 was functional in 
Ink4a/Arf
-/-
 PDGFR?-expressing mAst, p19ARF was unable to suppress soft agar growth of 
these cells.  Since p19ARF de-represses p53 signaling while PI3K/Akt activates p53 E3 ubiquitin 
ligase Mdm2 (285), it is plausible that the robust PI3K/Akt activation in PDGFR?-
overexpressing cells triggers Mdm2-mediated p53 degradation and thereby renders tumorigenic 
mAst resistant to p19ARF inhibition (269). It is also likely that loss of p19ARF is required for 
survival of glioma cells under certain condition such as treatment of DNA damage-inducing 
agent CDDP (Figure 21).  At least during the initiation or maintenance of cell transformation, 
p19ARF loss appears to be dispensable (44, 168), since knockdown of INK4A alone in 
INK4A/ARF-wt LN319 glioma cells restored PDGFR? stimulation of anchorage-independent 
growth in soft agar. Taken together, these data suggest that p16INK4a loss plays a predominant 
role in PDGFR?-promoted gliomagenesis. 
The third important aspect in this study is that we functionally assigned signal modules of 
PDGFR? in promoting gliomagenesis and tumor invasion in the brain of mice.  Previous studies 
by uncoupling individual signaling pathways from PDGFR? using a series of F-to-Y mutants 
revealed unequal contributions of each signaling pathway emanating from PDGFR? activation 
(71, 75, 76). Our in vivo and biochemical data corroborate these reports. When compared with 
PDGFR?-wt overexpression, loss of intrinsic tyrosine kinase activity (R627) of the RTK or 
  129 
binding capacity to PI3K (F731/42) or SHP-2 (F720) abrogated PDGFR?-promoted 
gliomagenesis, thus signifying the central roles of PI3K and SHP-2 signaling in PDGFR? 
function.  However, while disruption of PDGFR? association with SFKs (F572/74) or PLC? 
(F1018) only had a moderate impact on tumor formation in the brain, significant inhibition of 
tumor cell infiltration in the brain was seen in these tumors, as compared to the PDGFR?-wt 
tumors, thus validating the role of SFKs and PLC? in mediating PDGFR?-stimulated cell 
invasion (74). Moreover, a separate set of experiments with individual “add-back panel” mutants 
(Y731/42, Y572/74, Y720, Y988, and Y1018) could not fully restore PDGFR?-promoted 
tumorigenesis in the brain (data not shown), consistent with the previous findings using an 
identical set of PDGFR? “add-back panel” mutants (74). It is plausible that similar to this 
previous in vitro study (74), in which retention of a combination of two or three add-back 
signaling modules with comparable level of total RTK protein in PDGFR?-wt-expressing cells 
was able to restore PDGFR?-mediated biological responses, co-activation of PI3K (Y731/42)- 
and SHP-2 (Y720)-mediated signaling may be required for the full spectrum of wt PDGFR?-
promoted gliomagenesis in the brain.  
The most novel finding in this study is the emergence of SHP-2 as an essential mediator 
in PDGFR?-promoted gliomagenesis.  SHP-2 (encoded by PTPN11 gene) is a protein tyrosine 
phosphatase (PTP) identified as a bona fide proto-oncogene that activates Ras-MAPK-signaling 
through a yet-to-be-defined mechanism (286). Additionally, the role of SHP-2 in mediating 
PDGFR? signaling has not been clear (69, 71, 76).  In human cancers including GBMs, 
mutations of SHP-2 or its binding partners have been reported, leading to sustained Ras-MAPK 
signaling (287, 288). Recent automated signaling network-based analysis on the TCGA genomic 
data has designated PTPN11 as one of the six “Linker” genes, which are statistically enriched for 
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connections to various GBM altered genes, thus suggesting a critical role for SHP-2/PTPN11 in 
modulation of downstream biological signaling in gliomagenesis (289). Our data not only 
establish the critical role of SHP-2 in mediating PDGFR? activation for glioma formation but 
also functionally validate this hypothesis.   We showed that inhibition of SHP-2 function by 
removal of its binding module in PDGFR? (F720 mutant), gene knockdown or pharmacological 
inhibitors significantly impaired PDGFR? stimulation of tumorigenesis in vivo and in vitro and 
its downstream signaling effectors, Erk1/2 and PI3K/Akt/mTOR in Ink4a/Arf-deficient mAst and 
glioma cells.  Significantly, re-expression of a constitutively active p110, the catalytic subunit of 
PI3K, rescued the inhibition of SHP-2 in Ink4a/Arf-deficient mAst. In EGFRvIII-expressing 
U87MG glioma cells, SHP-2 regulates activities of ERK/2 and CDC2 that modulates cell cycle 
progression, but has a minimal effect on AKT activation (275).  On the contrary, we found that 
knockdown of SHP-2 not only attenuated PDGFR? stimulation of Erk1/2 activity but also 
impaired PI3K/Akt/mTOR activity in Ink4a/Arf-deficient mAst and human glioma cells.  The 
impact of inhibition of SHP-2 on PI3K/Akt signaling seems specific in astrocytic tumors since 
we did not observed an inhibition of PDGF-A stimulation of p-Akt or PI3K association with 
PDGFR? in SHP-2 knocking down NIH3T3 fibroblasts.  On the other hand, a MEK inhibitor 
PD98059 also reduced the tumorigenicity of Ink4a/Arf-deficient mAst, indicating that SHP-2-
mediated PDGFR? signaling requires not only PI3K/Akt but also Erk1/2 activation in 
gliomagenesis.  Additionally, SHP-2 was found to either positively or negatively regulate 
PI3K/AKT activity (287).   However, in our model systems, SHP-2 is required for full activation 
of PI3K/Akt/mTOR and inhibition of mTOR by rapamycin markedly suppressed PDGFR?-
promoted tumorigenesis.  These data are significant since a recent proteomic study revealed that 
mTOR signaling is predominantly activated in “PDGFRA co-cluster” glioblastomas (143), thus 
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corroborating our observations.  However, since phosphorylation of Akt Ser473 occurs both 
upstream and downstream to mTOR complex 2 (mTORC2) signaling, our data do not rule out 
the role of mTORC2 in PDGFR?-activated signaling.  Lastly, our data also demonstrated the 
importance of activation of PI3K/mTOR signaling by SHP-2 in PDGFR?- or EGFRvIII-
promoted tumorigenesis.  Taken together, our findings suggest SHP-2 as a critical modulator that 
regulates PDGFR?-mediated PI3K/AKT/mTOR activities in the development of malignant 
glioblastomas. 
To better understand the tumorigenesis processes in human brain and predict responses to 
therapeutic interventions such as PDGF/SHP-2/PI3K inhibition, it is necessary to develop animal 
models that re-capitulate the histology, progression, and microenvironment of the human 
malignant gliomas. We have demonstrated in this dissertation that we are able to generate a 
mouse model that developed malignant brain gliomas that displayed several neuro-pathological 
features found in clinical human gliomas, by using Sleeping Beauty Transposon-driven NRAS 
and SV40 Large T antigen expression (174). The differential tumor incidences and survival time 
among these mice likely resulted from different transfection efficiency, different targeted 
insertion sites within the genome, or distinct types of cells targeted. We observed that mice 
developing hydrocephalus tended to develop tumors with markedly different histopathological 
features than those in mice without hydrocephalus. To decrease the incidence of hydrocephalus, 
we reduced the injection volume from 2 μl to 1 μl and observed a significant decrease of 
hydrocephalus in the injected mice. However, the penetrance of tumor development in these 
mice still needs to be improved (~60%). We are currently in the process of testing SB-induced 
tumor model in other strains of mice such as BALB/c mice with a newly improved animal 
protocol, which was reported to show a more favorable penetrance than did C57BL/6 mice (174).  
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We anticipate that the use of SB system in PDGF-induced gliomagenesis will help to 
better understand gliomas induced by aberrant activation of PDGF signaling and further provide  
a platform for pre-clinical testing of newly developed drugs targeting this molecular pathway. 
However, cautions should be taken when using mouse as a model system. The marked 
differences between mouse and human could compromise the use of these models in predicting 
human tumor responses to various therapeutic interventions. On the other hand, the tumors 
generated from xenografting of human glioma tissues into immuno-deficient mice are expected 
to intrinsically resemble human tumors more than do those derived from the mouse cells. 
However, several caveats exist in the xenograft mouse models. The xenograft tumors lack the 
interactions with functional immune systems and tumor microenvironment (e.g. the normal 
human brain cells and vasculatures). Several approaches to generate “humanized” tumor 
microenvironments have been proposed (179). This might be achieved by transgenic expression 
of human tumor microenvironment-specific genes in the mouse brain, or by introducing stem 
cells that can generate human-like stromal or perivascular cells. Interestingly, mouse HSCs have 
been shown to generate endothelial cells and pericytes that support glioma cell angiogenesis in 
the mouse brain (290, 291). The feasibility of generating human vasculatures in the mouse brain 
(a “humanized mouse brain”) using stem cell technology or transgenic approach for 
understanding of tumor pathogenesis and prediction of anti-tumor drug responses thus warrants 
further investigations. For these reasons, perhaps a model that incorporates spontaneous tumor 
induction by SB or other types of vectors with the use of “humanized mouse brains” will 
ultimately overcome the limitations presented by the current animal models. 
In summary, this dissertation provides molecular insights into the mechanisms by which 
PDGFRA amplification together with loss of INK4A/ARF promotes gliomagenesis in the brain.  
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Our data identified SHP-2, as well as PI3K, as a pivotal mediator of PDGFR? signaling in 
glioma formation. These results have direct clinical relevance since we not only establish a 
model system to demonstrate the co-operative role of PDGFRA overexpression and INK4A/ARF 
loss in clinical glioblastomas, but also provide functional evidence to validate genomic analyses 
demonstrating that SHP-2/PTPN11 is an essential “Linker” among glioma altered genes (289); 
secondly, activated mTOR signaling is predominantly found within the subclass of glioblastomas 
with abnormal PDGFR? signaling (143); and thirdly, activating PI3K mutations (PIK3CA and 
PIK3R1) occur mostly in clinical glioblastomas without PDGFRA aberrations (11). Given that 
the clinical experiences of most of the targeted therapies developed to date are disappointing, 
identifying and targeting molecules that are robust in the face of network interactions between 
different genetic aberrations may prove more effective (292); SHP-2/PTPN11 thus represents 
one of these candidates. Consequently, our results strongly suggest SHP-2/PTPN11 as a potential 
target for treatments of human glioblastomas with PDGFRA overexpression.  
 
 
6.2 FUTURE DIRECTIONS 
 
In order to develop a time- and cost-efficient mouse model for spontaneous glioma formation, 
we have collaborated with Dr. John R. Ohlfest at University of Minnesota and Dr. Okada Hideho 
at University of Pittsburgh and successfully generated spontaneous gliomas in C57BL/6 mice 
that received SB transposon-mediated NRASV12 and SV40 Large T antigen expression. In 
addition, vectors that encoding PDGF-B (pT2/EF1aRU5-mPDGFB) and EGFRvIII 
(pT3.5/CMV-EGFRvIII) were also obtained from Dr. Ohlfest and Dr. Okada, respectively. 
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Moreover, we have generated SB plasmid DNA constructs encoding PDGFR? (pT2/CMV- 
PDGFR?) and PDGF-A (pT2/MSCV-PDGFA). In order to assess the contributions of various 
genetic alterations to glioma formation, we will introduce the SB-mediated expression of PDGFs 
or EGFRvIII into several available transgenic/knock-out mice such as Ink4a/Arf
-/-
 (42), PTEN
-/-
 
(293) (in collaboration with Dr. Ronald A. Depinho at Harvard Medical School), and p53
-/-
 (294) 
(in collaboration with Dr. Lin Zhang at University of Pittsburgh) mice. We will then perform 
transcriptome analyses to determine whether tumors generated from these combinations of 
genetic aberrations harbor expression of signature genes found in the four subtypes of human 
GBMs within TCGA dataset (11). For example, we expect the combination of PDGF 
overexpression and p53 deletion in these mice will result in formation of gliomas resembling the 
Proneural subtype of GBMs, whereas introduction of EGFRvIII expression into PTEN-deficient 
mice could lead to development of tumors comparable to the Classical subtype of human GBMs.  
After identifying various mouse tumors that resemble human subtype of GBMs, we will 
treat the mice with these gliomas with various targeted pharmacological inhibitors, such as SHP-
2 inhibitors PHPS-1 and NSC87877 (described in Chapter 3) and determine whether these 
tumors are sensitive to SHP-2 inhibition by these inhibitors. Bioluminescence imaging will be 
performed to monitor the tumor growth before and after the treatments; histological and 
immunohistochemical analyses will also used to assess the neuropathological features present in 
these tumors (as described in Chapter 5 of this dissertation). Other treatment modalities will also 
be exploited in treating these mice, such as a novel fully human monoclonal PDGFR? 
neutralizing antibody, IMC-3G3 (249, 250, 295, 296) (obtained from Eli Lilly and Company, 
Indianapolis, IN). We expect to observe an initial regression of tumors after treatment of either 
SHP-2 inhibitors or the PDGFR? neutralizing antibody. However, we will deliberately keep 
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certain number of groups of mice up to 2 years in order to determine whether tumor recurrences 
will occur. After the tumor recurrence, subsequent transcriptome analyses will be performed to 
determine the presence of signature genetic changes that may indicate a shift of tumor subtypes 
within these recurrent tumors as compared to the primary tumors. We expect that mice treated 
with SHP-2 inhibitors will be less likely to suffer from tumor recurrence since we hypothesize 
that SHP-2 ablation leads to elimination of multiple oncogenic signaling pathways involved in 
all GBM subtypes and thus significantly reduces the possibility that alternative signaling 
pathways will be activated after the treatment. 
We will also isolate tumors cells from these SB-induced gliomas in the mouse brain, 
using methods described by the previous report (174). Briefly, we will performed FACS cell 
sorting by expression of GFP (encoded by SB vectors) or the putative glioma stem cell marker 
CD133 by utilizing a CD133/2 (clone 293C3, Miltenyi Biotec Inc, Auburn, CA) antibody 
conjugated with allophycocyanin (APC). We will then determine the tumorigenicity of 
secondary tumors generated from implantation of these sorted cells to assess whether CD133-
positive population of tumor cells represent the real CSCs in various tumors that resemble the 
four subtypes of human GBMs. We will also identify the integration sites of SB transposons 
within genomes of these sorted cells, as described in the previous report (174), to determine 
whether off-target disruptions of certain genes are required for generation of the tumors observed 
in these mice. We expect that the CD133-positive CSCs isolated from tumors that resemble 
various human GBM subtypes will display differential tumorigenic potentials. The CSCs isolated 
from Proneural-like tumors are the most likely to be highly tumorigenic compared with those 
from other subtypes, since Proneual human GBMs express genes characteristic of early CNS 
development and thus it is possible that initiation/maintenance of these tumors may re-capitulate 
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the process in normal CNS development. That is, the cell of origin of the Proneural GBMs is 
likely the neural stem/glial progenitor cells (such as CD133-positive cells) that generate various 
cells in the normal CNS. For this reason, we expect that compared with CD133-negative 
population, CD133-positive cells isolated from SB-induced Proneural-like tumors will be more 
tumorigenic after re-implantation into the mouse brain.  
Lastly, it is also of interest to determine whether the putative CD133-positive CSCs are 
responsible for the tumor recurrence after various PDGF-targeted therapies in the mice with SB-
mediated Proneural-like tumors. We will treat the mice with Proneural-like tumors with PDGF- 
or SHP-2-targeted therapies in combination with various differentiating agents such as all-trans 
retinoic acid (ATRA) to eliminate the CD133-positive CSC population in the tumor mass (297). 
In these experiments, immunohistochemistry with antibodies against various neural cells, such as 
nestin, GFAP, NG2, Olig2, and O4, will be performed on tumors before and after the ATRA 
treatment to confirm the differentiating effects of ATRA on the tumors. Mice will also be 
monitored for tumor recurrence for up to 2 years by bioluminescence imaging. We expect ATRA 
will be able to decrease the CD133-positive CSC population and increase the number of 
differentiated cells such as GFAP- or O4-positive glial cells in the tumors. Additionally, we 
expect by differentiating the CSCs, we will be able to render the tumor more sensitive to PDGF- 
or SHP-2-targeted treatments and decrease the possibility of tumor relapse.  
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